CN118119389A - Prodrugs and derivatives of des-phosphate nupharicin and uses thereof - Google Patents
Prodrugs and derivatives of des-phosphate nupharicin and uses thereof Download PDFInfo
- Publication number
- CN118119389A CN118119389A CN202280069600.6A CN202280069600A CN118119389A CN 118119389 A CN118119389 A CN 118119389A CN 202280069600 A CN202280069600 A CN 202280069600A CN 118119389 A CN118119389 A CN 118119389A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- solvate
- isotopologue
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940002612 prodrug Drugs 0.000 title abstract description 45
- 239000000651 prodrug Substances 0.000 title abstract description 45
- 229910019142 PO4 Inorganic materials 0.000 title abstract description 8
- 239000010452 phosphate Substances 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 376
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 44
- 230000001965 increasing effect Effects 0.000 claims abstract description 40
- 208000035475 disorder Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 230000009286 beneficial effect Effects 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 528
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 314
- 229910052739 hydrogen Inorganic materials 0.000 claims description 288
- 239000001257 hydrogen Substances 0.000 claims description 288
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 272
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 270
- 125000001072 heteroaryl group Chemical group 0.000 claims description 250
- 125000003118 aryl group Chemical group 0.000 claims description 238
- 150000003839 salts Chemical class 0.000 claims description 212
- 239000012453 solvate Substances 0.000 claims description 188
- -1 cyano, hydroxy Chemical group 0.000 claims description 187
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 171
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 144
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 128
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 110
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 100
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 88
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 82
- 125000003342 alkenyl group Chemical group 0.000 claims description 79
- 125000004429 atom Chemical group 0.000 claims description 63
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 62
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 55
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 55
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 54
- 125000005843 halogen group Chemical group 0.000 claims description 50
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 49
- 229910052736 halogen Inorganic materials 0.000 claims description 44
- 150000002367 halogens Chemical group 0.000 claims description 42
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 41
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 41
- 125000003386 piperidinyl group Chemical group 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 40
- 125000002757 morpholinyl group Chemical group 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 36
- 125000002393 azetidinyl group Chemical group 0.000 claims description 34
- 125000004069 aziridinyl group Chemical group 0.000 claims description 34
- 125000004193 piperazinyl group Chemical group 0.000 claims description 34
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 34
- 125000003566 oxetanyl group Chemical group 0.000 claims description 32
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 23
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 22
- 229910052805 deuterium Inorganic materials 0.000 claims description 22
- 125000003107 substituted aryl group Chemical group 0.000 claims description 20
- 201000000980 schizophrenia Diseases 0.000 claims description 18
- 208000024714 major depressive disease Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 4
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 1
- 241000209485 Nuphar Species 0.000 claims 1
- 102000007563 Galectins Human genes 0.000 abstract description 3
- 108010046569 Galectins Proteins 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical class O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 58
- 239000000203 mixture Substances 0.000 description 50
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 42
- 125000004432 carbon atom Chemical group C* 0.000 description 39
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 36
- 235000002639 sodium chloride Nutrition 0.000 description 31
- 239000002207 metabolite Substances 0.000 description 29
- 238000012453 sprague-dawley rat model Methods 0.000 description 29
- 125000000304 alkynyl group Chemical group 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 24
- 208000014644 Brain disease Diseases 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 19
- 208000011117 substance-related disease Diseases 0.000 description 19
- 208000012902 Nervous system disease Diseases 0.000 description 18
- 125000003545 alkoxy group Chemical group 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- 208000019901 Anxiety disease Diseases 0.000 description 16
- 206010012335 Dependence Diseases 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 15
- 230000007996 neuronal plasticity Effects 0.000 description 15
- 108010025020 Nerve Growth Factor Proteins 0.000 description 14
- 102000007072 Nerve Growth Factors Human genes 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 125000001188 haloalkyl group Chemical group 0.000 description 14
- 239000003900 neurotrophic factor Substances 0.000 description 14
- 208000025966 Neurological disease Diseases 0.000 description 13
- 230000036506 anxiety Effects 0.000 description 13
- 125000004043 oxo group Chemical group O=* 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 12
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000013519 translation Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 10
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 10
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 208000020925 Bipolar disease Diseases 0.000 description 10
- 206010042458 Suicidal ideation Diseases 0.000 description 10
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- 208000020016 psychiatric disease Diseases 0.000 description 10
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 10
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 10
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 10
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 9
- 150000002825 nitriles Chemical class 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 229940075993 receptor modulator Drugs 0.000 description 9
- 239000002399 serotonin 2A agonist Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 208000019695 Migraine disease Diseases 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 description 7
- 210000003520 dendritic spine Anatomy 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 7
- 206010027599 migraine Diseases 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 7
- 210000000225 synapse Anatomy 0.000 description 7
- 230000009529 traumatic brain injury Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 6
- 206010036618 Premenstrual syndrome Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- SPCIYGNTAMCTRO-UHFFFAOYSA-N psilocin Chemical compound C1=CC(O)=C2C(CCN(C)C)=CNC2=C1 SPCIYGNTAMCTRO-UHFFFAOYSA-N 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 5
- 208000006561 Cluster Headache Diseases 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- 206010013654 Drug abuse Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229960004372 aripiprazole Drugs 0.000 description 5
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Chemical group 0.000 description 5
- 208000018912 cluster headache syndrome Diseases 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 5
- 229960003529 diazepam Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
- GJJFMKBJSRMPLA-DZGCQCFKSA-N levomilnacipran Chemical compound C=1C=CC=CC=1[C@]1(C(=O)N(CC)CC)C[C@H]1CN GJJFMKBJSRMPLA-DZGCQCFKSA-N 0.000 description 5
- 229960000685 levomilnacipran Drugs 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 5
- 229960001534 risperidone Drugs 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 5
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 4
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 4
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 4
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 4
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229950002871 blonanserin Drugs 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 229960002866 duloxetine Drugs 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000007514 neuronal growth Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 229960001158 nortriptyline Drugs 0.000 description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 4
- 229960005017 olanzapine Drugs 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 4
- 229960004431 quetiapine Drugs 0.000 description 4
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- PVXVWWANJIWJOO-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine Chemical compound CCNC(C)CC1=CC=C2OCOC2=C1 PVXVWWANJIWJOO-UHFFFAOYSA-N 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000027534 Emotional disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 206010023230 Joint stiffness Diseases 0.000 description 3
- IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 201000009916 Postpartum depression Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 229960004538 alprazolam Drugs 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 229960000836 amitriptyline Drugs 0.000 description 3
- 150000003863 ammonium salts Chemical group 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 3
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 3
- JHYNXXBAHWPABC-UHFFFAOYSA-N chloromethyl propan-2-yl carbonate Chemical compound CC(C)OC(=O)OCCl JHYNXXBAHWPABC-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004606 clomipramine Drugs 0.000 description 3
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 3
- 229960003120 clonazepam Drugs 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229960003914 desipramine Drugs 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 3
- 229960004341 escitalopram Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 3
- 229960004801 imipramine Drugs 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 3
- 229960005417 ketanserin Drugs 0.000 description 3
- 229960001848 lamotrigine Drugs 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 208000013465 muscle pain Diseases 0.000 description 3
- 210000002241 neurite Anatomy 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 229960000964 phenelzine Drugs 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 229960003300 pimavanserin Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009933 reproductive health Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 3
- 229960002073 sertraline Drugs 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 229960004394 topiramate Drugs 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- 229960000604 valproic acid Drugs 0.000 description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
- 229960004688 venlafaxine Drugs 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 2
- NHUCANAMPJGMQL-ZDUSSCGKSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoate Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)ON1C(CCC1=O)=O)C1=CC=CC=C1 NHUCANAMPJGMQL-ZDUSSCGKSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 2
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- DICWIJISMKZDDY-VIFPVBQESA-N 1-o-tert-butyl 2-o-(2,5-dioxopyrrolidin-1-yl) (2s)-pyrrolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)ON1C(=O)CCC1=O DICWIJISMKZDDY-VIFPVBQESA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- HXCNRYXBZNHDNE-UHFFFAOYSA-N 3-[2-[4-[(4-fluorophenyl)-oxomethyl]-1-piperidinyl]ethyl]-2-methyl-4-pyrido[1,2-a]pyrimidinone Chemical compound CC=1N=C2C=CC=CN2C(=O)C=1CCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 HXCNRYXBZNHDNE-UHFFFAOYSA-N 0.000 description 2
- ZGUPMFYFHHSNFK-UHFFFAOYSA-N 3-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound CC=1N=C2C=CC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 ZGUPMFYFHHSNFK-UHFFFAOYSA-N 0.000 description 2
- MLDQSYUQSLUEPG-UHFFFAOYSA-N 3-[4-[4-(4-fluorobenzoyl)piperidin-1-yl]butyl]-1h-quinazoline-2,4-dione Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCCCN2C(C3=CC=CC=C3NC2=O)=O)CC1 MLDQSYUQSLUEPG-UHFFFAOYSA-N 0.000 description 2
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- GEICAQNIOJFRQN-UHFFFAOYSA-N 9-aminomethyl-9,10-dihydroanthracene Chemical compound C1=CC=C2C(CN)C3=CC=CC=C3CC2=C1 GEICAQNIOJFRQN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960002629 agomelatine Drugs 0.000 description 2
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229960003036 amisulpride Drugs 0.000 description 2
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005245 asenapine Drugs 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229950000295 butanserin Drugs 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 description 2
- 229950006044 caroxazone Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- RAMYCVMRCSNXGX-UHFFFAOYSA-N chloromethyl oxan-4-yl carbonate Chemical compound ClCOC(=O)OC1CCOCC1 RAMYCVMRCSNXGX-UHFFFAOYSA-N 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
- 229960001140 cyproheptadine Drugs 0.000 description 2
- 229940089052 depakene Drugs 0.000 description 2
- 229950011405 deramciclane Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- RRJHOMPUEYYASJ-UHFFFAOYSA-N ditert-butyl hydrogen phosphite Chemical compound CC(C)(C)OP(O)OC(C)(C)C RRJHOMPUEYYASJ-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 description 2
- 229960002053 flibanserin Drugs 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000380 hallucinogen Substances 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 229960003162 iloperidone Drugs 0.000 description 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 150000002467 indacenes Chemical class 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 229910052740 iodine Chemical group 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- JDYWZVJXSMADHP-UHFFFAOYSA-N lidanserin Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OCCCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 JDYWZVJXSMADHP-UHFFFAOYSA-N 0.000 description 2
- 229950003713 lidanserin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229960001432 lurasidone Drugs 0.000 description 2
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- RRIRDPSOCUCGBV-UHFFFAOYSA-N methylenedioxyphenethylamine Chemical compound NCCC1=CC=C2OCOC2=C1 RRIRDPSOCUCGBV-UHFFFAOYSA-N 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- GVXBHSBKKJRBMS-UHFFFAOYSA-N metralindole Chemical compound C1CN(C)C2=NCCC3=C2N1C1=CC=C(OC)C=C13 GVXBHSBKKJRBMS-UHFFFAOYSA-N 0.000 description 2
- 229960003955 mianserin Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 229960001785 mirtazapine Drugs 0.000 description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- QOBGWWQAMAPULA-RLLQIKCJSA-N n,n-dimethyl-2-[[(1r,3s,4r)-4,7,7-trimethyl-3-phenyl-3-bicyclo[2.2.1]heptanyl]oxy]ethanamine Chemical compound C1([C@@]2([C@]3(C)CC[C@@H](C3(C)C)C2)OCCN(C)C)=CC=CC=C1 QOBGWWQAMAPULA-RLLQIKCJSA-N 0.000 description 2
- 229960001800 nefazodone Drugs 0.000 description 2
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229960001057 paliperidone Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229940117803 phenethylamine Drugs 0.000 description 2
- AXNGJCOYCMDPQG-UHFFFAOYSA-N phenyl-[1-(2-phenylethyl)-4-piperidinyl]methanol Chemical compound C=1C=CC=CC=1C(O)C(CC1)CCN1CCC1=CC=CC=C1 AXNGJCOYCMDPQG-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229950009698 pirenperone Drugs 0.000 description 2
- 229950002220 pirlindole Drugs 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 2
- 229950009626 ritanserin Drugs 0.000 description 2
- RNRYULFRLCBRQS-UHFFFAOYSA-N roluperidone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 RNRYULFRLCBRQS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229950010947 seganserin Drugs 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000002400 serotonin 2A antagonist Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 229960003741 tranylcypromine Drugs 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- 229960004496 zotepine Drugs 0.000 description 2
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 2
- IQVLXQGNLCPZCL-ZDUSSCGKSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2,6-bis[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)ON1C(=O)CCC1=O IQVLXQGNLCPZCL-ZDUSSCGKSA-N 0.000 description 1
- POBDBYGSGKMZPH-NSHDSACASA-N (2,5-dioxopyrrolidin-1-yl) (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(C)C)C(=O)ON1C(=O)CCC1=O POBDBYGSGKMZPH-NSHDSACASA-N 0.000 description 1
- POBDBYGSGKMZPH-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)NC(C(C)C)C(=O)ON1C(=O)CCC1=O POBDBYGSGKMZPH-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HPLSWPFFBRSXNU-JZGIKJSDSA-N (2s)-2-amino-3-phenylpropanoic acid;dihydrochloride Chemical compound Cl.Cl.OC(=O)[C@@H](N)CC1=CC=CC=C1 HPLSWPFFBRSXNU-JZGIKJSDSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- GFAHDJZQCCOXCL-TZMCWYRMSA-N (6ar,10ar)-9,9-dimethyl-6,6a,7,8,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@@H]2[C@H](NCC(C2)(C)C)C2)=C3C2=CNC3=C1 GFAHDJZQCCOXCL-TZMCWYRMSA-N 0.000 description 1
- ZYACKOKSHZQYDS-NTVGDFDMSA-N (6ar,10ar)-9-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline Chemical compound C1=CC([C@@H]2[C@H](NCC(C2)C)C2)=C3C2=CNC3=C1 ZYACKOKSHZQYDS-NTVGDFDMSA-N 0.000 description 1
- KEMOOQHMCGCZKH-JMUQELJHSA-N (6ar,9r,10ar)-n-cyclohexyl-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound O=C([C@@H]1C[C@H]2[C@H](N(C1)C)CC1=CN(C=3C=CC=C2C1=3)C(C)C)NC1CCCCC1 KEMOOQHMCGCZKH-JMUQELJHSA-N 0.000 description 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- USWVWJSAJAEEHQ-UHFFFAOYSA-N 1,3-benzodioxolyl-n-methylbutanamine Chemical compound CCC(NC)CC1=CC=C2OCOC2=C1 USWVWJSAJAEEHQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VYGXSMYEELSIAI-UHFFFAOYSA-N 1,3-oxazolidin-3-ium;chloride Chemical compound Cl.C1COCN1 VYGXSMYEELSIAI-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- AEIQNPMGFQNZNV-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-n-(cyclopropylmethyl)propan-2-amine Chemical compound C=1C=C2OCOC2=CC=1CC(C)NCC1CC1 AEIQNPMGFQNZNV-UHFFFAOYSA-N 0.000 description 1
- WAXHXZWOUQTVQZ-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-n-propylpropan-2-amine;hydrochloride Chemical compound Cl.CCCNC(C)CC1=CC=C2OCOC2=C1 WAXHXZWOUQTVQZ-UHFFFAOYSA-N 0.000 description 1
- VNICFCQJUVFULD-UHFFFAOYSA-N 1-(1-naphthalenyl)piperazine Chemical compound C1CNCCN1C1=CC=CC2=CC=CC=C12 VNICFCQJUVFULD-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- CJAUQHPXNICIJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-[[4-(2-methylpropoxy)phenyl]methyl]-1-piperidin-4-ylurea Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCNCC1)CC1=CC=C(F)C=C1 CJAUQHPXNICIJI-UHFFFAOYSA-N 0.000 description 1
- AHYUVVGZPAWTKK-UHFFFAOYSA-N 1-azanylidyne-N-diazomethanesulfinamide Chemical compound C(#N)S(=O)N=[N+]=[N-] AHYUVVGZPAWTKK-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- RPSOLZRELOLSFM-UHFFFAOYSA-N 2-(1-benzyl-5-methoxy-2-methylindol-3-yl)ethanamine Chemical compound CC1=C(CCN)C2=CC(OC)=CC=C2N1CC1=CC=CC=C1 RPSOLZRELOLSFM-UHFFFAOYSA-N 0.000 description 1
- AHGNJBSTWQOSAB-UHFFFAOYSA-N 2-(4-methoxyphenyl)-n-[(4-methylphenyl)methyl]-n-(1-methylpiperidin-4-yl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)N(C1CCN(C)CC1)CC1=CC=C(C)C=C1 AHGNJBSTWQOSAB-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical group COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- LBXMQBTXOLBCCA-UHFFFAOYSA-N 3,4-methylenedioxy-n-propylamphetamine Chemical compound CCCNC(C)CC1=CC=C2OCOC2=C1 LBXMQBTXOLBCCA-UHFFFAOYSA-N 0.000 description 1
- MVVJINIUPYKZHR-UHFFFAOYSA-N 3-[[4-[5-(methoxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy]methyl]benzonitrile Chemical compound O=C1OC(COC)CN1C(C=C1)=CC=C1OCC1=CC=CC(C#N)=C1 MVVJINIUPYKZHR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- HOIIHACBCFLJET-SFTDATJTSA-N 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido-[3',4':4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7h)-yl)-1-(4-fluorophenyl)-1-butanone Chemical compound C([C@@H]1N2CCN(C=3C=CC=C(C2=3)[C@@H]1C1)C)CN1CCCC(=O)C1=CC=C(F)C=C1 HOIIHACBCFLJET-SFTDATJTSA-N 0.000 description 1
- ANZVBVKYXOGOQC-UHFFFAOYSA-N 4-(6-ethoxy-1-methoxythioxanthen-9-ylidene)-1-methylpiperidine Chemical compound C12=C(OC)C=CC=C2SC2=CC(OCC)=CC=C2C1=C1CCN(C)CC1 ANZVBVKYXOGOQC-UHFFFAOYSA-N 0.000 description 1
- PCOCFIOYWNCGBM-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)CCC(O)=O PCOCFIOYWNCGBM-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- ZEHMWPBRDVLBMH-UHFFFAOYSA-N 4-o-tert-butyl 1-o-(chloromethyl) butanedioate Chemical compound CC(C)(C)OC(=O)CCC(=O)OCCl ZEHMWPBRDVLBMH-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical compound O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- SMYALUSCZJXWHG-UHFFFAOYSA-N Altanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=S)=O)CC1 SMYALUSCZJXWHG-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- NSQJBWPKJQMACZ-UHFFFAOYSA-N C1C2=CC=CC=C2C2C1(N)OCO2 Chemical compound C1C2=CC=CC=C2C2C1(N)OCO2 NSQJBWPKJQMACZ-UHFFFAOYSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- DVTZYMANNNJGFT-UHFFFAOYSA-N CC(C)(C)OC(=O)C(CCl)CC(O)=O Chemical compound CC(C)(C)OC(=O)C(CCl)CC(O)=O DVTZYMANNNJGFT-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 150000000703 Cerium Chemical class 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- VGIGHGMPMUCLIQ-UHFFFAOYSA-N LSM-2183 Chemical compound C1=CC(F)=CC=C1N1CCN(CCCN2S(C=3C=CC=C4C=CC=C2C=34)(=O)=O)CC1 VGIGHGMPMUCLIQ-UHFFFAOYSA-N 0.000 description 1
- BJIPVHLRWSDKOS-UHFFFAOYSA-N LY-367,265 Chemical compound C1=2C3=CC=CC=2CCCN1S(=O)(=O)N3CCN(CC1)CC=C1C1=CNC2=CC(F)=CC=C21 BJIPVHLRWSDKOS-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- QMMZSJPSPRTHGB-UHFFFAOYSA-N MDEA Natural products CC(C)CCCCC=CCC=CC(O)=O QMMZSJPSPRTHGB-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102400000282 Manserin Human genes 0.000 description 1
- 101800001616 Manserin Proteins 0.000 description 1
- JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
- RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- XHLOUFPZLUULGI-UHFFFAOYSA-N N-[(4-bromophenyl)methyl]-2-(5-methoxy-1H-indol-3-yl)ethanamine Chemical compound C12=CC(OC)=CC=C2NC=C1CCNCC1=CC=C(Br)C=C1 XHLOUFPZLUULGI-UHFFFAOYSA-N 0.000 description 1
- HZZZZODVDSHQRG-UHFFFAOYSA-N N-[5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxopentyl]-2,4-dimethoxyphenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound COC1=CC(OC)=C(C(=O)CCCCN2CCC3(CC2)C(NC(=O)N3)=O)C=C1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 HZZZZODVDSHQRG-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 150000008522 N-ethylpiperidines Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- COSPVUFTLGQDQL-UHFFFAOYSA-N Nelotanserin Chemical compound C1=C(C=2N(N=CC=2Br)C)C(OC)=CC=C1NC(=O)NC1=CC=C(F)C=C1F COSPVUFTLGQDQL-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- AQRLDDAFYYAIJP-UHFFFAOYSA-N Pruvanserin Chemical compound C1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C=3NC=C(C=3C=CC=2)C#N)CC1 AQRLDDAFYYAIJP-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- OJZZJTLBYXHUSJ-UHFFFAOYSA-N SB 200646 Chemical compound C=1C=C2N(C)C=CC2=CC=1NC(=O)NC1=CC=CN=C1 OJZZJTLBYXHUSJ-UHFFFAOYSA-N 0.000 description 1
- ZETBBVYSBABLHL-UHFFFAOYSA-N SB 243213 Chemical compound C1=2C=C(C(F)(F)F)C(C)=CC=2CCN1C(=O)NC(C=N1)=CC=C1OC1=CC=CN=C1C ZETBBVYSBABLHL-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- FYVSAFKZTFPIJW-AOTCJWPLSA-N Spiramide Natural products O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@]23[C@H]([C@]45[C@H]1[C@](C)(C(=O)N1[C@@H]4OCC1)CCC5)C[C@H](C(=C)C2)CC3)C FYVSAFKZTFPIJW-AOTCJWPLSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- MNLVCBKWEVXHGE-UHFFFAOYSA-N [CH]1[CH]CC[CH]1 Chemical group [CH]1[CH]CC[CH]1 MNLVCBKWEVXHGE-UHFFFAOYSA-N 0.000 description 1
- RJBJIKXTJIZONR-HSWWXKJFSA-N [H][C@@]12CC3=CN(C(C)C)C4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2C)C(=O)O[C@H]1CC[C@@H](CC1)OC Chemical compound [H][C@@]12CC3=CN(C(C)C)C4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2C)C(=O)O[C@H]1CC[C@@H](CC1)OC RJBJIKXTJIZONR-HSWWXKJFSA-N 0.000 description 1
- 229940056213 abilify Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- HPFLVTSWRFCPCV-UHFFFAOYSA-N adatanserin Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)NCCN(CC1)CCN1C1=NC=CC=N1 HPFLVTSWRFCPCV-UHFFFAOYSA-N 0.000 description 1
- 229950008881 adatanserin Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229950009005 altanserin Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229950010679 amesergide Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- HFQMYSHATTXRTC-JTQLQIEISA-N amiflamine Chemical compound C[C@H](N)CC1=CC=C(N(C)C)C=C1C HFQMYSHATTXRTC-JTQLQIEISA-N 0.000 description 1
- 229950004939 amiflamine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 description 1
- 229950000388 amperozide Drugs 0.000 description 1
- 229940025141 anafranil Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000004653 anthracenylene group Chemical group 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229950000017 befloxatone Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WMRPOCDOMSNXCQ-UHFFFAOYSA-N bicyclo[3.3.2]decane Chemical compound C1CCC2CCCC1CC2 WMRPOCDOMSNXCQ-UHFFFAOYSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 description 1
- 229960001210 brexpiprazole Drugs 0.000 description 1
- 229950004068 brofaromine Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001661 cadmium Chemical class 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- PJBIHXWYDMFGCV-UHFFFAOYSA-N chloro(chlorosulfonyloxy)methane Chemical compound ClCOS(Cl)(=O)=O PJBIHXWYDMFGCV-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 229950001660 cimoxatone Drugs 0.000 description 1
- RSUVYMGADVXGOU-BUHFOSPRSA-N cinanserin Chemical compound CN(C)CCCSC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 RSUVYMGADVXGOU-BUHFOSPRSA-N 0.000 description 1
- 229950001684 cinanserin Drugs 0.000 description 1
- ZDLBNXXKDMLZMF-UHFFFAOYSA-N cinitapride Chemical compound CCOC1=CC(N)=C([N+]([O-])=O)C=C1C(=O)NC1CCN(CC2CC=CCC2)CC1 ZDLBNXXKDMLZMF-UHFFFAOYSA-N 0.000 description 1
- 229960003875 cinitapride Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- SLFGIOIONGJGRT-UHFFFAOYSA-N cyamemazine Chemical compound C1=C(C#N)C=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 SLFGIOIONGJGRT-UHFFFAOYSA-N 0.000 description 1
- 229960004278 cyamemazine Drugs 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229940029644 cymbalta Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 229940075925 depakote Drugs 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940028937 divalproex sodium Drugs 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- UJKWLAZYSLJTKA-UHFFFAOYSA-N edma Chemical compound O1CCOC2=CC(CC(C)NC)=CC=C21 UJKWLAZYSLJTKA-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- YYFGRAGNYHYWEZ-UHFFFAOYSA-N eprobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCCN1CCOCC1 YYFGRAGNYHYWEZ-UHFFFAOYSA-N 0.000 description 1
- 229950011016 eprobemide Drugs 0.000 description 1
- 229940051493 equetro Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CHDGAVDQRSPBTA-UHFFFAOYSA-N esuprone Chemical compound CC1=C(C)C(=O)OC2=CC(OS(=O)(=O)CC)=CC=C21 CHDGAVDQRSPBTA-UHFFFAOYSA-N 0.000 description 1
- 229950007673 esuprone Drugs 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 229950002951 fananserin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229940003380 geodon Drugs 0.000 description 1
- 229950003791 glemanserin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011551 heat transfer agent Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- WICNYNXYKZNNSN-UHFFFAOYSA-N hydron;4-methylpiperazine-1-carbonyl chloride;chloride Chemical compound Cl.CN1CCN(C(Cl)=O)CC1 WICNYNXYKZNNSN-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- UXIPFQUBOVWAQW-UEBLJOKOSA-N iferanserin Chemical compound CN1CCCC[C@H]1CCC1=CC=CC=C1NC(=O)\C=C\C1=CC=CC=C1 UXIPFQUBOVWAQW-UEBLJOKOSA-N 0.000 description 1
- 229950003656 iferanserin Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical group 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 229950003467 lumateperone Drugs 0.000 description 1
- IMSDOBUYDTVEHN-ILMFXRJHSA-N ly-215,840 Chemical compound O=C([C@@H]1C[C@H]2[C@H](N(C1)C)CC1=CN(C=3C=CC=C2C1=3)C(C)C)N[C@H]1CCC[C@H]1O IMSDOBUYDTVEHN-ILMFXRJHSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- MTIKJUJMCMDSGM-UHFFFAOYSA-N mdmeo Chemical compound CONC(C)CC1=CC=C2OCOC2=C1 MTIKJUJMCMDSGM-UHFFFAOYSA-N 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229950008693 mesulergine Drugs 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- BMKCDDFQEGYEJC-UHFFFAOYSA-N methylenedioxyallylamphetamine Chemical compound C=CCNC(C)CC1=CC=C2OCOC2=C1 BMKCDDFQEGYEJC-UHFFFAOYSA-N 0.000 description 1
- DWLUHTUYTBWOLO-UHFFFAOYSA-N methylenedioxybenzylamphetamine Chemical compound C=1C=C2OCOC2=CC=1CC(C)NCC1=CC=CC=C1 DWLUHTUYTBWOLO-UHFFFAOYSA-N 0.000 description 1
- RDXVRDCQDITVDV-UHFFFAOYSA-N methylenedioxybutylamphetamine Chemical compound CCCCNC(C)CC1=CC=C2OCOC2=C1 RDXVRDCQDITVDV-UHFFFAOYSA-N 0.000 description 1
- FNDCTJYFKOQGTL-UHFFFAOYSA-N methylenedioxyhydroxyamphetamine Chemical compound ONC(C)CC1=CC=C2OCOC2=C1 FNDCTJYFKOQGTL-UHFFFAOYSA-N 0.000 description 1
- SCUUYKMQDUDNBP-UHFFFAOYSA-N methylenedioxyhydroxyethylamphetamine Chemical compound OCCNC(C)CC1=CC=C2OCOC2=C1 SCUUYKMQDUDNBP-UHFFFAOYSA-N 0.000 description 1
- LOZJEWOZOKSOKA-UHFFFAOYSA-N methylenedioxymethoxyethylamphetamine Chemical compound COCCNC(C)CC1=CC=C2OCOC2=C1 LOZJEWOZOKSOKA-UHFFFAOYSA-N 0.000 description 1
- OIZBHKBNZXRXSM-UHFFFAOYSA-N methylenedioxyphentermine Chemical compound CC(C)(N)CC1=CC=C2OCOC2=C1 OIZBHKBNZXRXSM-UHFFFAOYSA-N 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 229950006787 metralindole Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229960004758 minaprine Drugs 0.000 description 1
- LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N mono-n-propyl amine Natural products CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- HYOLQGVNMQNERE-UHFFFAOYSA-N n,n-dimethyl-2-(3-phenylquinolin-2-yl)sulfanylethanamine Chemical compound CN(C)CCSC1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 HYOLQGVNMQNERE-UHFFFAOYSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- QEILDAATRJDFET-UHFFFAOYSA-N n-[1-(1,3-benzodioxol-5-yl)propan-2-yl]-2-methylpropan-1-amine Chemical compound CC(C)CNC(C)CC1=CC=C2OCOC2=C1 QEILDAATRJDFET-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229940087524 nardil Drugs 0.000 description 1
- 229950006103 nelotanserin Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RSKQGBFMNPDPLR-UHFFFAOYSA-N niaprazine Chemical compound C=1C=CN=CC=1C(=O)NC(C)CCN(CC1)CCN1C1=CC=C(F)C=C1 RSKQGBFMNPDPLR-UHFFFAOYSA-N 0.000 description 1
- 229960002686 niaprazine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229940087480 norpramin Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229930185847 nupharin Natural products 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000005332 obsidian Substances 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940055692 pamelor Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940087824 parnate Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- WPKPLSFHHBBLRY-UHFFFAOYSA-N pelanserin Chemical compound O=C1NC2=CC=CC=C2C(=O)N1CCCN(CC1)CCN1C1=CC=CC=C1 WPKPLSFHHBBLRY-UHFFFAOYSA-N 0.000 description 1
- 229950005867 pelanserin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 125000005562 phenanthrylene group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- RGSULKHNAKTFIZ-CEAXSRTFSA-N pimavanserin tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1.C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RGSULKHNAKTFIZ-CEAXSRTFSA-N 0.000 description 1
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 description 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950003077 pruvanserin Drugs 0.000 description 1
- QVDSEJDULKLHCG-UHFFFAOYSA-N psilocybin Chemical compound C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- FTKTZRKAVSDSRA-UHFFFAOYSA-N sercloremine Chemical compound C1CN(C)CCC1C1=CC2=CC(Cl)=CC=C2O1 FTKTZRKAVSDSRA-UHFFFAOYSA-N 0.000 description 1
- 229950011041 sergolexole Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RBGAHDDQSRBDOG-UHFFFAOYSA-N setoperone Chemical compound CC=1N=C2SCCN2C(=O)C=1CCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 RBGAHDDQSRBDOG-UHFFFAOYSA-N 0.000 description 1
- 229950009024 setoperone Drugs 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- MOSCXNXKSOHVSQ-UHFFFAOYSA-M sodium;2-hydroxybutanoate Chemical compound [Na+].CCC(O)C([O-])=O MOSCXNXKSOHVSQ-UHFFFAOYSA-M 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- FJUKDAZEABGEIH-UHFFFAOYSA-N spiramide Chemical compound C1=CC(F)=CC=C1OCCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 FJUKDAZEABGEIH-UHFFFAOYSA-N 0.000 description 1
- 229950005784 spiramide Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009782 synaptic response Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- NDSGWNVNYIVEKU-UHFFFAOYSA-N tetrindole hydrochloride Chemical compound Cl.C1CCCCC1C1=CC=C(N2C3=C4CCCC3NCC2)C4=C1 NDSGWNVNYIVEKU-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003608 titanium Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229940041597 tofranil Drugs 0.000 description 1
- 229940035305 topamax Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229950008832 tropanserin Drugs 0.000 description 1
- HDDNYFLPWFSBLN-ZSHCYNCHSA-N tropanyl 3,5-dimethylbenzoate Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(C)=CC(C)=C1 HDDNYFLPWFSBLN-ZSHCYNCHSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229950002976 volinanserin Drugs 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Described herein are compounds that are derivatives (e.g., prodrugs) of des-phosphate nupharicin. Also described herein is the use of a compound provided herein for the treatment or prevention of a disease, disorder, or condition in which increased levels of dephosphorylated galectin are beneficial.
Description
Cross Reference to Related Applications
The present application claims the benefit of U.S. provisional patent application No. 63/235,543, filed 8/20 a 2021, and U.S. provisional patent application No. 63/289,025, filed 12/13 a 2021, the contents of each of which are incorporated herein by reference in their entirety.
Background
In the united states, nearly one fifth of adults suffer from mental disorders, and more than 50% of americans will be diagnosed with mental disorders at some point in their lifetime. Twenty-five of the americans have severe mental disorders such as major depressive disorder, schizophrenia, or bipolar disorder.
Disclosure of Invention
In one aspect, provided herein are compounds of formula (I), or a pharmaceutically acceptable salt, solvate, or isotopologue thereof:
Wherein:
R 1 is hydrogen, -OH, unsubstituted OR substituted alkyl, OR, OR C (O) OR; wherein R is unsubstituted alkyl;
R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7、-CH(R4)OC(O)NR6R7、-S(O)2NR6R7、-S(O)2OR5、-P(O)OR8(NR9R10)、-P(O)(OR11)(OR12)、-CH(R4)OP(O)(OR11)(OR12) or-Si (R 3)(R4)(R5);
Each of R 3、R4、R5 and R 8 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A;
Each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A; or R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A;
each of R 9 and R 10 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A, or R 9 and R 10 together with the atom to which they are attached form a heterocyclylalkyl ring or heteroaryl ring that is unsubstituted or substituted with one or more R A;
Each of R 11 and R 12 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A;
Each R A is independently alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl is unsubstituted OR substituted with one OR more alkyl, aryl, halogen 、-S-R13、-OR13、-NR(R18)R19、-C(O)R14、-OC(O)R15、-OC(O)OR16, OR-OC (O) N (R 18)R19;
Each of R 13、R14、R15、R16 or R 17 is independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or substituted with one or more R B;
Each of R 18 and R 19 is independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R B; or R 18 and R 19 together with the atoms to which they are attached form a heterocyclylalkyl ring or heteroaryl ring, each of which is unsubstituted or substituted with one or more R B;
Each R B is independently halogen, amino, cyano, hydroxy, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, -OC (O) R 18、-C(O)R18、-C(O)OR18、NHC(O)OR18, or heteroarylalkyl, wherein cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more halogen, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, the compound of formula (I) has the structure of formula (Ia):
In certain embodiments, R 3 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl. In certain embodiments, R 3 is unsubstituted or substituted alkyl. In certain embodiments, R 3 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21. In certain embodiments, R 3 is unsubstituted alkyl. In certain embodiments, R 3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In certain embodiments, R 3 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In certain embodiments, R 3 is alkyl substituted with-C (O) OR 13. In certain embodiments, R 13 is hydrogen or alkyl. In certain embodiments, R 13 is hydrogen, methyl, ethyl, or tert-butyl.
In certain embodiments, R 3 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
In certain embodiments, R 3 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, benzoyl, phenyl, or NH-Boc.
In certain embodiments, R 3 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
In certain embodiments, R 3 is heterocyclylalkyl.
In certain embodiments, R 3 is
In certain embodiments, R 3 isWherein R C is the side chain of a natural amino acid and R' is hydrogen or-Boc.
In certain embodiments, R 3 is
In certain embodiments, R 3 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, R 3 is
In certain embodiments, R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 3 is heteroalkyl.
In certain embodiments, an unsubstituted or substituted aryl (e.g., phenyl).
In certain embodiments, substituted phenyl.
In certain embodiments, R 3 is phenyl substituted with-OC (O) R 18, wherein R 18 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl.
In certain embodiments, the compound of formula (I) has the structure of formula (Ib):
In certain embodiments, R 3 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, R 3 is unsubstituted or substituted alkyl.
In certain embodiments, R 3 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In certain embodiments, R 3 is alkyl substituted with heterocyclylalkyl.
In certain embodiments, wherein R 3 is aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Substituted alkyl, wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, R 3 is unsubstituted alkyl.
In certain embodiments, R 3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 3 is heteroalkyl.
In certain embodiments, R 3 is heterocyclylalkyl.
In certain embodiments, R 3 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, R 3 is alkyl substituted with one or more-OC (O) R 15.
In certain embodiments, R 3 is isopropyl substituted with two-OC (O) R 15, wherein each R 15 is alkyl.
In certain embodiments, R 3 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
In certain embodiments, R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 3 is oxetanyl.
In certain embodiments, the compound of formula (I) has the structure of formula (Ic):
In certain embodiments, each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form
In certain embodiments, R 6 is methyl.
In certain embodiments, R 7 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen OR alkyl.
In certain embodiments, R 7 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen, methyl, ethyl, OR tert-butyl.
In certain embodiments, the compound of formula (I) has the structure of formula (Id):
In certain embodiments, R 4 is hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, R 4 is hydrogen or unsubstituted or substituted alkyl.
In certain embodiments, R 4 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 4 is hydrogen.
In certain embodiments, R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, R 5 is unsubstituted or substituted alkyl.
In certain embodiments, R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In certain embodiments, R 5 is unsubstituted alkyl.
In certain embodiments, R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 5 is alkyl substituted with C (O) OR 13.
In certain embodiments, R 13 is hydrogen or alkyl.
In certain embodiments, R 13 is hydrogen, methyl, ethyl, or tert-butyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 36 to 39, wherein R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 5 is heterocyclylalkyl.
In certain embodiments, R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Wherein-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, R 5 is optionally substituted piperidinyl.
In certain embodiments, R 5 is
In certain embodiments, R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 5 is heteroalkyl.
In certain embodiments, R 5 is unsubstituted or substituted aryl (e.g., phenyl).
In certain embodiments, R 5 is tert-butyl 、-CH(NH2)CH(CH3)2、-CH2N(CH3)2、-CH2CH2OCH3、-CH2CH2NH(CH3)2、-CH2CH2C(CH3)2OC(O)CH3、-CH2CH2C(CH3)2NHC(O)CH3 or-CH 2CH2C(CH3)2NHC(O)OCH2 CH 3.
In certain embodiments, the compound of formula (I) has the structure of formula (Ie):
In certain embodiments, R 4 is hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, R 4 is unsubstituted or substituted alkyl.
In certain embodiments, R 4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 4 is hydrogen.
In certain embodiments, R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, R 5 is unsubstituted or substituted alkyl.
In certain embodiments, R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In certain embodiments, R 5 is unsubstituted alkyl.
In certain embodiments, R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
In certain embodiments, R 5 is heterocyclylalkyl.
In certain embodiments, R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, R 5 is morpholinyl, isopropyl, or ethyl.
In certain embodiments, R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 5 is heteroalkyl.
In certain embodiments, R 5 is unsubstituted or substituted aryl (e.g., phenyl).
In certain embodiments, R 5 is-CH 2CH2NHCH3、-CH2CH 2NHCOCH3 or-CH 2CH2NHCO(O)CH2CH3.
In certain embodiments, the compound of formula (I) has the structure of formula (If):
In certain embodiments, R 4 is hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, R 4 is unsubstituted or substituted alkyl.
In certain embodiments, R 4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 4 is hydrogen.
In certain embodiments, each of R 6 and R 7 is independently alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A.
In certain embodiments, R 6 is hydrogen or methyl, and R 7 is hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form an optionally substituted piperidinyl group.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form
In certain embodiments, the compound of formula (I) has the structure of formula (Ig):
In certain embodiments, each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A.
In certain embodiments, each of R 6 and R 7 is independently hydrogen or alkyl.
In certain embodiments, each of R 6 and R 7 is independently hydrogen or methyl.
In certain embodiments, R 6 and R 7 are each hydrogen.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A.
In certain embodiments, R 6 and R 7 together with the atoms to which they are attached form aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, the compound of formula (I) has the structure of formula (Ih):
In certain embodiments, each of R 11 and R 12 is hydrogen, independently unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, each of R 11 and R 12 is independently hydrogen or unsubstituted or substituted alkyl.
In certain embodiments, each of R 11 and R 12 is independently alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In certain embodiments, each of R 11 and R 12 is independently unsubstituted alkyl.
In certain embodiments, each of R 11 and R 12 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H2.
In certain embodiments, each of R 11 and R 12 is independently alkyl substituted with-OC (O) R 5A, wherein R 5A is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, each of R 11 and R 12 is independently alkyl substituted with-OC (O) OR 16, wherein R 16 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted OR further substituted with one OR more halo, amino, cyano, hydroxy, alkyl, acetyl, OR benzoyl.
In certain embodiments, R 16 is hydrogen or alkyl.
In certain embodiments, R 16 is hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
In certain embodiments, each of R 11 and R 12 is independently heteroalkyl.
In certain embodiments, each of R 11 and R 12 is independently unsubstituted or substituted aryl (e.g., phenyl).
In certain embodiments, the compound of formula (I) has the structure of formula (Ih'):
Wherein the method comprises the steps of
R 4A and R 4A 'are each independently hydrogen or alkyl, and R 5A and R 5A' are each independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 4A and R 4A' are each hydrogen.
In certain embodiments, R 5A and R 5A' are each methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 5A and R 5A' are each isopropyl or tert-butyl.
In certain embodiments, the compound has the structure of formula (Ib'):
Wherein R 6A and R 6A' are each independently hydrogen or alkyl.
In certain embodiments, R 6A and R 6A' are each independently -CH3、-C2H5、C3H7、C4H9、C5H11、C6H13、C7H15、C8H17、C9H19、C10H21、C11H23、C12H25、C13H27、C14H29、C15H31、C16H33 or C 17H35.
In certain embodiments, R 6A and R 6A' are the same.
In certain embodiments, the compound has the structure of formula (Ib "):
Wherein each of R 6A、R1B、R2B and R 3B is independently hydrogen or alkyl.
In certain embodiments, R 6A is -CH3、-C2H5、C3H7、C4H9、C5H11、C6H13、C7H15、C8H17、C9H19、C10H21、C11H23、C12H25、C13H27、C14H29、C15H31、C16H33 or C 17H35.
In certain embodiments, R 1B、R2B and R 3B are each independently alkyl.
In certain embodiments, each of R 1B、R2B and R 3B is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 1B、R2B and R 3B are each methyl.
In certain embodiments, R 1 is hydrogen.
In certain embodiments, the compound of formula (I) has the structure of formula (Ii):
in certain embodiments, each of R 3、R4 and R 5 is independently hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, each of R 3、R4 and R 5 is unsubstituted or substituted alkyl.
In certain embodiments, each of R 3、R4 and R 5 is independently alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In certain embodiments, each of R 3、R4 and R 5 is independently unsubstituted alkyl.
In certain embodiments, each of R 3、R4 and R 5 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 3、R4 and R 5 are the same unsubstituted alkyl.
In certain embodiments, R 3 and R 4 are methyl, ethyl, or isopropyl.
In certain embodiments, R 5 is ethyl, isopropyl, or tert-butyl.
In certain embodiments, (i) R 3 and R 4 are methyl, and R 5 is ethyl; (ii) R 3、R4 and R 5 are isopropyl; or (iii) R 3、R4 and R 5 are ethyl.
In certain embodiments, each of R 3、R4 and R 5 is independently heteroalkyl.
In certain embodiments, each of R 3、R4 and R 5 is independently unsubstituted or substituted aryl (e.g., phenyl).
In certain embodiments, the compound of formula (I) has the structure of formula (Ij):
In certain embodiments, R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In certain embodiments, R 5 is unsubstituted or substituted alkyl.
In certain embodiments, R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In certain embodiments, R 5 is unsubstituted alkyl.
In certain embodiments, R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In certain embodiments, R 5 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen OR alkyl.
In certain embodiments, R 5 is hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In certain embodiments, R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
In certain embodiments, R 5 is heterocyclylalkyl.
In certain embodiments, R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In certain embodiments, the compound of formula (I) is selected from the group consisting of:
/>
/>
In another aspect, provided herein is a compound of formula (II), or a pharmaceutically acceptable salt, solvate, or isotopologue thereof:
Wherein:
r 21 is CH 3、CH2D、CHD2 or CD 3;
Each of R 22 and R 23 is independently hydrogen or alkyl, wherein one or more hydrogens in the alkyl are optionally substituted with deuterium;
Each of Y 1、Y2、Y3、Y4、Y5、Y6、Y7、Y8 and Y 9 is independently hydrogen or deuterium; and
Wherein when R 21 is CH 3 and R 22 and R 23 do not include deuterium, at least one of Y 1、Y2、Y3、Y4、Y5、Y6、Y7、Y8 and Y 9 is deuterium.
In certain embodiments, R 21 is-CH 3.
In certain embodiments, R 21 is-CD 3.
In certain embodiments, R 22 and R 23 are each independently-CH 3、-CH2D、-CH D2 or-CD 3.
In certain embodiments, at least one of R 22 and R 23 comprises deuterium.
In certain embodiments, one of R 22 and R 23 is-CD 3.
In certain embodiments, both R 22 and R 23 are-CD 3.
In certain embodiments, Y 1 is D.
In certain embodiments, Y 3 is D.
In certain embodiments, Y 1 and Y 2 are each D.
In certain embodiments, Y 3 and Y 4 are each D.
In certain embodiments, Y 1、Y2、Y3 and Y 4 are each D.
In certain embodiments, Y 6 is H.
In certain embodiments, the compound of formula (II) is selected from the group consisting of:
In certain embodiments, the compound of formula (I) is a compound described in table 1.
In yet another aspect, provided herein are pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
In yet another aspect, provided herein is a method of treating or preventing a disease, disorder, or condition in which increased levels of dephosphorylated nupharmorin are beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt, solvate, or isotopologue described herein or a pharmaceutical composition described herein.
In certain embodiments, the disease, disorder or condition is selected from post-traumatic stress disorder, major depressive disorder, schizophrenia, alzheimer's disease, frontotemporal dementia, parkinson's disease, parkinson's dementia, dementia with lewy bodies, multiple system atrophy and drug abuse.
Drawings
FIG. 1 shows the average concentration-time profile of dephosphorylated ouabain after Intravenous (IV) administration of dephosphorylated ouabain (1 mg/kg) to male Sprague Dawley (SD) rats.
FIG. 2 shows the average concentration-time profile of dephosphorylated ouabain after oral (PO) administration of dephosphorylated ouabain (2 mg/kg) to male Sprague Dawley (SD) rats.
FIG. 3 shows the average concentration-time profile of metabolite dephosphorylated ouabain after oral administration of ouabain (2 mg/kg) to male Sprague Dawley (SD) rats.
FIG. 4 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-TBDMS ether prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 5 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-TIPS ether prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 6 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-adipate hydrochloride prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 7 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of tetrahydrofuran-3-ester hydrochloride prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 8 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of the trimethyl locked formate prodrug (2 mg/Kg) of dephosphorylated ouabain to male Sprague Dawley (SD) rats.
FIG. 9 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of 2-oxa-6-azaspiro [3.3] heptanecarboxylate formate prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 10 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-TES ether prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 11 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of lysine tri-hydrochloride prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 12 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of an oxazolidine hydrochloride prodrug (2 mg/Kg) of dephosphorylated ouabain to male Sprague Dawley (SD) rats.
FIG. 13 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of morpholinocarbamate hydrochloride prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 14 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-methylethyl carbonate prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 15 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of di-t-butyl phosphonate hydrochloride prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 16 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of Boc-valine formate prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 17 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of Boc-proline formate prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 18 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of phenylalanine dihydrochloride prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 19 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of Boc-phenylalanine formate prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 20 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of Pivaloyloxymethyl (POM) prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 21 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-proline ester dihydrochloride prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 22 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of N-POM ether prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 23 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of N-POM ether O-pivaloyl prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 24 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-methylglutarate ether tert-butyl ester prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 25 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-methylsuccinate ether tert-butyl ester prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 26 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of O-methyl adipate ether tert-butyl ester prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 27 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of valine dihydrochloride prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 28 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of N-Boc-L-phenylalanine-sarcosinate prodrug of dephosphorylated ouabain (2 mg/Kg) to male Sprague Dawley (SD) rats.
FIG. 29 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dimethylglycinate diformate prodrug (2 mg/Kg) of dephosphorylated ouabain to male Sprague Dawley (SD) rats.
Detailed Description
Described herein are compound analogs, including prodrugs and deuterated analogs of desphosphoric acid galectin. The prodrug analog of the des-phosphate nupharicin can be metabolically converted to the des-phosphate nupharicin or a derivative thereof upon administration to a subject. The compounds disclosed herein may be useful in the treatment of neurological disorders such as psychotic disorders, substance abuse disorders, or conditions in which increasing neuronal plasticity would be beneficial.
And (5) defining.
The compounds herein may include all stereoisomers, enantiomers, diastereomers, mixtures, racemates, atropisomers and tautomers thereof.
Any of the compounds disclosed herein may be substituted unless otherwise specified. Non-limiting examples of optional substituents include hydroxy, mercapto, halogen, amino, nitro, nitroso, cyano, azido, sulfoxide, sulfone, sulfonamide, carboxyl, formaldehyde, imine, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, alkoxy, aryl, aryloxy, aralkyl, arylalkoxy, heterocyclylalkyl, heteroaryl, cycloalkyl, acyl, acyloxy, carbamate, amide, urea, epoxy, and ester groups.
Non-limiting examples of alkyl groups include straight, branched, and cyclic alkyl groups and alkylene groups. Alkyl groups may be, for example, substituted or unsubstituted C1、C2、C3、C4、C5、C6、C7、C8、C9、C10、C11、C12、C13、C14、C15、C16、C17、C18、C19、C20、C21、C22、C23、C24、C25、C26、C27、C28、C29、C30、C31、C32、C33、C34、C35、C36、C37、C38、C39、C40、C41、C42、C43、C44、C45、C46、C47、C48、C49 or C 50 groups.
Alkyl groups may include branched and unbranched alkyl groups. Non-limiting examples of straight chain alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.
Branched alkyl includes any linear alkyl substituted with any number of alkyl groups. Non-limiting examples of branched alkyl groups include isopropyl, isobutyl, sec-butyl, and tert-butyl.
Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1, 2-difluoroethyl and 3-carboxypropyl.
Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl also includes fused, bridged and spiro-bicyclic and higher fused, bridged and spiro-systems. Cycloalkyl groups may be substituted with any number of straight, branched or cyclic alkyl groups. Non-limiting examples of cycloalkyl include cyclopropyl, 2-methyl-cyclopropyl-1-yl, cyclopropyl-2-en-1-yl, cyclobutyl, 2, 3-dihydroxycyclobut-1-yl, cyclobut-2-en-1-yl, cyclopentyl, cyclopent-2-en-1-yl, cyclopent-2, 4-dien-1-yl, cyclohexyl, cyclohex-2-en-1-yl, cycloheptyl, cyclooctyl, 2, 5-dimethylcyclopent-1-yl, 3, 5-dichlorocyclohex-1-yl, 4-hydroxycyclohex-1-yl, 3, 5-trimethylcyclohex-1-yl, octahydropentenyl, octahydro-1H-indenyl, 3a,4,5,6,7 a-hexahydro-3H-inden-4-yl, decahydro azulenyl, bicyclo- [2.1.1] hexyl, bicyclo [2.2.1] heptyl, bicyclo [3.1.1] heptyl, 4-hydroxy-1, 3, 2.2.1-bicyclooctyl ] 2.2.2-undecyl and bicyclo [ 2.3.2.3 ] bicyclo-1-yl.
Non-limiting examples of alkenyl groups include straight chain, branched, and cyclic alkenyl groups. The one or more olefins of the alkenyl group may be, for example, E, Z, cis, trans, terminal or exomethylene. Alkenyl groups may be, for example, substituted or unsubstituted C2、C3、C4、C5、C6、C7、C8、C9、C10、C11、C12、C13、C14、C15、C16、C17、C18、C19、C20、C21、C22、C23、C24、C25、C26、C27、C28、C29、C30、C31、C32、C33、C34、C35、C36、C37、C38、C39、C40、C41、C42、C43、C44、C45、C46、C47、C48、C49 or C 50 groups. Non-limiting examples of alkenyl and alkenylene groups include vinyl, prop-1-en-1-yl, isopropenyl, but-1-en-4-yl; 2-chlorovinyl, 4-hydroxybuten-1-yl, 7-hydroxy-7-methylooct-4-en-2-yl and 7-hydroxy-7-methylooct-3, 5-dien-2-yl.
Non-limiting examples of alkynyl groups include straight, branched, and cyclic alkynyl groups. The triple bond of the alkynyl group may be internal or terminal. Alkynyl or alkynylene groups may be, for example, substituted or unsubstituted C2、C3、C4、C5、C6、C7、C8、C9、C10、C11、C12、C13、C14、C15、C16、C17、C18、C19、C20、C21、C22、C23、C24、C25、C26、C27、C28、C29、C30、C31、C32、C33、C34、C35、C36、C37、C38、C39、C40、C41、C42、C43、C44、C45、C46、C47、C48、C49 or C 50 groups. Non-limiting examples of alkynyl groups include ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, and 2-methyl-hex-4-yn-1-yl; 5-hydroxy-5-methylhex-3-yn-1-yl, 6-hydroxy-6-methylhept-3-yn-2-yl and 5-hydroxy-5-ethylhept-3-yn-1-yl.
Haloalkyl can be any alkyl substituted with any number of halogen atoms (e.g., fluorine, chlorine, bromine, and iodine atoms). The haloalkenyl group may be any alkenyl group substituted with any number of halogen atoms. A haloalkynyl group may be any alkynyl group substituted with any number of halogen atoms.
Alkoxy groups may be, for example, oxygen atoms substituted with any alkyl, alkenyl or alkynyl groups. The ether or ether group comprises an alkoxy group. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy.
A heterocycle may be any ring containing a ring atom other than carbon (e.g., N, O, S, P, si, B, or any other heteroatom). The heterocycle may be substituted with any number of substituents (e.g., alkyl groups and halogen atoms). The heterocycle may be aromatic (heteroaryl) or non-aromatic. Non-limiting examples of heterocycles include pyrrole, pyrrolidine, pyridine, piperidine, succinimide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran, and tetrahydropyran.
Non-limiting examples of heterocycles include: non-limiting examples of heterocyclic units having a single ring containing one or more heteroatoms include diazacyclopropenyl, aziridinyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, oxathiazolidinonyl, oxazolidinonyl, hydantoin, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl, 2,3,4, 5-tetrahydro-1H-azetidinyl, 2, 3-dihydro-1H-indole, and 1,2,3, 4-tetrahydroquinoline; and ii) a heterocyclic unit having 2 or more rings, one of which is a heterocyclic ring, non-limiting examples of which include hexahydro-1H-pyrrolizinyl, 3a,4,5,6,7 a-hexahydro-1H-benzo [ d ] imidazolyl, 3a,4,5,6,7 a-hexahydro-1H-indolyl, 1,2,3, 4-tetrahydroquinolinyl and decahydro-1H-cycloocta [ b ] pyrrolyl.
Non-limiting examples of heteroaryl groups include: i) Heteroaryl rings containing a single ring, non-limiting examples of which include 1,2,3, 4-tetrazolyl, [1,2,3] triazolyl, [1,2,4] triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thienyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl; and ii) a heteroaryl ring containing 2 or more fused rings, one of which is a heteroaryl ring, non-limiting examples of which include: 7H-purinyl, 9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo [3,2-d ] pyrimidinyl, 7H-pyrrolo [2,3-d ] pyrimidinyl, pyrido [2,3-d ] pyrimidinyl, 4,5,6, 7-tetrahydro-1-H-indolyl, quinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl and isoquinolinyl.
"Alkyl" refers to an optionally substituted straight or optionally substituted branched saturated hydrocarbon having from one to about ten carbon atoms, or from one to six carbon atoms, wherein the sp 3 hybridized carbon of the alkyl residue is attached to the remainder of the molecule by a single bond. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2-dimethyl-1-butyl, 3-dimethyl-1-butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, Isopentyl, neopentyl, tertiary pentyl and hexyl, and longer alkyl groups such as heptyl, octyl and the like. Whenever it appears herein, a numerical range such as "C 1-C6 alkyl" means that the alkyl consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, however the present definition also covers the appearance of the term "alkyl" without specifying a numerical range. In some embodiments, alkyl is C 1-C10 alkyl, C 1-C9 alkyl, C 1-C8 alkyl, C 1-C7 alkyl, C 1-C6 alkyl, C 1-C5 alkyl, C 1-C4 alkyl, C 1-C3 alkyl, C 1-C2 alkyl, or C 1 alkyl. Unless otherwise specifically indicated in the specification, alkyl groups are optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxy, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, alkyl is optionally substituted with oxo, halogen, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, alkyl is optionally substituted with oxo, halogen, -CN, -CF 3, -OH, or-OMe. In some embodiments, the alkyl group is optionally substituted with halo.
"Alkenyl" refers to an optionally substituted straight or optionally substituted branched hydrocarbon having one or more carbon-carbon double bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms, wherein the sp 2 hybridized carbon of the alkenyl residue is attached to the remainder of the molecule by a single bond. The group may be in cis or trans configuration with respect to the double bond and is understood to include both isomers. Examples include, but are not limited to, vinyl (-ch=ch 2), 1-propenyl (-CH 2CH=CH2), isopropenyl [ -C (CH 3)=CH2), butenyl, 1, 3-butadienyl, and the like. Whenever it appears herein, a numerical range such as "C 2-C6 alkenyl" means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, however the present definition also covers the occurrence of the term "alkenyl" for which a numerical range is not specified. In some embodiments, the alkenyl is C 2-C10 alkenyl, C 2-C9 alkenyl, C 2-C8 alkenyl, C 2-C7 alkenyl, C 2-C6 alkenyl, C 2-C5 alkenyl, C 2-C4 alkenyl, C 2-C3 alkenyl, or C 2 alkenyl. Unless otherwise specifically indicated in the specification, alkenyl groups are optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxy, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, alkenyl is optionally substituted with oxo, halogen, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, alkenyl is optionally substituted with oxo, halogen, -CN, -CF 3, -OH, or-OMe. In some embodiments, alkenyl is optionally substituted with halo.
"Alkynyl" refers to an optionally substituted straight or optionally substituted branched hydrocarbon having one or more carbon-carbon triple bonds and from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1, 3-butadiynyl, and the like. Whenever it appears herein, a numerical range such as "C 2-C6 alkynyl" means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, however the present definition also covers the occurrence of the term "alkynyl" where a numerical range is not specified. In some embodiments, the alkynyl is C 2-C10 alkynyl, C 2-C9 alkynyl, C 2-C8 alkynyl, C 2-C7 alkynyl, C 2-C6 alkynyl, C 2-C5 alkynyl, C 2-C4 alkynyl, C 2-C3 alkynyl, or C 2 alkynyl. Unless explicitly stated otherwise in the specification, alkynyl groups are optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxy, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, alkynyl is optionally substituted with oxo, halogen, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, alkynyl is optionally substituted with oxo, halogen, -CN, -CF 3, -OH, or-OMe. In some embodiments, alkynyl is optionally substituted with halo.
"Alkoxy" refers to a group of formula-OR a, wherein R a is alkyl as defined. Unless otherwise specifically indicated in the present specification, an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxy, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, the alkoxy group is optionally substituted with oxo, halogen, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, the alkoxy group is optionally substituted with oxo, halogen, -CN, -CF 3, -OH, or-OMe. In some embodiments, the alkoxy group is optionally substituted with halogen.
"Aminoalkyl" refers to an alkyl group as defined above substituted with one or more amines. In some embodiments, the alkyl group is substituted with one amine. In some embodiments, the alkyl group is substituted with one, two, or three amines. Hydroxyalkyl includes, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl or aminopentyl. In some embodiments, the hydroxyalkyl group is an aminomethyl group.
"Aryl" refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms, and at least one aromatic ring. Aryl groups may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may include fused rings (when fused to a cycloalkyl or heterocyclylalkyl ring, the aryl groups are bonded through an aromatic ring atom) or bridged ring systems. In some embodiments, the aryl is a6 to 10 membered aryl. In some embodiments, the aryl is a6 membered aryl. Aryl groups include, but are not limited to, those derived from anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene,Aryl groups of hydrocarbon ring systems of fluoranthene, fluorene, asymmetric indacene, symmetric indacene, indane, indene, naphthalene, phenalene, phenanthrene, obsidian, pyrene, and triphenylene. In some embodiments, the aryl group is phenyl. Unless otherwise specifically indicated in the present specification, aryl groups may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3, -OH, or-OMe. In some embodiments, aryl is optionally substituted with halo.
"Cycloalkyl" refers to a stable, partially or fully saturated, monocyclic or polycyclic carbocycle, which may include fused rings (which cycloalkyl is bonded through a non-aromatic ring atom when fused to an aryl or heteroaryl ring), bridged rings, or spiro ring systems. Representative cycloalkyl groups include, but are not limited to, cycloalkyl groups having three to fifteen carbon atoms (C 3-C15 cycloalkyl), three to ten carbon atoms (C 3-C10 cycloalkyl), three to eight carbon atoms (C 3-C8 cycloalkyl), three to six carbon atoms (C 3-C6 cycloalkyl), three to five carbon atoms (C 3-C5 cycloalkyl), or three to four carbon atoms (C 3-C4 cycloalkyl). In some embodiments, cycloalkyl is 3 to 6 membered cycloalkyl. In some embodiments, cycloalkyl is 5-to 6-membered cycloalkyl. Monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl or carbocycles include, for example, adamantyl, norbornyl, decalinyl, bicyclo [3.3.0] octane, bicyclo [4.3.0] nonane, cis decalin, trans decalin, bicyclo [2.1.1] hexane, bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, bicyclo [3.2.2] nonane and bicyclo [3.3.2] decane, and 7, 7-dimethyl-bicyclo [2.2.1] heptyl. Partially saturated cycloalkyl groups include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless explicitly stated otherwise in the specification, cycloalkyl is optionally substituted, for example, by oxo, halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3, -OH, or-OMe. In some embodiments, cycloalkyl is optionally substituted with halo.
"Deuterated alkyl" refers to an alkyl group as defined above substituted with one or more deuterium. In some embodiments, the alkyl group is substituted with one deuterium. In some embodiments, the alkyl group is substituted with one, two, or three deuterium. In some embodiments, the alkyl group is substituted with one, two, three, four, five, or six deuterium. Deuterated alkyl includes (e.g., )CD3、CH2D、CHD2、CH2CD3、CD2CD3、CHDCD3、CH2CH2D or CH 2CHD2. In some embodiments, deuterated alkyl is CD 3.
"Haloalkyl" refers to an alkyl group as defined above substituted with one or more halogens. In some embodiments, the alkyl is substituted with one, two, or three halogens. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six halogens. Haloalkyl includes, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2-trifluoroethyl, 1, 2-difluoroethyl, 3-bromo-2-fluoropropyl, 1, 2-dibromoethyl and the like. In some embodiments, the haloalkyl is trifluoromethyl.
"Halo" or "halogen" refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine or chlorine. In some embodiments, the halogen is fluorine.
"Heteroalkyl" refers to an alkyl group in which one or more backbone atoms of the alkyl group are selected from atoms other than carbon (e.g., oxygen, nitrogen (e.g., -NH-, -N (alkyl) -), sulfur, or a combination thereof). The heteroalkyl group is attached to the remainder of the molecule at a carbon atom of the heteroalkyl group. In one aspect, the heteroalkyl is a C 1-C6 heteroalkyl, wherein the heteroalkyl contains 1 to 6 carbon atoms and one or more atoms other than carbon, for example, oxygen, nitrogen (e.g., -NH-, -N (alkyl) -), sulfur, or a combination thereof, wherein the heteroalkyl is attached to the remainder of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyl groups are (e.g., )-CH2OCH3、-CH2CH2OCH3、-CH2CH2OCH2CH2OCH3 or-CH (CH 3)OCH3. Unless specifically indicated otherwise in this specification, heteroalkyl groups are optionally substituted, e.g., with oxo, halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, etc.. In some embodiments, heteroalkyl groups are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, heteroalkyl groups are optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3, -OH, or-OMe.
"Hydroxyalkyl" refers to an alkyl group as defined above substituted with one or more hydroxy groups. In some embodiments, the alkyl group is substituted with one hydroxy group. In some embodiments, the alkyl group is substituted with one, two, or three hydroxyl groups. Hydroxyalkyl includes, for example, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl or hydroxypentyl. In some embodiments, the hydroxyalkyl group is hydroxymethyl.
"Heterocyclylalkyl" refers to a stable 3-to 24-membered partially or fully saturated cyclic group containing 2 to 23 carbon atoms and 1 to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus and sulfur. Unless explicitly stated otherwise in the specification, the heterocyclylalkyl groups may be monocyclic, bicyclic, tricyclic or tetracyclic ring systems, which may include fused rings (when fused to an aryl or heteroaryl ring, the heterocyclylalkyl groups are bonded through non-aromatic ring atoms) or bridged ring systems; and the nitrogen, carbon or sulfur atom in the heterocyclylalkyl group may optionally be oxidized; the nitrogen atom may optionally be quaternized.
Representative heterocyclylalkyl groups include, but are not limited to, heterocyclylalkyl groups having from two to fifteen carbon atoms (C 2-C15 heterocyclylalkyl), from two to ten carbon atoms (C 2-C10 heterocyclylalkyl), from two to eight carbon atoms (C 2-C8 heterocyclylalkyl), from two to six carbon atoms (C 2-C6 heterocyclylalkyl), from two to five carbon atoms (C 2-C5 heterocyclylalkyl), or from two to four carbon atoms (C 2-C4 heterocyclylalkyl). In some embodiments, the heterocyclylalkyl is a 3-to 6-membered heterocyclylalkyl. In some embodiments, cycloalkyl is 5-to 6-membered heterocyclylalkyl. Examples of such heterocyclylalkyl groups include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, thienyl [1,3] dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl (thiomorpholinyl), thiomorpholinyl (thiamorpholinyl), 1-oxo-thiomorpholinyl, 1-dioxo-thiomorpholinyl, 1, 3-dihydroisobenzofuran-1-yl, 3-oxo-1, 3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1, 3-dioxol-4-yl and 2-oxo-1, 3-dioxol-4-yl. The term heterocyclylalkyl also includes all cyclic forms of carbohydrates, including but not limited to monosaccharides, disaccharides, and oligosaccharides. It will be appreciated that when referring to the number of carbon atoms in a heterocyclylalkyl group, the number of carbon atoms in the heterocyclylalkyl group is different from the total number of atoms (including heteroatoms) that make up the heterocyclylalkyl group (i.e., the backbone atoms of the heterocyclylalkyl ring). Unless otherwise specifically indicated in the specification, heterocyclylalkyl groups are optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, the heterocyclylalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, the heterocyclylalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3, -OH, or-OMe. In some embodiments, the heterocyclylalkyl is optionally substituted with halo. In one embodiment, the heterocyclylalkyl is
"Heteroaryl" means a 5-to 14-membered ring system group comprising a hydrogen atom, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorus and sulfur, and at least one aromatic ring. Heteroaryl groups may be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which may include fused rings (when fused to a cycloalkyl or heterocyclylalkyl ring, heteroaryl groups are bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl group may optionally be oxidized; the nitrogen atom may optionally be quaternized. In some embodiments, the heteroaryl is a 5-to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5-to 6-membered heteroaryl. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo [ b ] [1,4] dioxazolyl, 1, 4-benzodioxanyl, benzonaphtalenofuranyl, benzoxazolyl, benzodioxolyl, benzodioxanyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo [4,6] imidazo [1,2-a ] pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothienyl, furanyl, furanonyl, isothiazolyl imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolinyl, indolazinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxopyridinyl, 1-oxopyrazinyl, 1-oxopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless otherwise specifically indicated in the specification, heteroaryl groups are optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxy, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocyclylalkyl, heteroaryl, and the like. In some embodiments, heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3、-OH、-OMe、-NH2, or-NO 2. In some embodiments, heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3, -OH, or-OMe. In some embodiments, heteroaryl is optionally substituted with halo.
Any of the compounds herein may be purified. The compounds herein may be at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 41%, at least 42%, at least 36%, at least at least 43% pure, at least 44% pure, at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure, at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure, at least 84% pure, at least, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure, at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure.
Pharmaceutically acceptable salts.
The present disclosure provides for the use of pharmaceutically acceptable salts of any of the compounds described herein. Pharmaceutically acceptable salts include, for example, acid addition salts and base addition salts. The acid that may be added to the compound to form the acid addition salt may be an organic acid or an inorganic acid. The base that may be added to the compound to form the base addition salt may be an organic base or an inorganic base. In some embodiments, the pharmaceutically acceptable salt is a metal salt. In some embodiments, the pharmaceutically acceptable salt is an ammonium salt.
The metal salt may result from the addition of an inorganic base to the compounds of the present disclosure. Inorganic bases consist of metal cations paired with basic counter ions such as, for example, hydroxides, carbonates, bicarbonates or phosphates. The metal may be an alkali metal, an alkaline earth metal, a transition metal, or a main group metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.
In some embodiments, the metal salt is a lithium salt, sodium salt, potassium salt, cesium salt, cerium salt, magnesium salt, manganese salt, iron salt, calcium salt, strontium salt, cobalt salt, titanium salt, aluminum salt, copper salt, cadmium salt, or zinc salt.
Ammonium salts may be produced by adding ammonia or an organic amine to the compounds of the present disclosure. In some embodiments, the organic amine is trimethylamine, triethylamine, diisopropylamine, ethanolamine, diethanolamine, triethanolamine, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, benzhydrylamine, piperazine, pyridine, pyrazole, pyrazolidine, pyrazoline, pyridazine, pyrimidine, imidazole, or pyrazine.
In some embodiments, the ammonium salt is a triethylamine salt, trimethylamine salt, diisopropylamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, morpholine salt, N-methylmorpholine salt, piperidine salt, N-methylpiperidine salt, N-ethylpiperidine salt, benzhydryl amine salt, piperazine salt, pyridine salt, pyrazole salt, pyridazine salt, pyrimidine salt, imidazole salt, or pyrazine salt.
Acid addition salts may result from the addition of an acid to the compounds of the present disclosure. In some embodiments, the acid is organic. In some embodiments, the acid is inorganic. In some embodiments, the acid is hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisic acid, gluconic acid, glucuronic acid, glucaric acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, oxalic acid, or maleic acid.
In some embodiments, the salt is a hydrochloride, hydrobromide, hydroiodide, nitrate, nitrite, sulfate, sulfite, phosphate, isonicotinate, lactate, salicylate, tartrate, ascorbate, gentisate, gluconate, glucuronate, glucarate, formate, benzoate, glutamate, pantothenate, acetate, propionate, butyrate, fumarate, succinate, mesylate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, citrate, oxalate, or maleate.
Pharmaceutical compositions.
According to another embodiment, the present disclosure provides a composition comprising a compound of the present disclosure and a pharmaceutically acceptable carrier, adjuvant or vehicle. The amount of the compound in the composition is an amount effective to treat the relevant disease, disorder or condition in a patient in need thereof ("effective amount"). In some embodiments, the compositions of the present disclosure are formulated for oral administration to a patient.
The term "pharmaceutically acceptable carrier, adjuvant or vehicle" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the formulation with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the disclosed compositions include, but are not limited to, ion exchangers, alumina, stearates such as aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin.
The compositions of the present disclosure may be administered orally, parenterally, enterally, intracisternally, intraperitoneally, by inhalation spray, topically, rectally, nasally, bucally, vaginally, or via an implantable reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In some embodiments, the composition is administered orally, intraperitoneally, or intravenously. In some embodiments, the composition is a transmucosal formulation. The sterile injectable form of the compositions of the present disclosure may be an aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in l, 3-butanediol. Acceptable vehicles and solvents that may be employed are water, ringer's solution, and isotonic sodium chloride solution. In addition, sterile, nonvolatile oils are conventionally employed as a solvent or suspending medium.
To aid in the delivery of the composition, any bland fixed oil may be employed including synthetic mono-or diglycerides. Fatty acids (such as oleic acid and its glyceride derivatives) are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents, which are commonly used in the formulation of pharmaceutically acceptable dosage forms (including emulsions and suspensions). Other commonly used surfactants commonly used in the manufacture of pharmaceutically acceptable solid, liquid or other dosage forms (such as Tweens, spans, and other emulsifying agents or bioavailability enhancers) may also be used for formulation purposes.
The pharmaceutically acceptable composition may be administered orally in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, common carriers include lactose and corn starch. A lubricant (such as magnesium stearate) may also be added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweeteners, flavoring agents or coloring agents may also be added.
Or the pharmaceutically acceptable composition may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
In some embodiments, the pharmaceutically acceptable composition is formulated for oral administration. Such formulations may be administered with or without feeding. In some embodiments, the pharmaceutically acceptable composition is administered without feeding. In other embodiments, the pharmaceutically acceptable composition is administered in the presence of food.
It will also be appreciated that the particular dosage and treatment regimen for any particular patient will depend upon a variety of factors including the activity of the particular compound employed, the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water, or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable formulations (e.g., sterile injectable aqueous or oleaginous suspensions) may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in l, 3-butanediol. Acceptable vehicles and solvents that may be employed are water, ringer's solution, u.s.p. And isotonic sodium chloride solution. In addition, sterile, nonvolatile oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids (such as oleic acid) are useful in the preparation of injectables.
The injectable formulation may be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which may be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
To prolong the effect of the compounds of the present disclosure, it may be desirable to slow down the absorption of the compounds from subcutaneous or intramuscular injection. This can be done by using a liquid suspension of a poorly water-soluble crystalline or amorphous material. The absorption rate of a compound then depends on its dissolution rate, which in turn may depend on crystal size and crystalline form. Or delayed absorption of the parenterally administered compound form is performed by dissolving or suspending the compound in an oil vehicle. The injectable depot form (depot form) is made by forming a microcapsule matrix of the compound in a biodegradable polymer such as polylactide-polyglycidylester. Depending on the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions which are compatible with body tissues.
Compositions for rectal or vaginal administration are preferably suppositories, which can be prepared by mixing the compounds of the present disclosure with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) Binders such as, for example, carboxymethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; c) Humectants, such as glycerin; d) Disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) Dissolution retarders such as paraffin; f) Absorption enhancers such as quaternary ammonium compounds; g) Wetting agents such as, for example, cetyl alcohol and glycerol monostearate; h) Absorbents such as kaolin and bentonite; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid compositions of a similar type may also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose (lactos e or milk sugar) and high molecular weight polyethylene glycols and the like. Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulating art. It may optionally contain an opacifying agent and may also have a composition which releases the active ingredient only, or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be used as fillers in soft and hard filled gelatin capsules using excipients such as lactose and high molecular weight polyethylene glycols and the like.
The therapeutic agent may also be in microencapsulated form together with one or more excipients as noted above. Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, controlled release coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also contain, in accordance with conventional practice, additional substances other than inert diluents, for example, tabletting lubricants and other tabletting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. It may optionally contain an opacifying agent and may also have a composition which releases the active ingredient only, or preferentially in a certain part of the intestinal tract, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
Dosage forms for topical or transdermal administration of the compounds of the present disclosure include ointments, pastes, creams, emulsions, gels, powders, solutions, sprays, inhalants or patches. The active ingredient may be admixed under sterile conditions with a pharmaceutically acceptable carrier and any required preservatives or buffers, as required. Ophthalmic formulations, ear drops, and eye drops are also contemplated as falling within the scope of the present disclosure. In addition, the present disclosure contemplates the use of transdermal patches that have the added advantage of providing controlled delivery of the compound into the body. Such dosage forms may be prepared by dissolving or dispersing the compound in a suitable medium. Absorption enhancers may also be used to increase the flux of a compound across the skin. The rate may be controlled by providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
Compounds of formula (I)
In one aspect, disclosed herein are dephosphorylated galectin analogs.
Provided herein are compounds of formula (I), or a pharmaceutically acceptable salt, solvate, or isotopologue thereof:
Wherein:
r 1 is hydrogen, -OH, unsubstituted OR substituted alkyl, -OR, OR C (O) OR; wherein R is unsubstituted alkyl;
R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7、-CH(R4)OC(O)NR6R7、-S(O)2NR6R7、-S(O)2OR5、-P(O)OR8(NR9R10)、-P(O)(OR11)(OR12)、-CH(R4)OP(O)(OR11)(OR12) or-Si (R 3)(R4)(R5);
Each of R 3、R4、R5 and R 8 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A;
Each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A; or R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A;
each of R 9 and R 10 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A, or R 9 and R 10 together with the atom to which they are attached form a heterocyclylalkyl ring or heteroaryl ring that is unsubstituted or substituted with one or more R A;
Each of R 11 and R 12 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A;
Each R A is independently alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl is unsubstituted OR substituted with one OR more alkyl, aryl, halogen 、-S-R13、-OR13、-NR(R18)R19、-C(O)R14、-OC(O)R15、-OC(O)OR16, OR-OC (O) N (R 18)R19;
Each of R 13、R14、R15、R16 or R 17 is independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or substituted with one or more R B;
Each of R 18 and R 19 is independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R B; or R 18 and R 19 together with the atoms to which they are attached form a heterocyclylalkyl ring or heteroaryl ring, each of which is unsubstituted or substituted with one or more R B;
Each R B is independently halogen, amino, cyano, hydroxy, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, -OC (O) R 18、-C(O)R18、-C(O)OR18、NHC(O)OR18, or heteroarylalkyl, wherein cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more halogen, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 1 is hydrogen, -OH, unsubstituted OR substituted alkyl, OR C (O) OR; wherein R is unsubstituted alkyl. In some embodiments, R 1 is hydrogen or unsubstituted or substituted alkyl. In some embodiments, R 1 is hydrogen. In some embodiments, R 1 is unsubstituted or substituted alkyl. In some embodiments, R 1 is unsubstituted alkyl. In some embodiments, R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 1 is methyl.
In some embodiments, R is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R is methyl.
In some embodiments, R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7、-CH(R4)OC(O)NR6R7、-S(O)2NR6R7、-P(O)OR8(NR9R10) OR-P (O) (OR 11)(OR12).
In some embodiments, R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7、-CH(R4)OC(O)NR6R7、-P(O)OR8(NR9R10) OR-P (O) (OR 11)(OR12).
In some embodiments, R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7、-CH(R4)OC(O)NR6R7 or-S (O) 2NR6R7.
In some embodiments, R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7、-CH(R4)OC(O)NR6R7、-S(O)2NR6R7 OR-P (O) (OR 11)(OR12).
In some embodiments, R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7、-CH(R4)OC(O)NR6R7、-S(O)2NR6R7 OR-P (O) OR 8(NR9R10.
In some embodiments, R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7 or-CH (R 4)OC(O)NR6R7. In some embodiments, R 2 is -C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7 or-CH (R 4)OC(O)NR6R7. In some embodiments, R 2 is -C(O)R3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7 or-CH (R 4)OC(O)NR6R7. In some embodiments, R 2 is-C (O) R 3、-C(O)OR3、-CH(R4)OC(O)OR5、-C(O)NR6R7 or-CH (R 4)OC(O)NR6R7. In some embodiments, R 2 is-C (O) R 3、-C(O)OR3、-CH(R4)OC(O)R5、-C(O)NR6R7 or-CH (R 4)OC(O)NR6R7). In some embodiments, R 2 is-C (O) R 3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5 or-CH (R 4)OC(O)NR6R7. In some embodiments, R 2 is-C (O) R 3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5 or-C (O) NR 6R7.
In some embodiments, R 2 is-C (O) R 3、-C(O)OR3 or-C (O) NR 6R7. In some embodiments, R 2 is-C (O) OR 3 OR-C (O) NR 6R7. In some embodiments, R 2 is-C (O) R 3 or-C (O) NR 6R7. In some embodiments, R 2 is-C (O) R 3 OR-C (O) OR 3. In some embodiments, R 2 is-CH (R 4)OC(O)R5、-CH(R4)OC(O)OR5 or-CH (R 4)OC(O)NR6R7. In some embodiments, R 2 is-CH (R 4)OC(O)OR5 or-CH (R 4)OC(O)NR6R7. In some embodiments, R 2 is-CH (R 4)OC(O)R5 or-CH (R 4)OC(O)NR6R7. In some embodiments, R 2 is-CH (R 4)OC(O)R5 or-CH (R 4)OC(O)OR5).
In some embodiments, R 2 is-C (O) R 3. In some embodiments, R 2 is-C (O) OR 3. In some embodiments, R 2 is-CH (R 4)OC(O)R5. In some embodiments, R 2 is-CH (R 4)OC(O)OR5. In some embodiments, R 2 is-C (O) NR 6R7. In some embodiments, R 2 is-CH (R 4)OC(O)NR6R7).
In some embodiments, R 2 is-S (O) 2NR6R7、-P(O)OR8(NR9R10) OR-P (O) (OR 11)(OR12).
In some embodiments, R 2 is-S (O) 2NR6R7.
In some embodiments, R 2 is-P (O) OR 8(NR9R10) OR-P (O) (OR 11)(OR12).
In some embodiments, R 2 is-P (O) OR 8(NR9R10.
In some embodiments, R 2 is OR-P (O) (OR 11)(OR12).
Ester prodrugs
In some embodiments of the compounds of formula (I), the compounds have the structure of formula (Ia):
In some embodiments, R 3 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In some embodiments, R 3 is unsubstituted or substituted alkyl. In some embodiments, R 3 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In some embodiments, R 3 is unsubstituted alkyl. In some embodiments, R 3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In some embodiments, R 3 is alkyl substituted with-C (O) OR 13. In some embodiments, R 13 is hydrogen or alkyl. In some embodiments, R 13 is hydrogen, methyl, ethyl, or tert-butyl.
In some embodiments, R 3 is
In some embodiments, R 3 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In some embodiments, R 3 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
In some embodiments, R 3 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, benzoyl, phenyl, or NH-Boc.
In some embodiments, R 3 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
In some embodiments, R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 3 is heterocyclylalkyl.
In some embodiments, R 3 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe-.
In some embodiments, R 3 is heterocyclylalkyl. In some embodiments, R 3 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe. In some embodiments, R 3 is/>In some embodiments, R 3 is oxetanyl.
In some embodiments, R 3 is heteroalkyl.
In some embodiments, R 3 is unsubstituted or substituted aryl (e.g., phenyl). In some embodiments, R 3 is substituted phenyl. In some embodiments, R 3 is phenyl substituted with-OC (O) R 18, wherein R 18 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R B.
In some embodiments, R 3 isWherein R C is the side chain of a natural amino acid and R' is hydrogen or-Boc. In some embodiments, R 3 is/>
In some embodiments, R 3 is selected from the group consisting of alkyl, cycloalkyl, substituted alkyl, substituted cycloalkyl, vinyl, aryl, heteroaryl, substituted aryl, and substituted heteroaryl. In some embodiments, R 3 is selected from the group consisting of hydrogen, -CD 3, et, n-Pr, iPr, tBu, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, CH 2CF3、-CH2 -cyclopropyl, ph, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, and 6-pyrimidinyl.
In some embodiments, R 3 is alkyl or heteroalkyl. In some embodiments, R 3 is unsubstituted alkyl or unsubstituted heteroalkyl. In some embodiments, R 3 is alkyl. In some embodiments, R 3 is unsubstituted alkyl. In some embodiments, R 1 is methoxy and R 3 is alkyl. In some embodiments, R 1 is methoxy and R 3 is unsubstituted alkyl. In some embodiments, R 1 is hydrogen and R 3 is alkyl. In some embodiments, R 1 is hydrogen and R 3 is unsubstituted alkyl.
In some embodiments, R 3 is heteroalkyl. In some embodiments, R 3 is unsubstituted heteroalkyl. In some embodiments, R 3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, or 3-methyl-1-butyl. In some embodiments, R 3 is aryl. In some embodiments, R 3 is phenyl. In some embodiments, R 3 is heterocyclylalkyl. In some embodiments, R 3 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, or 6-pyrimidinyl. In some embodiments, R 3 is ethyl. In some embodiments, R 1 is hydrogen and R 3 is ethyl. In some embodiments, R 1 is methoxy and R 3 is ethyl. In some embodiments, R 3 is alkyl substituted with heteroaryl. In some embodiments, R 3 isIn some embodiments, R 1 is methoxy and R 3 isIn some embodiments, R 1 is hydrogen and R 3 is/>
In some embodiments, the compound of formula (Ia) has a formula selected from the group consisting of:
Wherein each occurrence of R' is independently hydrogen or methyl; each occurrence of X is-CH 2-、-O-、-S-、-SO2 -, -NH-or-NMe-; r C1 is H, me, CH 2Ph、CH2CH(CH 3)2、CH(CH3)CH2CH3 or CH 2CH2SCH3;RC2 and R C3 are each H, CH 3 or CH 2CH3; and each occurrence of R C4 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, benzoyl, phenyl, or NH-Boc. In certain embodiments of formula (Iaa), R C1 is H, me, CH 2Ph、CH2CH(Me)2、CH(CH3)CH2CH3, or CH 2CH2SCH3. In certain embodiments of formula (Iac), R C2 and R C3 are each H, CH 3 or CH 2CH3. In certain embodiments of formula (Iac), R C2 and R C3 are each CH 3. In certain embodiments, R C4 is selected from the group consisting of hydrogen, -CD3, et, n-Pr, iPr, tBu, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, CH 2CF3、-CH2 -cyclopropyl, ph, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, and 6-pyrimidinyl.
In some embodiments, the compound of formula (Ia) is selected from the group consisting of:
Trimethyl lock prodrug
In some embodiments, the compound of formula (Ia) has the structure of formula (Ial):
Wherein R C5 is selected from the group consisting of hydrogen, -CD 3, et, n-Pr, iPr, tBu, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, CH 2CF3、-CH2 -cyclopropyl, ph, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl and 6-pyrimidinyl.
In some embodiments, the compound of formula (Ial) is selected from the group consisting of:
Carbamate prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Ic):
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A.
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form unsubstituted heterocyclylalkyl. In some embodiments, R 6 and R 7 together with the atoms to which they are attached form
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe. In some embodiments, R 6 and R 7 together with the atoms to which they are attached formIn some embodiments, R 6 and R 7 together with the atoms to which they are attached form an unsubstituted or substituted piperidinyl group. In some embodiments, R 6 and R 7 together with the atoms to which they are attached form an unsubstituted or substituted 1-piperidinyl group.
In some embodiments, the compound of formula (Ic) has a formula selected from the group consisting of:
Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe, and each R C6 is independently hydrogen, -CH 3、-CD3, or-CH 2CH3.
In some embodiments, the compound of formula (Ic) is selected from the group consisting of:
In some embodiments, R 7 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen OR alkyl. In some embodiments, R 7 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen, methyl, ethyl, OR tert-butyl.
In some embodiments, each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A.
In some embodiments, R 6 is hydrogen and R 7 is hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A. In some embodiments, R 6 is hydrogen and R 7 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl. In some embodiments, R 6 is hydrogen and R 7 is unsubstituted or substituted alkyl. In some embodiments, R 6 is hydrogen and R 7 is unsubstituted alkyl. In some embodiments, R 6 is hydrogen and R 7 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 6 is hydrogen and R 7 is alkyl substituted with heterocyclylalkyl. In some embodiments, R 6 is hydrogen and R 7 is aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazaidinyl, Substituted alkyl, wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or NMe.
In some embodiments, R 6 is methyl.
In some embodiments, the compound of formula (Ic) has the structure of formula (Icc):
in some embodiments, the compound of formula (Ic) is selected from the group consisting of:
Carbonate prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Ib):
in some embodiments, R 3 is hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more R A.
In some embodiments, R 3 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In some embodiments, R 3 is unsubstituted or substituted alkyl. In some embodiments, R 3 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In some embodiments, R 3 is unsubstituted alkyl. In some embodiments, R 3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In some embodiments, R 3 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In some embodiments, R 3 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
In some embodiments, R 3 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 3 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
In some embodiments, R 3 is alkyl substituted with one or more-OC (O) R 15. In some embodiments, R 3 is isopropyl substituted with two-OC (O) R 15, wherein each R 15 is alkyl. In some embodiments, R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 3 is heterocyclylalkyl.
In some embodiments, R 3 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In some embodiments, R 3 is alkyl substituted with heterocyclylalkyl. In some embodiments, R 3 is aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Substituted alkyl, wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In some embodiments, R 3 is heteroalkyl.
In some embodiments, R 3 is unsubstituted or substituted aryl (e.g., phenyl). In some embodiments, R 3 is substituted phenyl. In some embodiments, R 3 is phenyl substituted with-OC (O) R 18, wherein R 18 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R B.
In some embodiments, R 3 is selected from the group consisting of alkyl, cycloalkyl, substituted alkyl, substituted cycloalkyl, vinyl, aryl, heteroaryl, substituted aryl, and substituted heteroaryl. In some embodiments, R 3 is selected from the group consisting of hydrogen, -CD 3, et, n-Pr, iPr, tBu, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, CH 2CF3、-CH2 -cyclopropyl, ph, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, and 6-pyrimidinyl.
In some embodiments, R 3 is alkyl or heteroalkyl. In some embodiments, R 3 is unsubstituted alkyl or unsubstituted heteroalkyl. In some embodiments, R 3 is alkyl. In some embodiments, R 3 is unsubstituted alkyl. In some embodiments, R 1 is methoxy and R 3 is alkyl. In some embodiments, R 1 is methoxy and R 3 is unsubstituted alkyl. In some embodiments, R 1 is hydrogen and R 3 is alkyl. In some embodiments, R 1 is hydrogen and R 3 is unsubstituted alkyl.
In some embodiments, R 3 is heteroalkyl. In some embodiments, R 3 is unsubstituted heteroalkyl. In some embodiments, R 3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, or 3-methyl-1-butyl. In some embodiments, R 3 is aryl. In some embodiments, R 3 is phenyl. In some embodiments, R 3 is heterocyclylalkyl. In some embodiments, R 3 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, or 6-pyrimidinyl. In some embodiments, R 3 is ethyl. In some embodiments, R 1 is hydrogen and R 3 is ethyl. In some embodiments, R 1 is methoxy and R 3 is ethyl. In some embodiments, R 3 is alkyl substituted with heteroaryl. In some embodiments, R 3 isIn some embodiments, R 1 is methoxy and R 3 is/>In some embodiments, R 1 is hydrogen and R 3 is/>
In some embodiments, the compound of formula (Ib) has a structure selected from the following formulae:
Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe, each R' is independently hydrogen or-CH 3; and R 15 is defined herein above.
In some embodiments, the compound of formula (Ib) is selected from the group consisting of:
Acyloxymethyl prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Id):
In some embodiments, R 4 is hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl. In some embodiments, R 4 is unsubstituted or substituted alkyl. In some embodiments, R 4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 4 is hydrogen, methyl, or isopropyl. In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is methyl. In some embodiments, R 4 is isopropyl.
In some embodiments, R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In some embodiments, R 5 is unsubstituted or substituted alkyl. In some embodiments, R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In some embodiments, R 5 is unsubstituted alkyl. In some embodiments, R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In some embodiments, R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
In some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
In some embodiments, R 5 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 5 is alkyl substituted with-C (O) OR 15. In some embodiments, R 5 is alkyl substituted with-C (O) OR 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted OR further substituted with one OR more halo, amino, cyano, hydroxy, alkyl, acetyl, OR benzoyl. In some embodiments, R 13 is hydrogen or alkyl. In some embodiments, R 13 is hydrogen, methyl, ethyl, or tert-butyl.
In some embodiments, R 5 is heterocyclylalkyl.
In some embodiments, R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In some embodiments, R 5 is optionally substituted piperidinyl. In some embodiments, R 5 is
In some embodiments, R 5 is heterocyclylalkyl. In some embodiments, R 5 is aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Substituted alkyl, wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In some embodiments, R 5 is heteroalkyl.
In some embodiments, R 5 is unsubstituted or substituted aryl (e.g., phenyl). In some embodiments, R 5 is substituted phenyl. In some embodiments, R 5 is phenyl substituted with-OC (O) R 18, wherein R 18 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R B.
In some embodiments, R 5 is selected from the group consisting of alkyl, cycloalkyl, substituted alkyl, substituted cycloalkyl, vinyl, aryl, heteroaryl, substituted aryl, and substituted heteroaryl. In some embodiments, R 5 is selected from the group consisting of hydrogen, -CD 3, et, n-Pr, iPr, tBu, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, CH 2CF3、-CH2 -cyclopropyl, ph, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, and 6-pyrimidinyl.
In some embodiments, R 5 is alkyl or heteroalkyl. In some embodiments, R 5 is unsubstituted alkyl or unsubstituted heteroalkyl. In some embodiments, R 5 is alkyl. In some embodiments, R 5 is unsubstituted alkyl. In some embodiments, R 1 is methoxy and R 5 is alkyl. In some embodiments, R 1 is methoxy and R 5 is unsubstituted alkyl. In some embodiments, R 1 is hydrogen and R 5 is alkyl. In some embodiments, R 1 is hydrogen and R 5 is unsubstituted alkyl.
In some embodiments, R 5 is heteroalkyl. In some embodiments, R 5 is unsubstituted heteroalkyl. In some embodiments, R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, or 3-methyl-1-butyl. In some embodiments, R 5 is aryl. In some embodiments, R 5 is phenyl. In some embodiments, R 5 is heterocyclylalkyl. In some embodiments, R 5 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, or 6-pyrimidinyl. In some embodiments, R 5 is ethyl. In some embodiments, R 1 is hydrogen and R 5 is ethyl. In some embodiments, R 1 is methoxy and R 5 is ethyl. In some embodiments, R 5 is alkyl substituted with heteroaryl. In some embodiments, R 5 isIn some embodiments, R 1 is methoxy and R 5 is/>In some embodiments, R 1 is hydrogen and R 5 is/>
In some embodiments, the compound of formula (Id) has a structure of formula selected from:
Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe, each R' is independently hydrogen or-CH 3; RC7 is H, me, CH 2Ph、CH2CH(Me)2、CH(CH3)CH2CH3 or CH 2CH2SCH3,RC8 and R C9 are each H, CH 3 or CH 2CH3, and R 14 and R 15 are defined herein above.
In some embodiments, the compound of formula (Id) has the structure of formula (Ida). In some embodiments, the compound of formula (Id) has the structure of formula (Idb). In some embodiments, the compound of formula (Id) has the structure of formula (Idc). In some embodiments, the compound of formula (Id) has the structure of formula (Id). In some embodiments, the compound of formula (Id) has the structure of formula (Ide). In some embodiments, the compound of formula (Id) has the structure of formula (Idf). In some embodiments, the compound of formula (Id) has the structure of formula (Idg). In some embodiments, the compound of formula (Id) has the structure of formula (Idh). In some embodiments, the compound of formula (Id) has the structure of formula (Idi). In some embodiments, the compound of formula (Id) has the structure of formula (Idj).
In some embodiments, the compound of formula (Id) has the structure of formula (Idk):
in some embodiments, the compound of formula (Id) has the structure of formula (Idl):
in some embodiments, the compound of formula (Id) has the structure of formula (Idm):
in some embodiments, the compound of formula (Id) is selected from the group consisting of:
alkoxycarbonyloxymethyl prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Ie):
In some embodiments, R 4 is hydrogen, unsubstituted or substituted hydrogen, alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl. In some embodiments, R 4 is unsubstituted or substituted alkyl. In some embodiments, R 4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 4 is hydrogen, methyl, or isopropyl. In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is methyl. In some embodiments, R 4 is isopropyl.
In some embodiments, R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In some embodiments, R 5 is unsubstituted or substituted alkyl. In some embodiments, R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In some embodiments, R 5 is unsubstituted alkyl. In some embodiments, R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In some embodiments, R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
In some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
In some embodiments, R 5 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 5 is heterocyclylalkyl.
In some embodiments, R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In some embodiments, R 5 is heterocyclylalkyl. In some embodiments, R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In some embodiments, R 5 is heteroalkyl.
In some embodiments, R 5 is unsubstituted or substituted aryl (e.g., phenyl). In some embodiments, R 5 is substituted phenyl. In some embodiments, R 5 is phenyl substituted with-OC (O) R 18, wherein R 18 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R B.
In some embodiments, R 5 is selected from the group consisting of alkyl, cycloalkyl, substituted alkyl, substituted cycloalkyl, vinyl, aryl, heteroaryl, substituted aryl, and substituted heteroaryl. In some embodiments, R 5 is selected from the group consisting of hydrogen, -CD 3, et, n-Pr, iPr, tBu, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, CH 2CF3、-CH2 -cyclopropyl, ph, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, and 6-pyrimidinyl.
In some embodiments, R 5 is alkyl or heteroalkyl. In some embodiments, R 5 is unsubstituted alkyl or unsubstituted heteroalkyl. In some embodiments, R 5 is alkyl. In some embodiments, R 5 is unsubstituted alkyl. In some embodiments, R 1 is methoxy and R 5 is alkyl. In some embodiments, R 1 is methoxy and R 5 is unsubstituted alkyl. In some embodiments, R 1 is hydrogen and R 5 is alkyl. In some embodiments, R 1 is hydrogen and R 5 is unsubstituted alkyl.
In some embodiments, R 5 is heteroalkyl. In some embodiments, R 5 is unsubstituted heteroalkyl. In some embodiments, R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, or 3-methyl-1-butyl. In some embodiments, R 5 is aryl. In some embodiments, R 5 is phenyl. In some embodiments, R 5 is heterocyclylalkyl. In some embodiments, R 5 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, or 6-pyrimidinyl. In some embodiments, R 5 is ethyl. In some embodiments, R 1 is hydrogen and R 5 is ethyl. In some embodiments, R 1 is methoxy and R 5 is ethyl. In some embodiments, R 5 is alkyl substituted with heteroaryl. In some embodiments, R 5 isIn some embodiments, R 1 is methoxy and R 5 isIn some embodiments, R 1 is hydrogen and R 5 is/>
In some embodiments, R 5 is morpholinyl, isopropyl, or ethyl.
In some embodiments, the compound of formula (Ie) has a structure of formula selected from:
/>
Wherein R C10 and R C11 are each H, CH 3 or CH 2CH3; and R 4 and R 14 are defined herein above.
In some preferred embodiments, the compound of formula (Ie) is selected from the group consisting of:
aminocarbonyloxymethyl prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (If):
In some embodiments, R 4 is hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl. In some embodiments, R 4 is unsubstituted or substituted alkyl. In some embodiments, R 4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 4 is hydrogen, methyl, or isopropyl. In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is methyl. In some embodiments, R 4 is isopropyl.
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A.
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form unsubstituted heterocyclylalkyl. In some embodiments, R 6 and R 7 together with the atoms to which they are attached form/>
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form an unsubstituted or substituted piperidinyl group. In some embodiments, R 6 and R 7 together with the atoms to which they are attached form an unsubstituted or substituted 1-piperidinyl group. In some embodiments, R 6 and R 7 together with the atoms to which they are attached form
In some embodiments, the compound of formula (If) has the structure of formula (Ifa) or formula (Ifb):
wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe; r C12 and R C13 are each H, CH 3、CD3 or CH 2CH3; and R 4 is defined herein above.
In some embodiments, the compound of formula (If) is selected from the group consisting of:
In some embodiments, each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A.
In some embodiments, R 6 is hydrogen and R 7 is hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A. In some embodiments, R 6 is hydrogen and R 7 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl. In some embodiments, R 6 is hydrogen and R 7 is unsubstituted or substituted alkyl. In some embodiments, R 6 is hydrogen and R 7 is unsubstituted alkyl. In some embodiments, R 6 is hydrogen and R 7 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 6 is hydrogen and R 7 is alkyl substituted with heterocyclylalkyl. In some embodiments, R 6 is hydrogen and R 7 is aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazaidinyl, Substituted alkyl, wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or NMe.
In some embodiments, the compound of formula (If) is a compound of formula (If'):
in some embodiments, the compound of formula (If) is selected from the group consisting of:
Phosphonate prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Ih):
In some embodiments, R 11 and R 12 are independently unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl. In some embodiments, R 11 and R 12 are independently hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl. In some embodiments, each of R 11 and R 12 is independently hydrogen or unsubstituted or substituted alkyl. In some embodiments, each of R 11 and R 12 is independently unsubstituted or substituted alkyl.
In some embodiments, each of R 11 and R 12 is independently alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In some embodiments, each of R 11 and R 12 is independently unsubstituted alkyl.
In some embodiments, each of R 11 and R 12 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H2.
In some embodiments, each of R 11 and R 12 is independently alkyl substituted with-OC (O) R 5A, wherein R 5A is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, R 11 and R 12 are independently alkyl substituted with-OC (O) OR 16, wherein R 16 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted OR further substituted with one OR more halo, amino, cyano, hydroxy, alkyl, acetyl, OR benzoyl. In some embodiments, R 16 is hydrogen or alkyl. In some embodiments, R 16 is hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
In some embodiments, each of R 11 and R 12 is independently heteroalkyl.
In some embodiments, each of R 11 and R 12 is independently unsubstituted or substituted aryl (e.g., phenyl).
In some embodiments, the compound of formula (Ih) has the structure of formula (Ih'):
Wherein R 4A and R 4A' are each independently hydrogen or alkyl, and R 5A and R 5A' are each independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
In some embodiments, the compound of formula (Ih) is selected from the group consisting of:
sulfamate prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Ig):
In some embodiments, each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A.
In some embodiments, R 6 and R 7 are each independently hydrogen or alkyl. In some embodiments, R 6 and R 7 are each independently hydrogen or methyl.
In some embodiments, R 6 and R 7 are each hydrogen.
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A.
In some embodiments, R 6 and R 7 together with the atoms to which they are attached form aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-O-, -S-, a-SO 2, -NH-or-NMe.
In some embodiments, the compound of formula (Ig) is:
Glyceride prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Ib'):
Wherein R 6A and R 6A' are each independently hydrogen or alkyl.
In some embodiments, R 6A and R 6A' are each independently -CH3、-C2H5、C3H7、C4H9、C5H11、C6H13、C7H15、C8H17、C9H19、C10H21、C11H23、C12H25、C13H27、C14H29、C15H31、C16H33 or C 17H35. In some embodiments, R 6A and R 6A' are the same. In some embodiments, R 6A and R 6A' are each C 15H31 or C 17H35. In some embodiments, R 6A and R 6A' are each C 15H31. In some embodiments, R 6A and R 6A' are each C 17H35.
In some embodiments, the compound of formula (Ib') is:
in some embodiments, the compound of formula (I) has the structure of formula (Ib "):
Wherein each of R 6A、R1B、R2B and R 3B is independently hydrogen or alkyl.
In some embodiments, R 6A is -CH3、-C2H5、C3H7、C4H9、C5H11、C6H13、C7H15、C8H17、C9H19、C10H21、C11H23、C12H25、C13H27、C14H29、C15H31、C16H33 or C 17H35. In some embodiments, R 6A is C 15H31 or C 17H35. In some embodiments, R 6A is C 15H31. In some embodiments, R 6A is C 17H35.
In some embodiments, R 1B、R2B and R 3B are each independently alkyl. In some embodiments, each of R 1B、R2B and R 3B is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 1B、R2B and R 3B are each methyl.
In some embodiments, the compound of formula (Ib') is:
In some embodiments, the compound of formula (I) has the structure of formula (Ia'):
Wherein R C14 is hydrogen or alkyl.
In some embodiments, R C14 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In some embodiments, the compound of formula (Ia) has the structure of formula (Ia-1):
Wherein R D1 and R D2 together with the atoms to which they are attached form a cycloalkyl or heterocyclylalkyl ring that is unsubstituted or substituted with one or more R A; r D3 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, -OC (O) R 15, OR-C (O) OR 13, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl are unsubstituted OR substituted with one OR more alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21); m is 0 to 10.
In some embodiments, R D1 and R D2 together with the atoms to which they are attached form an unsubstituted or substituted cycloalkyl ring. In some embodiments, R D1 and R D2 together with the atoms to which they are attached form an unsubstituted cycloalkyl ring. In some embodiments, R D1 and R D2 together with the atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl ring. In one embodiment, R D1 and R D2 together with the atoms to which they are attached form a cyclohexyl group.
In some embodiments, m is 0 to 8. In some embodiments, m is 0 to 6. In some embodiments, m is 0 to 4. In some embodiments, m is 1 to 4. In some embodiments, m is 1 to 3. In some embodiments, m is 1 to 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.
In some embodiments, R D3 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21. In some embodiments, R D3 is alkyl substituted with-C (O) OR 13. In some embodiments, R D3 is alkyl substituted with-C (O) OR 13, wherein R 13 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, OR-C 10H21. In some embodiments, R 13 is methyl, ethyl, isopropyl, or tert-butyl. In some embodiments, R D3 is-CH 2OC(O)R13, wherein R 13 is methyl, ethyl, isopropyl, or tert-butyl.
In some embodiments, the compound of formula (Ib) has the structure of formula (Ib-1):
Wherein R D1 and R D2 together with the atoms to which they are attached form a cycloalkyl or heterocyclylalkyl ring that is unsubstituted or substituted with one or more R A; r D3 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, -OC (O) R 15, OR-C (O) OR 13, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl are unsubstituted OR substituted with one OR more alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21); m is 0 to 10.
In some embodiments, R D1 and R D2 together with the atoms to which they are attached form an unsubstituted or substituted cycloalkyl ring. In some embodiments, R D1 and R D2 together with the atoms to which they are attached form an unsubstituted cycloalkyl ring. In some embodiments, R D1 and R D2 together with the atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl ring. In one embodiment, R D1 and R D2 together with the atoms to which they are attached form a cyclohexyl group.
In some embodiments, m is 0 to 8. In some embodiments, m is 0 to 6. In some embodiments, m is 0 to 4. In some embodiments, m is 1 to 4. In some embodiments, m is 1 to 3. In some embodiments, m is 1 to 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.
In some embodiments, R D3 is-C (O) OR 13. In some embodiments, R 13 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 13 is methyl, ethyl, isopropyl, or tert-butyl.
In some embodiments, the compound of formula (Ic) has the structure of formula (Ic-1):
Wherein R 6 is defined herein above; r D1 and R D2 together with the atoms to which they are attached form a cycloalkyl or heterocyclylalkyl ring that is unsubstituted or substituted with one or more R A; r D3 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, -OC (O) R 15, OR-C (O) OR 13, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl are unsubstituted OR substituted with one OR more alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21); m is 0 to 10.
In some embodiments, R D1 and R D2 together with the atoms to which they are attached form an unsubstituted or substituted cycloalkyl ring. In some embodiments, R D1 and R D2 together with the atoms to which they are attached form an unsubstituted cycloalkyl ring. In some embodiments, R D1 and R D2 together with the atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl ring. In one embodiment, R D1 and R D2 together with the atoms to which they are attached form a cyclohexyl group.
In some embodiments, m is 0 to 8. In some embodiments, m is 0 to 6. In some embodiments, m is 0 to 4. In some embodiments, m is 1 to 4. In some embodiments, m is 1 to 3. In some embodiments, m is 1 to 2. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3.
In some embodiments, R D3 is-C (O) OR 13. In some embodiments, R 13 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21. In some embodiments, R 13 is methyl, ethyl, isopropyl, or tert-butyl.
In some embodiments, R 6 is hydrogen or alkyl. In some embodiments, R 6 is hydrogen. In some embodiments, R 6 is alkyl. In some embodiments, R 6 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
Silyl prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Ii):
In some embodiments, each of R 3、R4 and R 5 is independently hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In some embodiments, each of R 3、R4 and R 5 is unsubstituted or substituted alkyl. In some embodiments, each of R 3、R4 and R 5 is independently alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In some embodiments, each of R 3、R4 and R 5 is independently unsubstituted alkyl. In some embodiments, each of R 3、R4 and R 5 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In some embodiments, R 3、R4 and R 5 are the same unsubstituted alkyl. In some embodiments, R 3 and R 4 are methyl, ethyl, or isopropyl.
In some embodiments, R 5 is ethyl, isopropyl, or tert-butyl.
In some embodiments, (i) R 3 and R 4 are methyl, and R 5 is ethyl; (ii) R 3、R4 and R 5 are isopropyl; or (iii) R 3、R4 and R 5 are ethyl.
In some embodiments, each of R 3、R4 and R 5 is independently heteroalkyl.
In some embodiments, each of R 3、R4 and R 5 is independently unsubstituted or substituted aryl (e.g., phenyl).
Sulfate prodrugs
In some embodiments, the compound of formula (I) has the structure of formula (Ij):
In some embodiments, R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
In some embodiments, R 5 is unsubstituted or substituted alkyl. In some embodiments, R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
In some embodiments, R 5 is unsubstituted alkyl. In some embodiments, R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
In some embodiments, R 5 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen OR alkyl.
In some embodiments, R 5 is hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
In some embodiments, R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
In some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl, in some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl groups.
In some embodiments, R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
In some embodiments, R 5 is heterocyclylalkyl. In some embodiments, R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
Selected compounds of the present disclosure
In some embodiments, the compound of formula (I) is selected from:
/>
In some embodiments, one or more hydrogens in the compound of formula (I) are replaced with deuterium.
Selected compounds of the present disclosure having corresponding simplified molecular input column input system (SIMPLIFIED MOL ECULAR-input line-ENTRY SYSTEM, SMILES) strings are provided in table 1.
TABLE 1
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
In certain embodiments, the compound of formula (I), or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:
/>
/>
Deuterated analogs of O-acetyl dephosphorylated nupharmorin in another aspect, provided herein are compounds of formula (II):
Wherein:
R 21 is-CH 3、-CH2D、-CHD2 or-CD 3;
Each of R 22 and R 23 is independently hydrogen or alkyl, wherein one or more hydrogens in the alkyl are optionally substituted with deuterium;
Each of Y 1、Y2、Y3、Y4、Y5、Y6、Y7、Y8 and Y 9 is independently hydrogen or deuterium; and
Wherein when R 21 is CH 3 and R 22 and R 23 do not include deuterium, at least one of Y 1、Y2、Y3、Y4、Y5、Y6、Y7、Y8 and Y 9 is deuterium.
In certain embodiments, R 21 is-CH 3、-CH2D、-CHD2 or-CD 3. In certain embodiments, R 21 is-CH 2D、-CHD2 or-CD 3. In certain embodiments, R 21 is-CH 3、-CHD2 or-CD 3. In certain embodiments, R 21 is-CH 3、-CH2 D or-CD 3. In certain embodiments, R 21 is-CH 3、-CH2 D or-CHD 2.
In certain embodiments, R 21 is-CH 3. In certain embodiments, R 21 is-CD 3. In certain embodiments, R 21 is-CH 2 D. In certain embodiments, R 21 is-CH D 2.
In certain embodiments, R 22 and R 23 are each independently-CH 3、-CH2D、-CH D2 or-CD 3. In certain embodiments, at least one of R 22 and R 23 comprises deuterium. In certain embodiments, one of R 22 and R 23 is-CD 3. In certain embodiments, both R 22 and R 23 are-CD 3.
In certain embodiments, Y 1 is D. In certain embodiments, Y 3 is D. In certain embodiments, Y 1 and Y 2 are each D. In certain embodiments, Y 3 and Y 4 are each D. In certain embodiments, Y 1、Y2、Y3 and Y 4 are each D.
In certain embodiments, Y 6 is H.
In some embodiments, disclosed herein are deuterated analogs of O-acetyl dephosphorylated nupharin.
In some embodiments, the compound of formula (II) is a compound of formula (IIa) or formula (IIb):
Wherein the method comprises the steps of
R 21 is CH 3、CH2D、CHD2 or CD 3;
Each of R 22 and R 23 is independently hydrogen or alkyl, wherein one or more hydrogens in the alkyl are optionally substituted with deuterium; and
At least one of R 21、R22 and R 23 comprises one or more deuterium.
In some embodiments, the compound of formula (II) is selected from the group consisting of:
In another aspect, the present disclosure provides a pharmaceutically acceptable composition comprising a compound according to any one of formulas (I), (Ia '), (Ib '), (Ic), (Id), (Ie), (If), (Ig), (Ih '), (Ia-1), (Ib-1), (Ic-1) or (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
In another aspect, the present disclosure provides a pharmaceutically acceptable composition comprising a compound as any one of formulas (Ii) or (Ii), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
The pharmaceutical compositions of the present disclosure may comprise a racemic, non-racemic (scalemic) or diastereomerically enriched mixture of any compound described herein, including a stereogenic center.
Therapeutic method
In another aspect, the present disclosure provides a method of treating or preventing a disease, disorder, or condition in which increased levels of a phenethylamine hallucinogen, such as MDMA, are beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound of formula (I), (Ia '), (Ib '), (Ic), (Id), (Ie), (If), (Ig), (Ih '), (Ia-1), (Ib-1), (Ic-1), or (II), or a pharmaceutically acceptable salt thereof. In some embodiments, the condition comprises post-traumatic stress disorder, major depressive disorder, schizophrenia, alzheimer's disease, frontotemporal dementia, parkinson's disease, parkinson's dementia, dementia with lewy bodies, multiple system atrophy, or drug abuse. In some embodiments, the condition comprises a musculoskeletal pain disorder, including fibromyalgia, muscle pain, joint stiffness, osteoarthritis, rheumatoid arthritis, muscle spasms. In some embodiments, the present disclosure provides a method of treating reproductive health disorders in women, including premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), postnatal depression, and menopause. The compounds of the invention may also be used to treat any brain disease.
In one embodiment, the present disclosure provides a method of treating or preventing a disease, disorder, or condition in which increased levels of a phenethylamine hallucinogen, such as MDMA, are beneficial, comprising administering to a subject in need thereof an effective amount of a compound of formula (Ii) or (Ij), or a pharmaceutically acceptable salt thereof. In some embodiments, the condition comprises post-traumatic stress disorder, major depressive disorder, schizophrenia, alzheimer's disease, frontotemporal dementia, parkinson's disease, parkinson's dementia, dementia with lewy bodies, multiple system atrophy, or drug abuse. In some embodiments, the condition comprises a musculoskeletal pain disorder, including fibromyalgia, muscle pain, joint stiffness, osteoarthritis, rheumatoid arthritis, muscle spasms. In some embodiments, the invention provides a method of treating female reproductive health disorders, the method comprising premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), postnatal depression, and menopause. The compounds of the invention are also useful in the treatment of any brain disease.
In some embodiments, the compounds disclosed herein have activity as 5-HT 2A modulators. In some embodiments, the compounds disclosed herein elicit a biological response by activating the 5-HT 2A receptor (e.g., allosteric modulation or modulation of a biological target that activates the 5-HT 2A receptor). 5-HT 2A agonism has been associated with promotion of neuroplasticity. 5-HT 2A antagonists abrogate the neurite-generating and dendritic spinogenic effects of fanciful compounds (e.g., DMT, LSD and DOI) with 5-HT 2A agonistic activity. In some embodiments, the compounds disclosed herein are 5-HT 2A modulators and promote neuroplasticity (e.g., cortical structural plasticity). In some embodiments, the compounds disclosed herein are selective 5-HT 2A modulators and promote neuroplasticity (e.g., cortical structural plasticity). Promoting neuroplasticity may include, for example, increasing dendritic spine growth, increasing synthesis of synaptoproteins, enhancing synaptic responses, increasing dendritic axis (DENDRITIC ARBOR) complexity, increasing dendritic branch content, increasing dendritic spine production, increasing neurite production, or any combination thereof. In some embodiments, increasing neuroplasticity comprises increasing cortical structural plasticity in the anterior portion of the brain.
In some embodiments, the 5-HT 2A modulator (e.g., 5-HT 2A agonist) is non-fanciful. In some embodiments, a non-fanciful 5-HT 2A modulator (e.g., a 5-HT 2A agonist) is used to treat a neurological disease, the modulator not eliciting dissociative side effects. In some embodiments, the fanciful potential of the compounds described herein is assessed in vitro. In some embodiments, the fanciful potential of a compound described herein evaluated in vitro is compared to the fanciful potential of a fanciful homolog evaluated in vitro. In some embodiments, the compounds described herein cause less in vitro camouflage potential than the camouflage homolog.
In some embodiments, a serotonin receptor modulator, such as a modulator of serotonin receptor 2A (5-HT 2A modulator, e.g. 5-HT 2A agonist), is used to treat a brain disorder. In some embodiments, the compounds of the present disclosure are used as 5-HT 2A agonists alone or in combination with a second therapeutic agent, which is also a 5-HT 2A modulator. In such cases, the second therapeutic agent may be an agonist or an antagonist. In some cases, it may be helpful to administer a 5-HT 2A antagonist in combination with a compound of the disclosure to mitigate undesirable effects of 5-HT 2A agonism, such as potential illusive effects. Serotonin receptor modulators suitable as a second therapeutic agent for combination therapy as described herein are known to those of skill in the art and include, but are not limited to, ketanserin (KETA NSERIN), flurbiprofen (volinanserin) (MDL-100907), irinotelin (EPLIVANSERI N) (SR-46349), pinacolin (PIMAVANSERIN) (ACP-103), gliochrin (GLE MANSERIN) (MDL-11939), ritanserin (ritanserin), letan (EPLIVANSERI N), Flibanserin (flibanserin), neban Luo Selin (nelotanserin), blonanserin (blonanserin), mianserin (mianserin), mirtazapine (mirtazapine), luo Lupai ketone (roluperiodone) (CYR-101, MIN-101), quetiapine (quetiapine), olanzapine (olanzapine), atain (altanserin), levulinic acid (acepromazine), nefazodone (nefazodone), Risperidone (risperidone), pu Mo Selin (pruvanserin), AC-90179, AC-279, adapalene (adatanserin), farneserin (fananserin), HY10275, benjamin (benanserin), blonanserin (butanserin), mansalin (manserin), ifer serin (iferanserin), lidanserin (LIDAN SERIN), perlanin (pelanserin), seganserin (seganserin), blonanserin (butanserin), Tropane-color-line (tropan serin), chlorocarbaerin (lorcaserin), ICI-169369, methipine (methiothepin), dimethylergoline (METHYSERGIDE), trazodone (trazodone), cilazapril (cinitapride), cyproheptadine (cyproheptadine), bripiprazole (brexpiprazole), calicheazine (cariprazi ne), agomelatine (agomelatine), setopine (setoperone), and, 1- (1-naphthyl) piperazine, LY-367265, pirenperone (pirenperone), methylergoline (metergoline), deramciclane (DERAMCICLANE), bupivaloine (amperozide), AMDA, cinaloline (CINANSE RIN), LY-86057, GSK-215083, cyanocarbamazine (cyamemazine), messaging ergot (mesulergine), BF-1, LY-215840, ergoline (sergolexole), Spiromide (SPI RAMIDE), LY-53857, an Maijiao (amesergide), LY-108742, piparone (pipa mperone), LY-314228, 5-I-R91150, 5-MeO-NBpBrT, 9-aminomethyl-9, 10-dihydroanthracene, nipradizine (niaprazine), SB-215505, SB-204741, SB-206553, SB-242084, LY-272015, SB-243213, SB-200646, RS-102221, zotepine (zotepine), clozapine (clozapine), chlorpromazine (chlorpromazine), sertindole (sertindone), iloperidone (iloperidone), risperidone, paliperidone (PALIPERID ONE), asenapine (asenapine), amisulpride (amisulpride), aripiprazole (arip iprazole), bripiprazole, lurasidone (lurasidone), ji Pai cilidone (ziprasidone) or lumeperide (lumateperone), or a pharmaceutically acceptable salt, solvate, metabolite, deuterated analog, derivative, prodrug, or combination thereof. In some embodiments, the serotonin receptor modulator used as the second therapeutic agent is pimavanserin or a pharmaceutically acceptable salt, solvate, metabolite, derivative or prodrug thereof. In some embodiments, the serotonin receptor modulator is administered prior to administration of the compound disclosed herein, such as about three hours or several hours prior to administration of the compound. In some embodiments, the serotonin receptor modulator is administered up to about one hour prior to the compound. In some embodiments, the second therapeutic agent is a serotonin receptor modulator. In some embodiments, the serotonin receptor modulator is provided in a dose of from about 10mg to about 350 mg. In some embodiments, the serotonin receptor modulator is provided in a dosage of from about 20mg to about 200 mg. In some embodiments, the serotonin receptor modulator is provided in a dosage of from about 10mg to about 100 mg. In certain such embodiments, the compounds of the invention are provided in a dose of about 10mg to about 100mg, or about 20 to about 200mg, or about 15 to about 300mg, and the serotonin receptor modulator is provided in a dose of about 10mg to about 100 mg.
In some embodiments, a non-fanciful 5-HT2 A modulator (e.g., a 5-HT2 A agonist) is used to treat a neurological disease. In some embodiments, the neurological disorder comprises reduced neuroplasticity, reduced cortical structure plasticity, reduced 5-HT 2A receptor content, reduced dendritic shaft complexity, loss of dendritic spines, reduced dendritic branch content, reduced dendritic spinogenesis, reduced neurite formation, axonal contractions, or any combination thereof.
In some embodiments, a non-fanciful 5-HT 2A modulator (e.g., a 5-HT 2A agonist) is used to increase neuronal plasticity. In some embodiments, a non-fanciful 5-HT 2A modulator (e.g., a 5-HT 2A agonist) is used to treat a brain disorder. In some embodiments, a non-fanciful 5-HT 2A modulator (e.g., a 5-HT 2A agonist) is used to increase at least one of translation, transcription, or secretion of a neurotrophic factor.
The pharmaceutical composition is administered in a manner suitable for the disease to be treated (or prevented). The appropriate dosage and the appropriate duration and frequency of administration will be determined by factors such as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient and the method of administration. In general, the appropriate dosage and treatment regimen provides sufficient therapeutic and/or prophylactic benefit (e.g., improved clinical outcome, such as more frequent complete or partial remission, or longer disease-free and/or overall survival, or reduction in symptom severity).
Suitable oral dosage forms include, for example, tablets, pills, sachets or capsules of hard or soft gelatin, methylcellulose or another suitable material which is readily soluble in the digestive tract. In some embodiments, suitable non-toxic solid carriers are used, including, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. (see, e.g., remington: THE SCIENCE AND PRACTICE of Pharmacy (Gen naro, 21 Plate for printing Mack pub. Co., easton, PA (2005)).
In some embodiments, the compounds described herein are administered to a patient at a low dose that is below that which would produce a pronounced illusive effect but high enough to provide a therapeutic benefit. This dose range is expected to be between 200 μg (micrograms) and 2 mg.
In some embodiments, the oral dosage is typically in the range of about 1.0mg to about 350mg, one to four or more times per day. In certain embodiments, the compound is administered to the subject in a daily dose of between 0.01mg/kg to about 50mg/kg body weight. In other embodiments, the dose is 1 to 350 mg/day. In certain embodiments, the daily dose is from 1 to 750 mg/day; or 10 to 350 mg/day. In certain embodiments, the compounds disclosed herein, including those described in table 1, are provided in daily doses of about 2mg to about 5mg, or about 5mg to about 10mg, or about 10mg to about 100mg, or about 20 to about 200mg, or about 15 to about 300mg, or 10mg, or 15mg, or 20mg, or 25mg, or 30mg, or 35mg, or 40mg, or 45mg, or 50mg, or 55mg, or 60mg, or 65mg, or 70mg, or 75mg, or 80mg, or 85mg, or 90mg, or 95mg, or 100 mg.
In some embodiments, the compounds described herein are used to treat neurological disorders. For example, the compounds provided herein may exhibit anti-addictive properties, antidepressant properties, anxiolytic properties, or a combination thereof. In some embodiments, the neurological disease is a neuropsychiatric disease. In some embodiments, the neuropsychiatric disorder is an emotional or anxiety disorder. In some embodiments, the neurological disorder is migraine, headache (e.g., cluster headache), post Traumatic Stress Disorder (PTSD), anxiety, depression, neurodegenerative disease, alzheimer's disease, parkinson's disease, psychological disorders, refractory depression, suicidal ideation, major depression, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and addiction (e.g., substance use disorders). In some embodiments, the neurological disorder is migraine or cluster headache. In some embodiments, the neurological disease is a neurodegenerative disease, alzheimer's disease, or parkinson's disease. In some embodiments, the neurological disorder is a psychological disorder, refractory depression, suicidal ideation, major depression, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety. In some embodiments, the neuropsychiatric disease is a psychological disorder, refractory depression, suicidal ideation, major depression, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), depression, or anxiety. In some embodiments, the neuropsychiatric disease or neurological disease is post-traumatic stress disorder (PTSD), addiction (e.g., substance use disorder), schizophrenia, depression, or anxiety. In some embodiments, the neuropsychiatric disease or neurological disease is an addiction (e.g., substance use disorder). In some embodiments, the neuropsychiatric disease or neurological disease is depression. In some embodiments, the neuropsychiatric disease or neurological disease is anxiety. In some embodiments, the neuropsychiatric disease or neurological disease is post-traumatic stress disorder (PTSD). In some embodiments, the neurological disorder is stroke or traumatic brain injury. In some embodiments, the neuropsychiatric disease or neurological disease is schizophrenia.
In some embodiments, the compounds of the present disclosure are used to increase neuronal plasticity. In some embodiments, the compounds described herein are used to treat a brain disorder. In some embodiments, the compounds described herein are used to increase translation, transcription, or secretion of neurotrophic factors.
The compounds disclosed herein may also be useful for increasing neuronal plasticity in a subject. As used herein, "neuronal plasticity" may refer to the ability of the brain to change structure and/or function throughout the life of a subject. New neurons may be created and integrated into the central nervous system throughout the life of a subject. Increasing neuronal plasticity may include, but is not limited to, promoting neuronal growth, promoting neurite generation, promoting synapse generation, promoting dendritic generation, increasing dendritic shaft complexity, increasing dendritic spine density, and increasing excitatory synapses in the brain. In some embodiments, increasing neuronal plasticity includes promoting neuronal growth, promoting neurite formation, promoting synapse formation, promoting dendritic formation, increasing dendritic shaft complexity, and increasing dendritic spine density.
In some embodiments, increasing neuronal plasticity by treating a subject with a compound of the present disclosure treats neurodegenerative diseases, alzheimer's disease, parkinson's disease, psychological disorders, depression, addiction, anxiety, post-traumatic stress disorder, refractory depression, suicidal ideation, major depression, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or substance use disorder.
In some embodiments, the present disclosure provides a method for increasing neuronal plasticity comprising contacting a neuronal cell with a compound of the present disclosure. In some embodiments, increasing neuronal plasticity improves the brain disorders described herein.
In some embodiments, the compounds disclosed herein are useful for increasing neuronal plasticity and have, for example, anti-addiction properties, anti-depressant properties, anxiolytic properties, or a combination thereof. In some embodiments, reduced neuronal plasticity is associated with neuropsychiatric disorders. In some embodiments, the neuropsychiatric disorder is an emotional or anxiety disorder. In some embodiments, neuropsychiatric disorders include, for example, migraine, cluster headache, post-traumatic stress disorder (PTSD), schizophrenia, anxiety, depression, and addiction (e.g., drug abuse disorders). Brain disorders may include, for example, migraine, addiction (e.g., substance use disorders), depression, and anxiety.
In some embodiments, the assay or assay to determine increased neuronal plasticity resulting from administration of any of the compounds of the present disclosure is a phenotypic assay, a dendritic generation assay, a synapse generation assay, a shore (Sholl) assay, a concentration response assay, a 5-HT 2A agonist assay, a 5-HT 2A antagonist assay, a 5-HT 2A binding assay, or a 5-HT 2A blocking assay (e.g., a ketanserin blocking assay). In some embodiments, the experiment or assay to determine the fantasy potential of any of the compounds of the present disclosure is a mouse head-flick reaction (HTR) assay.
In some embodiments, the disorder is a musculoskeletal pain disorder, including fibromyalgia, muscle pain, joint stiffness, osteoarthritis, rheumatoid arthritis, muscle spasms. In some embodiments, the present disclosure provides a method of treating reproductive health disorders in women, including premenstrual dysphoric disorder (PMDD), premenstrual syndrome (PMS), postnatal depression, and menopause. In some embodiments, the present disclosure provides a method of treating a brain disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure. In some embodiments, the present disclosure provides a method of treating a brain disorder with a combination therapy, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure and at least one additional therapeutic agent.
In some embodiments, the compounds of the present disclosure are used to treat brain disorders. In some embodiments, the compound has, for example, an anti-addiction property, an anti-depressant property, an anti-anxiety property, or a combination thereof. In some embodiments, the brain disorder is a neuropsychiatric disease. In some embodiments, the neuropsychiatric disorder is an emotional or anxiety disorder. In some embodiments, brain disorders include, for example, migraine, cluster headache, post-traumatic stress disorder (PTSD), anxiety, depression, panic disorder, suicidal tendencies, schizophrenia, and addiction (e.g., drug abuse disorders). In some embodiments, brain disorders include, for example, migraine, addiction (e.g., substance use disorders), depression, and anxiety.
In some embodiments, the present disclosure provides a method of treating a brain disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein. In some embodiments, the brain disorder is a neurodegenerative disease, alzheimer's disease, parkinson's disease, psychological disorders, depression, addiction, anxiety, post-traumatic stress disorder, refractory depression, suicidal ideation, major depression, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or substance use disorder.
In some embodiments, the brain disorder is a neurodegenerative disease, alzheimer's disease, or parkinson's disease. In some embodiments, the brain disorder is a psychological disorder, depression, addiction, anxiety, or post-traumatic stress disorder. In some embodiments, the brain condition is depression. In some embodiments, the brain disorder is addiction. In some embodiments, the brain condition is refractory depression, suicidal ideation, major depression, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or substance use disorder. In some embodiments, the brain condition is refractory depression, suicidal ideation, major depression, bipolar disorder, schizophrenia, or substance-use disorder. In some embodiments, the brain disorder is stroke or traumatic brain injury. In some embodiments, the brain condition is refractory depression, suicidal ideation, major depression, bipolar disorder, or substance use disorder. In some embodiments, the brain disorder is schizophrenia. In some embodiments, the brain disorder is an alcohol use disorder.
In some embodiments, the method further comprises administering one or more additional therapeutic agents. Non-limiting examples of additional therapeutic agents suitable for administration with the compounds of the present invention may include lithium, olanzapine (representate), quetiapine (cispran), risperidone (risplal), aripiprazole (An Lifu (Abilify)), ji Pai citalone (Geodon)), clozapine (Clozaril), sodium valproate (Depakote), lamotrigine (lamotrigine) (labetan), valproic acid (valproic acid) (dypran (Depakene)), carbamazepine (carbamazepine) (carbamazepine (Equetro)), topiramate (topiramate) (Topamax), levomilnacipran (levomilnacipran) (levomilnacipran (Fetzima)), duloxetine (duxeline) (Cymbalta), duloxetine (hci), duloxetine (YINCP) and (venlafaxine) (32) and fluplazine (3283) (32), fluplazine (3283) (32) and fluplazine (37) and (67) (valproate (Depakene) Clomipramine (clomipramine) (Annofenil (ANAFRANIL)), amitriptyline (AMITRIPTYLINE) (amitriptyline hydrochloride (elafil)), desipramine (desipramine) (norbomine (Norpramin)), imipramine (imipramine) (tofubrain (Tofranil)), nortriptyline (nortriptyline) (noramitriptyline (Pamelor)), phenelzine (phenelzine) (nadir (Nardil)), strong-inner hundred Le Ming (tranylcypromine) (tranylcypromine (Parnate)), diazepam (diazepam) (diazepam (Valium)), alprazolam (alprazolam) (prandial An Nuo (Xanax)) or clonazepam (clonazepam) (knopin)).
In some embodiments, the additional therapeutic agent is a monoamine oxidase inhibitor (MAOI), which may be, for example, molobetaine (moclobemide), ka Luo Shatong (caroxazone) (acetominophen (Surodil), ti Mo Sitai ni (Timostenil)), bromaromine (brofaromine) (bromaromine (Consonar)), methylene blue (METHYLENE BLUE), pirzadil (pirlindole) (pirlindol (Pirazidol)), milnaciplin (minaprine) (Kang Duoer (Cantor)), Me Qu Yinduo (metralindole) (due to Renzan (Inkazan)), epbezamine (eprobemide), te Qu Yinduo (tetrindole), harmine (harmine), ha Ma Ling (harmaline), A Mi Fuan (amiflamine), beofloxacin (befloxatone) (MD-370,503), western Mo Shatong (cimoxat one) (MD-780,515), mechloretamine (sercloremine) (CGP-4718-A), Ethylsulfoplon (esuprone) or CX157. In some embodiments, the additional therapeutic agent is phenethylamine, such as 3, 4-methylene-dioxymethamphetamine (MDMA) and analogs thereof. Other heat transfer agents suitable for use in combination with the compounds of the present disclosure include, but are not limited to, N-allyl-3, 4-methylenedioxy-amphetamine (MDAL), N-butyl-3, 4-methylenedioxy-amphetamine (MDB U), N-benzyl-3, 4-methylenedioxy-amphetamine (MDBZ), N-cyclopropylmethyl-3, 4-methylenedioxy-amphetamine (MDCPM), N-dimethyl-3, 4-methylenedioxy-amphetamine (MDDM), N-ethyl-3, 4-methylenedioxy-amphetamine (MDE; MDEA), N- (2-hydroxyethyl) -3, 4-Methylenedioxyamphetamine (MDHOET), N-isopropyl-3, 4-Methylenedioxyamphetamine (MDIP), N-methyl-3, 4-ethylenedioxyamphetamine (MDMC), N-methoxy-3, 4-methylenedioxyamphetamine (MDMEO), N- (2-methoxyethyl) -3, 4-methylenedioxyamphetamine (MDMEOET), alpha, N-trimethyl-3, 4-methylenedioxyphenethylamine (MDMP), 3, 4-methylenedioxy-N-methylbenzenebutylamine, N-hydroxy-3, 4-Methylenedioxyamphetamine (MDOH), 3, 4-Methylenedioxyphenethylamine (MDPEA), α -dimethyl-3, 4-methylenedioxyphenethylamine (MDPH; 3, 4-methylenedioxybenzene butylamine), N-propargyl-3, 4-methylenedioxybenzene propylamine (MDPL), methylenedioxy-2-aminoindan (MD AI), 1, 3-benzodioxolyl-N-Methylbutylamine (MBDB), N-methyl-1, 3-benzodioxolyl butylamine, 3, 4-methylenedioxy-N-methyl-alpha-ethylphenylethylamine, 3, 4-methylenedioxybenzene propylamine (MDA), methanone (3, 4-methylenedioxy-N-methylcarbazepine), ethanone (3, 4-methylenedioxy-N-ethylcarbazepine), GHB or gamma hydroxybutyrate or sodium hydroxybutyrate, N-propyl-3, 4-Methylenedioxyamphetamine (MDPR) and the like.
In some embodiments, the compounds of the present disclosure are used in combination with standard care therapies for neurological diseases described herein. Non-limiting examples of standard care therapies may include, for example, lithium, olanzapine, quetiapine, risperidone, aripiprazole (ariprazole), ji Pai cilone, clozapine, sodium divalproex (divalproex sodium), lamotrigine, valproic acid, carbamazepine, topiramate, levomilnacipran, duloxetine, venlafaxine, citalopram, fluvoxamine, escitalopram, fluoxetine, paroxetine, sertraline, clomipramine, amitriptyline, desipramine, imipramine, nortriptyline, phenelzine, cardiac internal bailamine, diazepam, alprazolam, clonazepam, or any combination thereof. Non-limiting examples of standard care therapies for depression are sertraline, fluoxetine, escitalopram, venlafaxine or aripiprazole. Non-limiting examples of standard care therapies for depression are citalopram (citralopram), escitalopram, fluoxetine, paroxetine, diazepam or sertraline. Additional examples of standard care therapies are known to the average skilled artisan.
Methods of increasing at least one of translation, transcription, or secretion of a neurotrophic factor.
As used herein, the term "neurotrophic factor" may refer to a family of soluble peptides or proteins that support survival, growth, and differentiation of developing and mature neurons. Increasing at least one of translation, transcription, or secretion of a neurotrophic factor may be useful, for example, in increasing neuronal plasticity, promoting neuronal growth, promoting neurite generation, promoting synapse generation, promoting dendritic generation, increasing dendritic shaft complexity, increasing dendritic spine density, and increasing excitatory synapses in the brain. In some embodiments, increasing at least one of translation, transcription, or secretion of the neurotrophic factor increases neuronal plasticity. In some embodiments, increasing at least one of translation, transcription, or secretion of a neurotrophic factor promotes neuronal growth, promotes neurite formation, promotes synapse formation, promotes dendritic formation, increases dendritic shaft complexity, and/or increases dendritic spine density.
In some embodiments, a 5-HT 2A modulator (e.g., a 5-HT 2A agonist) is used to increase at least one of translation, transcription, or secretion of a neurotrophic factor. In some embodiments, the compounds of the present disclosure are used to increase translation, transcription, or secretion of neurotrophic factors. In some embodiments, increasing translation, transcription, or secretion of a neurotrophic factor is sufficient to treat migraine, headache (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, neurodegenerative disease, alzheimer's disease, parkinson's disease, psychological disorders, refractory depression, suicidal ideation, major depression, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or addiction (e.g., substance use disorder).
Experiments or assays useful for detecting increased translation of neurotrophic factors include, for example, ELISA, western blot, immunofluorescence assay, proteomic experiments, and mass spectrometry. In some embodiments, the assay or assay for detecting increased transcription of a neurotrophic factor is a gene expression assay, PCR, or microarray. In some embodiments, the assay or assay for detecting increased secretion of a neurotrophic factor is an ELISA, western blot, immunofluorescent assay, proteomic assay, or mass spectrometry assay.
In some embodiments, the present disclosure provides a method for increasing translation, transcription, or secretion of a neurotrophic factor, wherein the method comprises contacting a neuronal cell with a compound disclosed herein.
Examples
The following examples are intended to illustrate the invention and should not be construed as limiting the invention. The temperature is given in degrees celsius. If not mentioned otherwise, all the evaporation is carried out in vacuo, preferably between about 15mm Hg and 100mm Hg (=20-133 mbar). The structures of the final product, intermediates and starting materials are confirmed by standard analytical methods (e.g., MS and NMR). Abbreviations used are those conventional in the art. If undefined, the term has its commonly accepted meaning.
Preparation of selected compounds and intermediates.
The following preparations of the compounds and intermediates are given to enable those skilled in the art to more clearly understand and practice the present invention. It is not to be taken as limiting the scope of the disclosure, but rather as being illustrative and representative only.
Abbreviations (abbreviations)
App appearance
Boc carbamic acid tert-butyl ester
Boc-Lys (Boc) -OSu nα, nε -di-Boc-L-lysine hydroxysuccinimide ester
Boc-Phe-OSu Boc-L-phenylalanine N-hydroxysuccinimide ester
Boc-Pro-OSu Boc-L-proline N-hydroxysuccinimide ester
Boc-Val-OSu Boc-L-valine hydroxysuccinimide ester
Br broad peak
CCl 4 Tetracarbonyl chloride
CDCl 3 d-chloroform
CD 3 OD methanol-d 4
D 2 O deuterium oxide
D double peak
Dd bimodal
DCM dichloromethane
DIPEA diisopropylethylamine
DMA dimethylacetamide
DMAP 4-dimethylaminopyridine
DMF N, N-dimethylformamide
DMSO dimethyl sulfoxide
EDCI. HCl N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride
Et 2 O diethyl ether
EtOAc ethyl acetate
HCl hydrochloric acid or hydrogen chloride
H six-fold state; six-fold peak
HBTU O- (benzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate
HPLC high pressure liquid chromatography
LC-MS liquid chromatography and mass spectrometry
MeOH methanol
MeCN acetonitrile
MgSO 4 magnesium sulfate
MS mass spectrometry
M multiple peaks
Min(s) min
ML of
Mu L microliters
Mass to charge ratio of m/z
Mol
NHS N-hydroxysuccinimide
P five-peak
Q quartet
N 2 Nitrogen
NaHCO 3 sodium bicarbonate
NaOH sodium hydroxide
Na 2SO4 sodium sulfate
NH 4 Cl ammonium chloride
NMP N-methyl-2-pyrrolidone
NMR nuclear magnetic resonance
Rt retention time
S single peak
T triplet
Tert-tert
TBDMSCl tertiary butyl dimethyl silyl chloride
TESCl chlorotriethylsilane
TFA trifluoroacetic acid
THF tetrahydrofuran
TIPSCl triisopropylchlorosilane
The various starting materials, intermediates and compounds of the preferred embodiments can be isolated and purified as desired using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation and chromatography. Salts may be prepared from the compounds by known salt formation procedures. Unless otherwise indicated, all starting materials were obtained from commercial suppliers and used without further purification.
General conditions for characterization:
Mass spectrometry was run on LC-MS systems using electrospray ionization. These were run using Waters Acquity Classic UPLC with PDA and SQ quality detection or Waters Acquity H-Class UPLC with PDA and QD a quality detection. [ M+H ] + refers to the monoisotopic molecular weight.
NMR analysis
The NMR spectra were run on Bruker Ultrashield MHz or 500MHz NMR spectrometers. Unless otherwise indicated, spectra were recorded at 298K and solvent peaks were used as reference. The offset (d) of each signal is measured in parts per million (ppm) relative to the residual solvent peak and the multiplicity is reported along with the associated coupling constant (J) as needed.
If not explicitly indicated, analytical HPLC conditions were as follows:
Instrument: LC-MS-1:
Method 2A
Column: acquity UPLC BEH C18.2.1X105 mm 1.7 μm
Column temperature: 50 DEG C
Flow rate: 0.8mL/min.
Eluent: a: h 2 O, 0.1% formic acid, B: meCN (MeCN)
Gradient: 0.0-1.8 min 2% -98% B,1.8-2.1 min 98% B, 2.1-2.5% A.
Method 2B
Column: acquity UPLC BEH C18.2.1X105 mm 1.7 μm
Column temperature: 50 DEG C
Flow rate: 0.8mL/min.
Eluent: a: h 2 O, 0.1% ammonia, B: meCN (MeCN)
Gradient: 0.0-1.8 min 2% -98% B,1.8-2.1 min 98% B, 2.1-2.5% A.
Instrument: LC-MS-2:
Method 2A
Column: acquity UPLC BEH C18.2.1X105 mm 1.7 μm
Column temperature: 50 DEG C
Flow rate: 0.8mL/min.
Eluent: a: h 2O,B:MeCN,C:50%H2 O/50% MeCN+2.0% formic acid
Gradient: 0.0-1.7 min 0% to 95% b,5% c; 95% B,5% C for 1.7-2.1 min
95% A,5% C for 2.1-2.5 minutes.
Method 2B
Column: acquity UPLC BEH C18.2.1X105 mm 1.7 μm
Column temperature: 50 DEG C
Flow rate: 0.8mL/min.
Eluent A is H2O, B: meCN, C:50% H2O/50% MeCN+2.0% Ammonia (aqueous)
Gradient: 0.0-1.7 min 0% -95% B,5% D; 95% B,5% D in 1.7-2.1 min
95% A,5% D for 2.1-2.5 minutes.
Example 1: 4-methylpiperazine-1-carboxylic acid [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] ester
A suspension of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (201 mg,0.98 mmol) and 4-methylpiperazine-1-carbonyl chloride hydrochloride (196 mg,0.98 mmol) in pyridine (4 mL) was stirred overnight at room temperature under N 2. The mixture was concentrated in vacuo and the residue was purified by column chromatography on silica gel eluting with 5% -15% meoh in CHCl 3 and then a gradient of 15% meoh and 1% tea in CH Cl 3 to give a solid. The solid was dissolved in H 2 O (2 mL) and freeze-dried to give 4-methylpiperazine-1-carboxylic acid [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] ester (50 mg,15% yield) as a solid. LC-MS (LCMS 2: method 2B): rt 1.20 minutes ;MS m/z 331.1=[M+H]+;1H NMR(400MHz,DMSO-d6)δ10.96(br.s,1H),7.19(d,J=7.8Hz,1H),7.10(d,J=2.3Hz,1H),7.00(t,J=7.8Hz,1H),6.61(d,J=7.8Hz,1H),3.66(br.s,2H),3.44(br.s,2H),2.80–2.75(m,2H),2.46–2.35(m,6H),2.23(s,3H),2.19(s,6H).
Alternatively, the compound may be purified by KP-amino D silica column chromatography eluting with a gradient of gasoline in EtOAc to MeOH to give the product as a diformate (14.7 mg). LC-MS (+ve mode) ):m/z=331.20[M+H]+;1H NMR(300MHz,CDCl3)δ8.20(s,2H,HCO),7.13(m,2H,2×ArH),6.92(s,1H,ArH),6.78(d,J=7.5Hz,1H,ArH),3.80(br.s,2H,CH2),3.64(br.s,2H,CH2),2.96(m,2H,CH2),2.64(m,2H,CH2),2.49(br.s,4H,2×CH2),2.36(s,3H,NMe)2.32(s,6H,2×NMe);13C NMR(75.5MHz,CDCl3)δ154.2,144.8,138.6,128.1,122.1,120.4,112.5,108.9,108.8,68.0,60.5,46.2,45.3,45.3,24.5.
Example 2: sulfamic acid [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] ester
Sulfamoyl chloride (135 mg,1.17 mmol) was added in one portion to a stirred suspension of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (199mg, 0.97 mmol) and K 2CO3 (404 mg,2.92 mmol) in THF (2 mL) at room temperature under N 2. The mixture was stirred at room temperature overnight, then the liquid was decanted from the solid and the solid was purified directly by silica gel column chromatography eluting with 10% meoh in DCM and then 15% meoh and 2% tea in DCM to give a solid. The solid was dissolved in H 2 O (2 mL) and freeze-dried to give [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] sulfamate (19 mg,7% yield) as a solid. LC-MS (LCMS 2: method 2B): no NH was observed for Rt 0.85 min ;MS m/z 283.9=[M+H]+;1H NMR(400MHz,D2O)δ7.48(d,J=7.9Hz,1H),7.36(s,1H),7.26(t,J=7.9Hz,1H),7.19(d,J=7.9Hz,1H),3.50(t,J=7.5Hz,2H),3.36(t,J=7.5Hz,2H),2.94(s,6H). and no NH 2 was observed for NH2;1H NM R(400MHz,DMSO-d6)δ11.27(br.s,1H),7.29(d,J=7.8Hz,1H),7.24(d,J=2.3Hz,1H),7.08(t,J=7.8Hz,1H),7.02(d,J=7.8Hz,1H),3.16(s,6H),3.00–2.95(m,2H),2.63–2.60(m,2H)..
Example 3: [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] phosphoric acid di-tert-butyl ester hydrochloride
NaOH (40 mg,1.0 mmol) was added at once to a stirred solution of di-tert-butyl phosphite (194 mg,1.00mmol, 195. Mu.L) and DMAP (123 mg,1.00 mmol) in THF (1.5 mL) and CCI 4 (0.50 mL) under an atmosphere of N 2 at 0deg.C. The mixture was warmed to room temperature and stirred for 10min and then a solution of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (205 mg,1.00 mmol) in THF (1.5 mL) was added dropwise over 5 min. The mixture was heated to 50 ℃ and stirred overnight, then cooled, filtered and the filtrate concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 10% meoh and 2% tea in CHCl 3 to give a solid. The solid was triturated with Et 2 O (3 x 5 ml) and then dried under vacuum to give [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] phosphate di-tert-butyl hydrochloride as a solid (40 mg,9% yield). LC-MS (LCMS 2: method 2B): no NH and NH groups were observed at Rt 1.62 min ;MS m/z 397.3=[M+H]+;1H NMR(400MHz,D2O)δ7.30–7.24(m,2H),7.18(t,J=7.9Hz,1H),7.07(d,J=7.9Hz,1H),3.52(t,J=7.4Hz,2H),3.36(t,J=7.4Hz,2H),2.93(s,6H),1.45(s,9H),1.25(s,9H). HCl;1H NMR(400MHz,DMSO-d6)δ11.17(br.s,1H),9.60(br.s,1H),7.25(d,J=2.4Hz,1H),7.18(d,J=7.9Hz,1H),7.05(t,J=7.9Hz,1H),6.93(d,J=7.9Hz,1H),3.30–3.24(m,2H),3.21–3.14(m,2H),2.82(s,6H),1.42(s,18H).
Example 4: [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] hydrogen phosphate tert-butyl ester
NaOH (81 mg,2.04 mmol) was added in one portion to a stirred solution of di-tert-butyl phosphite (216 mg,1.12mmol, 217. Mu.L) and DMAP (12 mg,0.10 mmol) in THF (1 mL) and CCI 4 (0.50 mL) at 0deg.C under an atmosphere of N 2. The mixture was stirred at room temperature for 10 min and then a solution of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (208 mg,1.02 mmol) in THF (2 mL) was added dropwise over 5 min. The mixture was heated to 50 ℃ and stirred overnight, then cooled to room temperature, filtered and the filtrate concentrated in vacuo. The residue was dissolved in DMSO (2 mL) and then purified by reverse phase chromatography eluting with a gradient of 5% -95% mecn in H 2 O and 0.1% ammonia to give a solid. The solid was purified by chromatography on silica, eluting with 5% -10% meoh in DCM, and then a gradient of 15% meoh and 2% tea in DCM to give the product as a solid (41 mg, 10%). LC-MS (LCMS 2: method 2B): no P (=o) OH was observed at Rt 0.95 min ;MS m/z 341.1=[M+H]+;1H NMR(400MHz,DMS O-d6)δ10.78(br.s,1H),7.03(d,J=2.2Hz,1H),7.00(d,J=7.8Hz,1H),6.93(t,J=7.8Hz,1H),6.66(d,J=7.8Hz,1H),3.24–3.20(m,2H),3.18–3.12(m,2H),2.71(s,6H),1.39(s,9H)..
Example 5: chloromethyl isopropyl carbonate
Chloromethyl chloroformate (2.29 g,17.8mmol,1.58 mL) was added dropwise to a stirred solution of isopropanol (785 mg,13.1mmol,1.00 mL) and pyridine (1.54 g,19.4mmol,1.57 mL) in DCM (15 mL) at room temperature under an atmosphere of N 2 over 15 minutes. The mixture was warmed to room temperature and stirred overnight, then diluted with DCM (15 mL) and washed with 1M aqueous HCl (30 mL) and H 2 O (2 x 30 mL). The organic layer was dried over Na 2SO4 and concentrated in vacuo to give crude chloromethyl isopropyl carbonate (1.93 g,97% yield) as an oil. The title compound was used without further purification. 1H NMR(400MHz,CDCl3 ) Delta 5.72 (s, 2H), 4.96 (hept, j=6.3 hz, 1H), 1.33 (d, j=6.3 hz, 6H).
The compounds of the following table examples (table example 5) were prepared in analogy to example 5 from chloromethyl chloroformate and the appropriate alcohols.
Table example 5
Example 6: [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] oxymethyl tetrahydropyran-4-yl carbonate
A solution of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (209 mg,1.02 mmol), tetrabutylammonium bromide (330 mg,1.02 mmol) and TEA (310 mg,3.07mmol, 428. Mu.L) in MeCN (5 mL) was stirred at room temperature under an atmosphere of N 2 for 15 minutes and then chloromethyl tetrahydropyran-4-yl carbonate (3998 mg,2.05 mmol) in MeCN (5 mL) was added dropwise over 10 minutes. The mixture was stirred at room temperature for 30min and then NaI (15 mg,0.10 mmol) was added in one portion. The mixture was stirred at room temperature for 2 days, then concentrated in vacuo. EtOAc (50 mL), H 2 O (50 mL) and brine (50 mL) were added to the residue. The separated aqueous phase was extracted with EtOAc (50 mL) and then the combined organic layers were dried over MgSO 4, filtered and the filtrate concentrated in vacuo to give the crude [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] oxymethyltetrahydropyran-4-yl carbonate as an oil. LC-MS (LCMS 2: method 2B): rt 1.31 min; MS M/z 363.2 = [ m+h ] +.
Alternative procedure:
Potassium carbonate (149 mg,1.08 mmol) and potassium iodide (18 mg,0.11 mmol) were added to a stirred solution of nupharmoreus dephosphorylation (220 mg,1.08 mmol) in anhydrous DMF (3 mL) at room temperature under an atmosphere of N 2. The resulting suspension was stirred at room temperature for 15 min, then a solution of chloromethyl carbonate (tetrahydro-2H-pyran-4-yl) ester (210 mg,1.08 mmol) in anhydrous DMF (3 mL) was added dropwise to the suspension and the mixture was stirred at room temperature for 16H. The solvent was removed under reduced pressure and the residual material was purified by column chromatography on silica gel eluting with a gradient of MeOH in EtOAc to provide fraction product a (54 mg) as a semi-solid and a fraction (192 mg) containing 3- (2- (dimethylamino) ethyl) -4- ((((((tetrahydro-2H-pyran-4-yl) oxy) carbonyl) oxy) methoxy) -1H-indole-1-carboxylic acid tetrahydro-2H-pyran-4-yl ester (B) as a semi-solid. LC-MS (+ve mode): m/z= 363.10 (a) and 491.10 (B) [ m+h ] +. The product a fraction (54 mg) was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in H 2 O to give the desired product (9 mg) as a solid. LC-MS (+ve mode): m/z=363.15 [ m+h ] +.
Example 7: [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] oxymethyl isopropyl carbonate
A solution of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (201 mg,0.98 mmol), bu 4 NBr (317 mg,0.98 mmol) and TEA (298 mg,2.95mmol, 411. Mu.L) in MeCN (5 mL) was stirred at room temperature under an atmosphere of N 2 for 15 minutes and then a solution of chloromethyl isopropyl carbonate (300 mg,1.97 mmol) in MeCN (5 mL) was added dropwise over 10 minutes. The mixture was stirred at room temperature for 30 min and then NaI (15 mg,0.10 mmol) was added in one portion. The mixture was stirred at room temperature for 3 days, then concentrated in vacuo. EtOAc (50 mL), H 2 O (50 mL) and brine (50 mL) were added to the residue. The separated aqueous phase was extracted with EtOAc (50 mL) and then the combined organic layers were dried over MgSO 4, filtered and the filtrate concentrated in vacuo. The residue was purified by column chromatography on silica gel with 10% -20% meoh in DCM and then a gradient of 20% meoh and 2% tea in DCM to give the product as a solid (5 mg, 2%). LC-MS (LCMS 2: method 2B): no NH was observed at Rt 1.35 min ;MS m/z 321.1=[M+H]+;1H NMR(400MHz,CD3OD)δ7.42(d,J=8.0Hz,1H),7.23–7.14(m,2H),6.90(d,J=8.0Hz,1H),5.55(s,2H),4.98(hept,J=6.2Hz,1H),3.06–2.95(m,4H),2.59(s,6H),1.38(d,J=6.2Hz,6H)..
Example 8: chloromethyl succinic acid tert-butyl ester
Chloromethyl chlorosulfate (3.41 g,20.7mmol,2.09 mL) was added dropwise to a vigorously stirred biphasic mixture of 4-tert-butoxy-4-oxo-butyric acid (3.00 g,17.2 mmol), sodium bicarbonate (5.79 g,68.9 mmol) and tetrabutylammonium bisulfate (585 mg,1.72 mmol) in DCM (45 mL) and H 2 O (30 mL) at room temperature under an atmosphere of N 2 over 10 min. The mixture was stirred vigorously at room temperature overnight, then diluted with DCM (40 mL) and H 2 O (40 mL). The separated organic phase was washed with saturated aqueous NaHCO 3 (40 mL), dried over Na 2SO4, filtered and the filtrate concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with a gradient of 0% -15% etoac in petroleum ether to give tert-butyl chloromethylsuccinate (3.15 g,82% yield) as an oil. 1H NMR(400MHz,CDCl3 ) Delta 5.71 (s, 2H), 2.69-2.61 (m, 2H), 2.62-2.54 (m, 2H), 1.45 (s, 9H).
The compounds of the following table examples (table example 8) were prepared from the appropriate carboxylic acids in analogy to example 8.
Table example 8
Example 9: [1,4 '-bipiperidine ] -1' -carboxylic acid chloromethyl ester hydrochloride
A solution of chloromethyl chloroformate (500 mg,3.88mmol, 345. Mu.L) in DCM (3 mL) was added dropwise to a stirred solution of 1,4' -bipiperidine (544 mg,3.23 mmol) in DCM (3 mL) at 5℃under an atmosphere of N 2 over 15 min. The mixture was stirred at 5 ℃ for 30 minutes and then warmed to room temperature and stirred overnight. H 2 O (0.2 mL) was added to the mixture and the mixture was then vigorously stirred at room temperature for 30 minutes. The mixture was concentrated in vacuo and the residue azeotroped with THF (2 x 4 ml) and then dried under vacuum to give chloromethyl [1,4 '-bipiperidine ] -1' -carboxylate hydrochloride as a solid (960 mg, assuming 100% yield). The title compound was used .1H NMR(400MHz,CD3OD)δ5.93–5.73(m,2H),4.41–4.22(m,2H),3.55–3.46(m,2H),3.42(tt,J=12.2,3.8Hz,1H),3.09–2.83(m,4H),2.22–2.07(m,2H),2.03–1.95(m,2H),1.89–1.62(m,5H),1.58–1.46(m,1H). without further purification, was not observed HCl;1H NM R(400MHz,DMSO-d6)δ10.20(br.s,1H),5.95–5.81(m,2H),4.17–4.02(m,2H),3.42–3.35(m,3H),2.98–2.82(m,4H),2.16–2.05(m,2H),1.87–1.53(m,7H),1.44–1.32(m,1H).
Example 10: {3- [2- (dimethylamino) ethyl ] -4-indolyloxy } methyl-hexanedioic acid tert-butyl ester
Aqueous NaOH (3.75 m,4.73mmol,1.26 mL) was added dropwise to a stirred suspension of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (322 mg,1.58 mmol) and tetrabutylammonium bisulfate (107 mg,0.32 mmol) in DCM (3 mL) at room temperature under an atmosphere of N 2 over 5 min. The mixture was stirred vigorously at room temperature for 5min and then a solution of t-butyl chloromethyladipate (399mg, 1.58 mmol) in DCM (2 mL) was added dropwise over 2 min. The mixture was stirred vigorously at room temperature for 15min, then diluted with DCM (20 mL) and H 2 O (20 mL). The separated aqueous phase was extracted with DCM (2×15 mL) and then the combined organic layers were washed with brine (20 mL), dried over Na 2SO4, filtered and the filtrate concentrated in vacuo to give crude {3- [2- (dimethylamino) ethyl ] -4-indolyloxy } methyl-adipate as a gum. LC-MS (LCMS 2: method 2B): rt 1.72 min; MS M/z 419.3= [ m+h ] +. A sample of the material was purified by column chromatography on silica gel eluting with MeOH in DCM (with 0.1% et 3 N) to provide the product as a semi-solid (41 mg). LC-MS (+ve mode) ):m/z=419.20[M+H]+;1H NMR(300MHz,CDCl3)δ7.12(t,J=7.9Hz,1H,ArH),6.94(dd,J=8.2,0.9Hz,1H,ArH),6.90(s,1H,ArH),6.61(dd,J=7.7,0.9Hz,1H,ArH),5.98(s,2H,CH2),2.93(m,2H,CH2),2.74(m,2H,CH2),2.40(s,6H,2×NCH3),2.31(t,J=7.1Hz,2H,CH2),2.18(t,J=7.0Hz,2H,CH2),1.59(m,4H,2×CH2),1.42(s,9H,3×CH3).
The compounds of the following table examples (table example 10) were prepared in analogy to example 10 from 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol and the appropriate chloride.
Table example 10
/>
Example 11: [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] oxetan-3-yl carbonate
Oxetan-3-ol (145 mg,1.96mmol,124 μl) was added dropwise to a stirred solution of bis (4-nitrophenyl) carbonate (328 mg,1.08 mmol) and DMAP (12 mg,0.10 mmol) in DCM (3 mL) at room temperature under an atmosphere of N 2 over 2 min. The mixture was stirred at room temperature for 1 hour, then 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (200 mg,0.98 mmol) was added to the mixture at room temperature in one portion followed by the dropwise addition of DIPEA (127 mg,0.98mmol,171 μl) over 2 minutes. The mixture was stirred at room temperature for 2 days, then H 2 O (4 mL) and EtOAc (4 mL) were added to the mixture. The separated organic layer was washed with brine (10 mL), dried over Na 2SO4 and concentrated in vacuo to give crude [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] oxetan-3-yl carbonate as a gum. LC-MS (LCMS 2: method 2B): rt 1.29 min; MS M/z 305.2= [ m+h ] +.
Example 12: [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] oxymethyl phosphate di-tert-butyl ester
Sodium hydride, 60% dispersion in mineral oil (60 mg,1.51 mmol) was added in one portion to a stirred solution of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (205 mg,1.00 mmol) in anhydrous DMF (2.5 mL) at room temperature under an atmosphere of N 2. The mixture was stirred at room temperature for 10 minutes, then di-tert-butyl chloromethyl phosphate (317 mg,1.10mmol, 305. Mu.L) was added dropwise over 2 minutes, followed by potassium iodide (500 mg,3.01 mmol) in one portion. The mixture was stirred at room temperature overnight, then H 2 O (1 mL) and EtOAc (20 mL) were added and then the mixture was washed with 90% brine solution (20 mL), 50% brine solution (3 x 20 mL) and saturated aqueous sodium thiosulfate solution (20 mL). The organic layer was dried over Na 2SO4, filtered and the filtrate concentrated in vacuo. The residue was purified by chromatography on silica gel with a gradient of 0% -5% meoh in DCM, and then a gradient of 5% -10% meoh and 0.5% tea in DCM to give the product as a gum (76 mg, 16%). LC-MS (LCMS 2: method 2B): rt 1.82 min ;MS m/z 427.3=[M+H]+;1H NMR(400MHz,CDCl3)δ8.24(br.s,1H),7.09–7.01(m,2H),6.95–6.88(m,1H),6.80(dd,J=6.6,1.9Hz,1H),5.76(d,J=11.4Hz,2H),3.13–3.04(m,2H),2.79–2.69(m,2H),2.42(s,6H),1.44(s,18H);1H-31P coupling: 31P NMR(162MHz,CDCl3)δ-11.83(t,J=11.4Hz);1H-31 P decoupling: 31P NMR(162MHz,CDCl3 ) Delta-11.83(s).
Example 13:5- ({ 3- [2- (dimethylamino) ethyl ] -4-indolyloxycarbonyl } -N-methylamino) pentanoic acid tert-butyl ester
/>
Triphosgene (109 mg,0.37 mmol) was added in one portion to a stirred suspension of 3- [2- (dimethylamino) ethyl ] -1H-indol-4-ol (203 mg,0.99 mmol) and DM AP (389 mg,3.18 mmol) in DCM (10 mL) at room temperature under an atmosphere of N 2. The mixture was stirred at room temperature for 1 hour, then tert-butyl 5- (methylamino) valerate hydrochloride (222 mg,0.99 mmol) was added to the mixture at room temperature in one portion, followed by dropwise addition of TEA (211 mg,2.09mmol, 291. Mu.L) over 2 minutes. The mixture was stirred at room temperature for 2 hours, then concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with a gradient of 0% -10% meoh in DCM to give an oil. The crude material was dissolved in DMSO (1.5 mL) and repurified by reverse phase chromatography eluting with a gradient of 10% -40% mecn in H 2 O and 0.1% formic acid to give tert-butyl 5- ({ 3- [2- (dimethylamino) ethyl ] -4-indolyloxycarbonyl } -N-methylamino) pentanoate as a gum (63 mg,13% yield). The spectroscopic data for the title compound were obtained as a mixture of rotamers. LC-MS (LCMS 2: method 2A): no CO 2 H was observed at Rt 1.17 min ;MS m/z418.2=[M+H]+;MS m/z 418.2=[M+H]+;1H NMR(400MHz,DMSO-d6)δ10.99(br.s,1H),8.19(s,1H),7.19(d,J=8.0Hz,1H),7.13(d,J=2.3Hz,1H),7.00(t,J=8.0Hz,1H),6.62–6.55(m,1H),3.47(t,J=7.0Hz,0.8H),3.30(t,J=6.6Hz,1.2H),3.10(s,1.8H),2.91(s,1.2H),2.84–2.78(m,2H),2.62–2.54(m,2H),2.30–2.21(m,8H),1.69–1.49(m,4H),1.39(s,5.4H),1.38(s,3.6H)..
Example 14:5- ({ 3- [2- (dimethylamino) ethyl ] -4-indolyloxycarbonyl } -N-methylamino) pentanoic acid formate trifluoroacetate salt
TFA (1.48 g,13.0mmol,1.00 mL) was added dropwise to a stirred solution of tert-butyl 5- ({ 3- [2- (dimethylamino) ethyl ] -4-indolyloxycarbonyl } -N-methylamino) pentanoate (38 mg,0.08 mmol) in DCM (1 mL) at room temperature under an atmosphere of N 2 over 5 minutes. The mixture was left at room temperature for 1 hour, then concentrated in vacuo to give the product as a gum (43 mg, 94%). The spectroscopic data for the title compound were obtained as a mixture of rotamers. LC-MS (LCMS 1: method 2A): rt 0.76 minutes; MS (MS)
m/z 362.4=[M+H]+;1H NMR(400MHz,DMSO-d6)δ12.07(br.
s,1H),11.20(s,1H),9.37(br.s,1H),7.29–7.21(m,2H),7.05(t,J=7.9Hz,1H),6.68–6.61(m,1H),3.52–3.47(m,0.8H),3.38–3.29(m,3.2H),3.12(s,1.8H),3.07–2.99(m,2H),2.93(s,1.2H),2.85–2.77(m,6H),2.32–2.24(m,2H),1.67–1.48(m,4H). No two CO 2H;19 F NMR (37MHz, DMSO-d 6) delta-73.9(s) were observed.
The compounds of the following table examples (table example 14) were prepared from the appropriate tert-butyl protected compounds in analogy to example 14.
Table example 14
Example 15:4- (((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) methoxy) -4-oxobutanoic acid trifluoroacetate salt
To tert-butyl (((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) methyl) succinate (68 mg,0.17 mmol) in DCM (5 mL) was added TFA (0.69 mL,0.96g,8.5 mmol) and the mixture was stirred at room temperature for 3H. The mixture was concentrated under reduced pressure and the residue was azeotroped with MeOH (3×10 mL) to afford the product as a semi-solid (122 mg). LC-MS (+ve mode): m/z=335.15 [ m+h ] +.
Example 16: (S) -2-amino-3-methylbutanoic acid ((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) methyl ester
(S) -2- (tert-Butoxycarbonylamino) -3-methyl-butanoic acid {3- [2- (dimethylamino) ethyl ] -4-indolyloxy } methyl ester (16 mg, 40. Mu. Mol) was dissolved in anhydrous dichloromethane (0.5 mL) and TFA (0.5 mL) was added. The reaction mixture was stirred at room temperature under nitrogen. After 5 minutes, the mixture turned dark blue. LC-MS (+ve mode): m/z=334.18 [ m+h ] +.
The following UPLC-MS methods and conditions were used in examples 17-45.
UPLC-MS analysis was performed on a Waters Acquity UPLC system consisting of an Acquisy I-Class sample manager-FL, an Acquisy I-Class binary solvent manager, and an Acquisy UPLC column manager. UV detection is provided using an Acquity UPLC PDA detector (scanning from 210 to 400 nm), whereas mass detection is achieved using an Acquity Quad detector (scanning from 100-1250Da mass; simultaneous positive and negative modes), and ELS detection is achieved using an Acquity UPLC ELS detector. Waters Acquity UPLC BEH C18 columns (2.1X105 mm,1.7 mm) were used for separating the analytes.
Samples were prepared by dissolution (with or without sonication) in 1mL of 50% (v/v) MeCN in water. The resulting solution was then filtered through a 0.2mm syringe filter and then presented for analysis. All solvents (including formic acid and 36% ammonia solution) were purchased as HPLC grade.
Conditions (2 minutes acid): 0.1% v/v formic acid in water [ eluent A ];0.1% v/v formic acid in MeCN [ eluent B ]; the flow rate is 0.8mL/min; column oven 50 ℃; sample manager 20 ℃; an equilibration time of 1.5 minutes between 2mL injection volume and sample. Gradient parameters are provided in table 2:
TABLE 2
Time (minutes) | Eluent A (%) | Eluent B (%) |
0.00 | 95 | 5 |
0.25 | 95 | 5 |
1.25 | 5 | 95 |
1.55 | 5 | 95 |
1.65 | 95 | 5 |
2.00 | 95 | 5 |
Conditions (acid 4 min): 0.1% v/v formic acid in water [ eluent A ];0.1% v/v formic acid in MeCN [ eluent B ]; the flow rate is 0.8mL/min; column oven 50 ℃; sample manager 20 ℃; injection volume 2mL and 1.5 min equilibration time between samples. Gradient parameters are provided in table 3.
Table 3.
Time (minutes) | Eluent A (%) | Eluent B (%) |
0.00 | 95 | 5 |
0.25 | 95 | 5 |
2.75 | 5 | 95 |
3.25 | 5 | 95 |
3.35 | 95 | 5 |
4.00 | 95 | 5 |
Conditions (acid 6 min): 0.1% v/v formic acid in water [ eluent A ];0.1% v/v formic acid in MeCN [ eluent B ]; the flow rate is 0.8mL/min; column oven 50 ℃; sample manager 20 ℃; injection volume 2mL and 1.5 min equilibration time between samples. Gradient parameters are provided in table 4.
Table 4.
Time (minutes) | Eluent A (%) | Eluent B (%) |
0.00 | 95 | 5 |
0.30 | 95 | 5 |
6.00 | 5 | 95 |
6.10 | 95 | 5 |
7.00 | 95 | 5 |
Conditions (alkaline 2 min): 0.1% ammonia in water [ eluent a ];0.1% ammonia in MeCN [ eluent B ]; the flow rate is 0.8mL/min; column oven 50 ℃; sample manager 20 ℃; injection volume 2mL and 1.5 min equilibration time between samples. Gradient parameters are provided in table 5.
Table 5.
Conditions (alkaline 4 min): 0.1% ammonia in water [ eluent a ];0.1% ammonia in MeCN [ eluent B ]; the flow rate is 0.8mL/min; column oven 50 ℃; sample manager 20 ℃; injection volume 2mL and 1.5 min equilibration time between samples. Gradient parameters are provided in table 6.
TABLE 6
Time (minutes) | Eluent A (%) | Eluent B (%) |
0.00 | 95 | 5 |
0.25 | 95 | 5 |
2.75 | 5 | 95 |
3.25 | 5 | 95 |
3.35 | 95 | 5 |
4.00 | 95 | 5 |
Conditions (alkaline 6 min): 0.1% ammonia in water [ eluent a ];0.1% ammonia in MeCN [ eluent B ]; the flow rate is 0.8mL/min; column oven 50 ℃; sample manager 20 ℃; injection volume 2mL and 1.5 min equilibration time between samples. Gradient parameters are provided in table 7.
TABLE 7
Time (minutes) | Eluent A (%) | Eluent B (%) |
0.00 | 95 | 5 |
0.30 | 95 | 5 |
6.00 | 5 | 95 |
6.10 | 95 | 5 |
7.00 | 95 | 5 |
Example 17: tetrahydro-2H-pyran-4-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester hydrochloride
/>
To a mixture of dephosphorized nupharmor-ol (170 mg,0.83 mmol) in anhydrous pyridine (10 mL) was added DMAP (10 mg,0.08 mmol) and the mixture was cooled to 0 ℃. Dioxane-3-carbonyl chloride (117 mg,97 μl,0.79 mmol) was carefully added and the mixture was warmed to room temperature and stirred for 16 hours. The mixture was concentrated under reduced pressure and the residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of acetonitrile in 0.02% hydrochloric acid to provide the product as a glassy solid (231 mg, 84%). LC-MS (+ve mode) ):m/z=317.15[M+H]+;1H NMR(300MHz,CD3OD)δ7.23(m,2H,2×ArH),7.07(t,J=9.0Hz,1H,ArH),6.67(dd,J=7.7,0.8Hz,1H,ArH),3.97(m,2H,CH2),3.54(td,J=11.5,2.5Hz,2H,CH2),3.43(t,J=7.3Hz,2H,CH2),3.15(t,J=7.2Hz,2H,CH2),2.86(s,6H,2×NMe),2.03(m,2H,CH2),1.87(m,2H,CH2);13C NMR(75.5MHz,CDCl3)δ200.5,174.0,143.9,139.3,123.9,121.7,111.7,109.4,107.0,66.6,58.2,42.4,39.9,28.6,21.6.
Example 18: oxetan-3-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester
Oxetane-3-carboxylic acid (79 mg,0.77 mmol) was dissolved in anhydrous DMF (5 mL) under N 2 and N, N-diisopropylethylamine (108 mg, 146. Mu.L, 0.84 mmol) was added followed by the addition of nupharmorin dephosphorylation (132 mg,0.65 mmol) and HBTU (267 mg,0.71 mmol). The mixture was stirred at room temperature for 20 hours, then volatiles were removed under reduced pressure and saturated aqueous NaHCO 3 (20 mL) was added. The resulting mixture was extracted with EtOAc (50 mL) and the organic layer was washed with H 2 O (20 mL), saturated brine (20 mL), dried (MgSO 4), filtered and the filtrate concentrated to give the product (200 mg). LC-MS (+ve mode): m/z=289.15 [ m+h ] +.
Example 19: tetrahydrofuran-3-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester hydrochloride
Tetrahydrofuran-3-carbonyl chloride (184 mg,145 μl,1.37 mmol) was added to a stirred solution of nupharmoreus dephosphorylation (200 mg,0.98 mmol) in anhydrous pyridine (2.4 mL) at room temperature. The mixture was heated to 40 ℃ and stirred for 16 hours, then volatiles were removed under reduced pressure. The residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of acetonitrile in 0.02% hydrochloric acid to provide the product as a solid (284 mg, 86%). LC-MS (+ve mode) ):m/z=303.10[M+H]+;1H NMR(300MHz,D2O)δ7.46(dd,J=8.3,0.6Hz,1H,ArH),7.30(s,1H,ArH),7.25(t,J=8.0Hz,1H,ArH),6.87(dd,J=7.7,0.7Hz,1H,ArH),4.23(dd,J=9.1,4.7Hz,1H,CH),4.05(m,2H,CH2),3.90(m,1H,CH),3.63(m,1H,CH),3.45(t,J=7.0Hz,2H,CH2),3.10(d,J=7.0Hz,2H,CH2),2.86(s,6H,2×NCH3),2.40(m,2H,CH2).
Example 20: 1-Methylazetidine-3-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester
N, N-diisopropylethylamine (278 mg, 384. Mu.L, 2.15 mmol), dimethylaminopyridine (27 mg,0.22 mmol) and 1-methylazetidine-3-carboxylic acid (248 mg,2.15 mmol) were added to a stirred mixture of desphosphoric acid oudemansin (220 mg,1.08 mmol) in DCM (5 mL) under an atmosphere of N 2. The resulting suspension was stirred at room temperature for 15 minutes, then N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride (454 mg,2.37 mmol) was added to this suspension and the reaction mixture was heated to 35 ℃ and stirred for 16 hours. The solvent was removed under reduced pressure to yield a crude residue containing the product. LC-MS (+ve mode): m/z=302.10 [ m+h ] +.
Example 21:3- (2-Acetyloxy-4, 6-dimethylphenyl) -3-methylbutanoic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
Step 1: preparation of 2- (4-chloro-2-methyl-4-oxobutan-2-yl) -3, 5-dimethylbenzene acetate
Oxalyl chloride (255 mg,152 μl,1.78 mmol) was added to a mixture of 3- (2-acetoxy-4, 6-dimethylphenyl) -3-methylbutanoic acid (311 mg,1.78 mmol) in anhydrous DCM (10 mL) at 0deg.C under N 2 atmosphere. The mixture was warmed to room temperature and stirred for 2 hours 45 minutes, then volatiles were removed under reduced pressure to provide the product as a semi-solid, which was used directly in the next step.
Step 2: preparation of 3- (2-acetoxy-4, 6-dimethylphenyl) -3-methylbutanoic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
To a mixture of dephosphorylated ouabain (200 mg,0.98 mmol) and DMAP (12 mg,0.098 mmol) in anhydrous pyridine (5 mL) was added a solution of 3- (2-acetoxy-4, 6-dimethylphenyl) -3-methylbutanoic acid chloride (1.78 mmol) in anhydrous pyridine (5 mL). The mixture was stirred at room temperature for 16 hours and then concentrated to give a semi-solid (0.75 g). The crude product was purified by reverse phase chromatography on C 18 silica eluting with a gradient of 0.1% formic acid in acetonitrile in water to provide the product as a solid (274 mg, 62%). LC-MS (+ve mode) ):m/z=451.20[M+H]+;1H NMR(300MHz,CD3OD)δ8.41(s,1H,HCO),7.23(m,2H,2×ArH),7.04(t,J=8.1Hz,1H,ArH,),6.89(s,1H,ArH),6.69(s,1H,ArH),6.42(dd,J=7.3,0.7Hz,1H,ArH,)3.34(t,J=7.1Hz,2H,CH2),3.20(s,2H,CH2),3.04(t,J=6.9Hz,2H,CH2),2.81(s,6H,2×NMe),2.61(s,3H,CH3),2.32(s,3H,CH3),2.24(s,3H,CH 3)1.73(s,6H,2×CH3);13C NMR(75.5MHz,CD3OD)δ171.2,170.3,167.2,149.8,143.6,139.3,138.3,136.3,132.9,131.9,124.0,123.0,121.6,119.0,111.7,109.3,106.8,58.3,42.3,39.0,30.9,24.3,21.5,20.5,18.8.
Example 22: dipalmitic acid 2- ((((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) carbonyl) oxy) propane-1, 3-diyl ester
To 2-hydroxypropionate-1, 3-diyl dipalmitate (200 mg,0.35 mmol) in DCM (10 mL) was added DMAP (136 mg,1.13 mmol) and triphosgene (40 mg,0.13 mmol), and the mixture was stirred at room temperature for 1 hour. To a mixture of the resulting 2- ((chlorocarbonyl) oxy) propane-1, 3-diyl dipalmitate (0.35 mmol) was added a solution of nula agenda dephosphorylation (71 mg,0.35 mmol) and TEA (40 mg,55 μl,0.42 mmol) in MeC N (5 mL), and the mixture was stirred for 16 hours. The mixture was filtered through Celite (Celite), the filter cake was washed with DCM (3×20 mL), and the combined filtrates were concentrated to give a solid. The crude product was purified by column chromatography on silica gel eluting with a gradient of EtOAc in petrol, then further purified by column chromatography on silica gel eluting with a gradient of EtOAc in MeOH to afford the product as a semi-solid (47.3 mg, 16%). LC-MS (+ve mode) ):m/z=799.55[M+H]+;1H NMR(300MHz,CD3OD)δ7.24(dd,J=8.7,0.7Hz,1H,ArH),7.07(m,2H,2×ArH),6.84(m,1H,ArH),5.24(m,1H,CH),4.48(dd,J=12.2,3.7Hz,2H,CH2),4.26(dd,J=12.0,6.3Hz,2H,CH2),2.93(m,2H,CH2),2.68(m,2H,CH2),2.34(s,6H,2×NMe),1.60(m,4H,2×CH2)1.26(m,42H,21×CH2),0.89(t,J=6.5Hz,6H,2×CH3).
Example 23:6- ((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) -6-oxohexanoic acid hydrochloride
Adipic anhydride (technical grade, 90%,143mg,1.00 mmol) was added to a suspension of dephosphorized nuphar mushroom extract (158 mg,0.77 mmol) in anhydrous DCM (7.5 mL) containing DMAP (19 mg,0.16 mmol) under an atmosphere of N 2, and the mixture was stirred at room temperature for 20 hours. The volatiles were removed under reduced pressure and the residue was purified using C 18 column reverse phase chromatography eluting with a gradient of acetonitrile in H 2 O to provide after freeze drying a solid (158 mg) which was further purified in the same manner to give the free base of the title compound as a very hygroscopic solid. The free base was dissolved in a mixture of 1, 4-dioxane (5 mL) and H 2 O (0.5 mL) and treated with 4M HCl in 1, 4-dioxane (193. Mu.L) at room temperature. Volatiles were removed under reduced pressure to provide the desired product as a solid (153 mg, 54%). LC-MS (+ve mode) ):m/z=333.10[M+H]+;1H NMR(300MHz,D2O)δ7.46(dd,J=8.3,0.8Hz,1H,ArH),7.32(s,1H,ArH),7.25(t,J=8.0Hz,1H,ArH)6.45(dd,J=7.7,0.8Hz,1H,ArH),3.46(t,J=7.0Hz,2H,CH2),3.12(t,J=7.0Hz,2H,CH2),2.87(s,6H,2×NCH3),2.79(m,2H,CH2),2.47(m,2H,CH2),1.78(m,4H,2×CH2);13C NMR(75.5MH z,D2O)δ178.6,175.8,142.9,138.8,125.2,122.4,118.5,112.1,110.5,106.5,58.2,42.9,33.4,23.7,23.5,21.3.
Example 24: (3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) hexanedioic acid tert-butyl ester
A mixture of dephosphorized nupharbitis (155 mg,0.76 mmol), HBTU (345 mg,0.91 mmol), 6- (tert-butoxy) -6-oxohexanoic acid (184 mg,0.91 mmol) and Cs 2CO3 (294 mg,0.91 mmol) in anhydrous DMF (10 mL) was stirred overnight at room temperature under nitrogen. The mixture was concentrated under reduced pressure and the residue was dissolved in a mixture of H 2 O (30 mL) and EtOAc (20 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2X 20 mL). The combined organic layers were washed with saturated brine (20 mL), dried (MgSO 4), filtered and the filtrate concentrated to give an oil (1.13 g) which was purified by column chromatography on silica gel eluting with MeOH in DCM (containing 0.1% et 3 N) to give the product as an oil (180 mg, 61%). LCMS (+ve mode) ):m/z=389.25[M+H]+;1H NMR(300MHz,CDCl3)δ8.79(br.s,1H,NH),7.24(dd,J=8.2,0.8Hz,1H,ArH),7.11(app t,1H,ArH),6.92(d,J=1.7Hz,1H,ArH),6.78(dd,J=7.6,0.8Hz,1H,ArH),3.04(m,2H,CH2),2.84(m,2H,CH2)2.72(m,2H,CH2),2.49(s,6H,2×NCH3),2.30(t,J=7.2Hz,2H,CH2),1.78(m,4H,2×CH2),1.45(s,9H,C(CH3)3);13C NMR(75.5MHz,CDC l3)δ172.9,172.6,143.9,138.6,123.2,122.2,119.5,112.4,110.5,109.5,80.3,59.6,44.2,35.2,34.1,28.1,24.6,24.3,23.2.
Example 25: n- ((tert-Butoxycarbonyl) -L-phenylalanyl) -N-methylglycine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
N-Boc-L-phenylalanine-sarcosine (120 mg,0.36 mmol), HBTU (164 mg,0.43 mmol) and Cs 2CO3 (190 mg,0.58 mmol) were dissolved in anhydrous DMF (4 mL) under N 2. The mixture was stirred at room temperature for 30 min, then a mixture of des-phosphoric acid nupharicin (35 mg,0.16 mmol) in anhydrous DMF (0.5 mL) was added. The mixture was stirred at room temperature for 20 hours, then filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of 0.1% acetonitrile in formic acid in H 2 O to provide the product as a semi-solid (32.5 mg, 39%). LC-MS (+ve mode) ):m/z=523.30[M+H]+;1H NM R(300MHz,CD3CN)δ9.55(s,1H,NH+),8.36(s,1H,HCO),7.35(m,1H,ArH),7.26(m,5H,5×ArH),7.12(m,2H,2×ArH),6.76(dd,J=7.7,0.8Hz,1H,ArH),5.88(d,J=8.8Hz,1H,NH),4.82(m,1H,CH),4.43(s,2H,CH2),3.11(7H,NCH3,2×CH2),2.75(s,6H,2×NCH3),1.31(s,9H,3×Bo c CH3).
Example 26: (tert-Butoxycarbonyl) -L-valine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
To a mixture of dephosphorylated nupharmor (200 mg,0.98 mmol) in MeCN (10 mL) was added K 2CO3 (149 mg,1.08 mmol) and Boc-Val-OSu (292 mg,0.93 mmol). The mixture was heated to 80 ℃ and stirred for 1 hour, allowed to cool to room temperature and stirred for 16 hours. The mixture was filtered through celite and the filter pad was washed with Me CN (2 x 20 mL) and the combined filtrates were concentrated. The crude product was purified using reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.1% formic acid in H 2 O to provide the product as a foam (184 mg, 46%). LC-MS (+ve mode) ):m/z=404.25[M+H]+;1H NMR(300MHz,CD3OD)δ8.42(s,1H,HC O),7.32(dd,J=8.2,0.8Hz,1H,ArH),7.26(s,1H,ArH),7.14(t,J=7.9Hz,1H,ArH),6.76(dd,J=7.7,0.8Hz,1H,ArH),4.36(d,J=5.9Hz,1H,CH),3.50(m,2H,CH2),3.26(t,J=7.5Hz,2H),2.99(s,6H,2×NMe),2.42(m,1H,CH),1.50(s,9H,3×Boc CH3),1.19(d,J=6.9Hz,3H,CH3),1.15(d,J=6.9Hz,3H,CH3);13C NMR(75.5MHz,CD3OD)δ210.6,202.1,174.1,167.4,159.0,145.6,141.2,126.3,123.4,121.0,113.2,111.5,109.4,81.3,61.5,60.4,44.2,32.3,29.4,23.3,20.4,19.2.
Example 27: l-valine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester dihydrochloride
A mixture of (tert-butoxycarbonyl) -L-valine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate (140 mg,0.35 mmol) in DCM (10 mL) was treated with TFA (1.33 mL,17.4 mmol) under an atmosphere of N 2. The mixture was stirred at room temperature for 3 hours, then volatiles were removed under reduced pressure and the crude residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.02% hydrochloric acid to provide the product as a semi-solid (19 mg, 14%). LC-MS (+ve mode) ):m/z=304.15[M+H]+;1H NMR(300MHz,CDCl3)δ7.34(dd,J=8.2,0.8Hz,1H,ArH),7.26(s,1H,ArH),7.13(t,J=8.0Hz,1H,ArH),6.80(dd,J=7.8,0.8Hz,1H,ArH),4.75(d,J=4.0Hz,1H,CH),3.47(m,2H,CH2),3.29(m,2H,CH2),2.93(s,3H,NCH3),2.92(s,3H,NCH3),2.62(m,1H,CH),1.27(dd,J=7.8,1.7Hz,6H,2×CH3).
Example 28: (tert-Butoxycarbonyl) -L-phenylalanine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
A suspension of Boc-Phe-OSu (0.67 mg,1.84 mmol), dephosphorylated ouabain (348 mg,1.68 mmol) and K 2CO3 (254 mg,1.84 mmol) in anhydrous MeCN (10 mL) was stirred under N 2 at room temperature for 1 hour, then heated to reflux and stirred for 30 minutes, then stored at room temperature for 20 hours. The mixture was poured into H 2 O (40 mL) and extracted with EtOAc (3×40 mL). The combined organic layers were washed with saturated brine (40 mL), dried (MgSO 4), filtered and the filtrate was concentrated to an oil (804 mg). The residue was purified by column chromatography on silica gel eluting with a gradient of MeOH in DCM to provide a mixture of the desired product (as its free base) and dephosphorylated ouabain (130 mg). This material was further purified using reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.1% formic acid in H 2 O to provide the product as a solid (174 mg, 21%). LC-MS (+ve mode) ):m/z=452.25[M+H]+;1H NMR(300MHz,DMSO-d6)δ11.05(s,1H,NH),8.21(s,1H,HCO),7.71(d,J=8.5Hz,1H,ArH),7.32(m,4H,ArH),7.24(m,2H,ArH+NH+),7.16(d,J=2.1Hz,1H,ArH),7.03(m,1H,ArH),6.60(d,J=7.4Hz,1H,ArH),4.58(m,1H,CH),3.30(dd,J=13.7,4.7Hz,1H,CHaHb(Phe)),3.05(dd,J=13.7,10.4Hz,1H,CHaHb(Phe)),2.85(m,2H,CH2),2.59(m,2H,CH2),2.27(s,6H,2×NCH3),1.34(s,9H,C(CH3)3);13C NMR(75.5MHz,DMSO-d6)δ171.7,164.2,156.0,144.2,139.1,138.1,129.7,128.7,127.0,124.1,121.4,119.8,111.5,111.4,109.9,78.9,60.6,55.8,45.3,40.8,28.6.
Example 29: l-phenylalanine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester 2HCl salt
(Tert-Butoxycarbonyl) -L-phenylalanine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate (110 mg,0.22 mmol) is dissolved in anhydrous DCM (2 mL) and TFA (0.5 mL) is added dropwise. The mixture was stirred for 30min, then volatiles were removed under reduced pressure and the residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of acetonitrile in 0.02% hydrochloric acid to provide the product as a solid (70 mg, 75%). LC-MS (+ve mode) ):m/z=352.20[M+H]+;1H NMR(300MHz,D2O)δ7.45(m,6H,ArH),7.35(s,1H,ArH),7.28(m,1H,ArH),6.93(d,J=0.6Hz,1H,ArH),4.82(m,1H,CH),3.62(dd,J=14.3,7.2Hz,1H,CHaHb(Phe)),3.50(dd,J=14.3,6.9Hz,1H,CHaHb(Phe)),3.35(m,2H,CH2),3.09(m,2H,CH2),2.86(s,3H,NCH3),2.79(s,3H,NCH3);13C NMR(75.5MHz,D2O)δ169.5,142.2,139.0,133.8,129.5,129.3,128.2,125.5,122.3,117.7,111.6,111.1,106.3,58.0,54.2,43.2,42.6,35.9,21.2.
Example 30:2- (3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) L-pyrrolidine-1, 2-dicarboxylic acid 1- (tert-butyl) ester formate salt
A suspension of Boc-Pro-OSu (261 mg,0.84 mmol), dephosphorylated ouabain (155 mg,0.76 mmol) and K 2CO3 (115 mg,0.84 mmol) in anhydrous MeCN (5 mL) was heated to 90℃and stirred for 18 hours. The mixture was poured into H 2 O (20 mL) and extracted with EtOAc (3X 20 mL). The combined organic layers were washed with saturated brine (20 mL), dried (MgSO 4), filtered and the filtrate concentrated to give crude oil which was purified using reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.1% formic acid in H 2 O to provide the product as a semi-solid (54 mg, 16%). LC-MS (+ve mode): m/z=402.25 [ m+h ] +;1H NMR(300MHz,CD3 CN) (mixture of two rotamers) )δ9.45(br.s,1H,NH+),8.36(s,1H,HC O),7.34(m,1H,ArH),7.15(m,2H,ArH),6.89-6.77(m,1H,ArH),4.63(m,1H,CH),3.47(m,2H,CH2),3.10(m,4H,2×CH2),2.69(s,3H,NCH3),2.48(s,3H,NCH3),2.28(m,2H,CH2),2.04(obs m,2H,CH2),1.47(s,9H,C(CH3)3).
Example 31: l-proline 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester dihydrochloride
Boc-Pro-dephosphorylated nupharin formate (242 mg,0.54 mmol) was dissolved in anhydrous DCM (4 mL) and TFA (1 mL) was added dropwise. The reaction mixture was stirred at room temperature for 2 hours, then volatiles were removed under reduced pressure and the residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.02% hydrochloric acid to provide the product as a semi-solid (178 mg, 70%). LC-MS (+ve mode) ):m/z=302.15[M+H]+;1H NMR(300MHz,D2O)δ7.50(d,,J=8.2Hz,1H,ArH),7.36(s,1H,ArH),7.27(t,J=7.8Hz,1H,ArH),6.98(d,J=7.8Hz,1H,ArH),4.92(t,J=8.2Hz,1H,CH),3.52(m,4H,2×CH2),3.19(t,J=6.7Hz,2H,CH2),2.89(s,6H,2×NCH3),2.72(m,1H,0.5×CH2),2.45(m,1H,0.5×CH2),2.23(m,2H,CH2);13C NMR(75.5MHz,D2O)δ169.6,142.5,139.0,125.4,122.3,117.9,111.7,111.0,106.4,59.6,58.0,46.3,42.9,42.8,28.3,23.5,21.4.
Example 32: n2, N6-bis (t-butoxycarbonyl) -L-lysine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester hydrochloride
To a mixture of dephosphorylated nupharmor (200 mg,0.98 mmol) in anhydrous MeCN (10 mL) was added K 2CO3 (149 mg,1.08 mmol), followed by the addition of Boc-Lys (Boc) -OSu (413 mg,0.93 mmol) in portions. The mixture was stirred at room temperature for 16 hours, the solvent was removed under reduced pressure and the crude residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.02% hydrochloric acid to provide the product as a solid (243 mg, 47%). LC-MS (+ve mode): m/z=533.35 [ m+h ] +.
Example 33: l-lysine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester tri-hydrochloride
A mixture of N2, N6-bis (t-butoxycarbonyl) -L-lysine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester hydrochloride (243 mg,0.46 mmol) in DCM (10 mL) was treated with TFA (1.76 mL,23.0 mmol) under an atmosphere of N 2. The mixture was stirred at room temperature for 16 hours, then volatiles were removed under reduced pressure and the crude residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.02% hydrochloric acid to provide the product as a solid (141 mg, 70%). LC-MS (+ve mode) ):m/z=333.20[M+H]+;1H NMR(300MHz,D2O)δ7.43(d,J=8.2Hz,1H,ArH),7.30(s,1H,ArH),7.20(t,J=8.0Hz,1H,ArH),6.85(d,J=7.8Hz,1H,ArH),4.57(m,1H,CH),3.44(t,J=7.8Hz,2H,CH2),3.13(t,J=6.0Hz,2H,CH2),3.00(t,J=7.5Hz,2H,CH2),2.82(d,J=6.0Hz,6H,2×NMe),2.22(m,2H,CH2),1.69(m,4H,2×CH2);13C NMR(75.5MHz,CDCl3)δ170.1,142.4,139.0,125.5,122.4,118.0,111.7,111.2,106.8,58.1,52.7,43.1,42.7,39.0,29.4,26.4,21.7,21.3.
Example 34: dimethylglycine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester diformate
A suspension of N, N-dimethylglycine (113 mg,1.10 mmol), N-hydroxysuccinimide (139 mg,1.21 mmol), N-diisopropylethylamine (156 mg, 211. Mu.L, 1.21 mmol) and HBTU (417 mg,1.10 mmol) in a mixture of EtOAc (10 mL) and DMF (5 mL) was stirred at room temperature for 18 h. The solvent was removed under reduced pressure and the residual material was dissolved in anhydrous MeCN (10 mL) and placed under an atmosphere of N 2. K 2CO3 (167 mg,1.21 mmol) and dephosphorylated ouabain (202 mg,0.99 mmol) were added and the mixture was heated to reflux and stirred for 30min, followed by stirring at room temperature for 18 h. The mixture was filtered through celite and the filter cake was washed with MeCN. The combined filtrates were concentrated under reduced pressure and the residue was purified using reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.1% formic acid in H 2 O to provide the product as an oil (79 mg, 21%). LC-MS (+ve mode) ):m/z=290.15[M+H]+;1HNMR(300MHz,D2O)δ8.35(br.s,2H,2×HCO),7.42(d,J=8.2Hz,1H,ArH),7.29(s,1H,ArH),7.20(m,1H,ArH),6.93(d,J=7.8Hz,1H,ArH),4.50(s,2H,CH2),3.43(m,2H,CH2),3.11(m,2H,CH2),3.00(s,6H,2×NCH3),3.81(s,6H,2×NCH3).
Example 35: 2-oxa-6-azaspiro [3.3] heptane-6-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
Step 1: preparation of 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl chloroformate (de-phosphate nupharmic acid ester)
To a solution of dephosphorylated ouabain (200 mg,0.98 mmol) in DCM (10 mL) was added DMAP (338 mg,3.2 mmol) and triphosgene (85 mg,0.36 mmol). The reaction mixture was stirred at room temperature for 1 hour and used directly in the next step.
Step 2: preparation of 2-oxa-6-azaspiro [3.3] heptane-6-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
To the solution of the des-phosphate bare cap fungus ester of chloroformate were added 2-oxa-azaspiro [3,3] heptane (194 mg,196 mmol) and TEA (118 mg, 156. Mu.L, 1.17 mmol) and the mixture was stirred at room temperature for 16 hours. H 2 O (1 mL) was added and the mixture was filtered through celite, washing the filter cake with DCM (10 mL) and MeCN (10 mL). The combined filtrates were concentrated to give a solid (0.80 g) which was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.1% formic acid in H 2 O to provide the product as a semi-solid (167 mg, 51%). LC-MS (+ve mode) ):m/z=330.10[M+H]+;1H NMR(300MHz,DMSO-d6)δ8.24(s,1H,HCO),7.20(dd,J=8.1,0.9Hz,1H,ArH),7.13(d,J=2.4Hz,1H,ArH),7.00(t,J=7.8Hz,1H,ArH),6.67(dd,J=7.6,0.8Hz,1H,ArH),4.72(s,4H,2×CH2),4.43(br.s,2H,CH2),4.18(br.s,2H,CH2),2.86(m,2H,CH2),2.61(m,2H,CH2),2.34(s,6H,2×NMe);13C NMR(75.5MHz,DMSO-d6)δ164.5,154.5,154.3,144.4,138.9,123.9,121.4,112.1,110.9,109.5,80.3,80.0,60.5,59.4,58.7,44.8,38.1,24.1.
Example 36: morpholine-4-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester hydrochloride
Pyridine (0.79 g, 809. Mu.L, 10.0 mmol) was added dropwise to triphosgene (294 mg,1.00 mmol) in anhydrous DCM (5 mL) at 0deg.C under an atmosphere of N 2. After stirring until the precipitate dissolved (about 20 minutes), morpholine (93 mg,92 μl,1.07 mmol) was introduced dropwise into the flask. The mixture was stirred at 0 ℃ for 15min and at room temperature for 1 hour, then the DCM was removed under reduced pressure and additional pyridine (3 mL) was added followed by the addition of nupharin dephosphorylation (204 mg,1.00 mmol). The mixture was heated to 80 ℃ and stirred for 16 hours, then volatiles were removed under reduced pressure and the residue was dissolved in MeOH (5 mL). EtOAc (20 mL) was added to give a solid, which was removed by filtration. The filtrate was concentrated under reduced pressure and the residue was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.02% hydrochloric acid to give the product as a solid (75 mg, 22%). LC-MS (+ve mode) ):m/z=318.15[M+H]+;1H NMR(300MHz,D2O)δ7.44(d,J=8.2Hz,1H,ArH),7.32(s,1H,ArH),7.24(t,J=7.7Hz,1H,ArH),6.85(d,J=7.7Hz,1H,ArH),3.83(br.s,6H,3×CH2),3.59(m,2H,CH2),3.44(m,2H,CH2),3.13(m,2H,CH2),2.87(s,6H,2×NCH3);13C NMR(75.5MHz,D2O)δ155.8,143.5,138.78,125.1,122.5,119.1,112.3,110.3,106.6,66.2,58.2,44.6,43.9,42.8,21.3.
Example 37: ((5-methyl-2-oxo-1, 3-dioxol-4-yl) methyl) carbonic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester
To a solution of des-phosphate bare cap fungus chloroformate (containing about 1mmol chloride) was added a solution of 4- (hydroxymethyl) -5-methyl-1, 3-dioxol-2-one (127 mg,0.98 mmol) and TEA (118 mg,156 μl,1.17 mmol) in DCM (5 mL). The mixture was stirred at room temperature for 16 hours, then filtered through celite, and the filter cake was washed with DC M (10 mL) and MeCN (10 mL). The combined filtrates were concentrated to give the product (0.63 g). LC-MS (+ve mode): m/z=361.10 [ m+h ] +.
Example 38:2- (4- ((tert-butyldimethylsilyl) oxy) -1H-indol-3-yl) -N, N-dimethylethan-1-amine
A solution of desphosphoric acid oudemansiella radicata (98 mg,0.48 mmol) in anhydrous DMF (3.5 mL) was treated with imidazole (65 mg,0.96 mmol) and TBDMSCl (174 mg,1.15 mmol) under an atmosphere of N 2 followed by dropwise addition of N, N-diisopropylethylamine (149 mg, 200. Mu.L, 1.15 mmol). The mixture was stirred at room temperature for 24 hours, then the volatiles were removed under reduced pressure and EtOAc (50 mL) and saturated aqueous NaHCO 3 (20 mL) were added. The organic layer was separated, washed with H 2 O (20 mL), saturated brine (20 mL), dried (MgSO 4) and concentrated to give a solid which was purified by column chromatography on silica gel, eluting with a gradient of MeOH in DCM to provide the product as a solid (112 mg, 73%). LC-MS (+ve mode) ):m/z=319.20[M+H]+;1H NMR(300MHz,CDCl3)δ7.98(br.s,1H,NH),6.94(m,3H,3×ArH),6.47(dd,J=7.2,1.3Hz,1H,ArH),3.12(m,2H,CH2),2.68(m,2H,CH2),2.32(s,6H,2×NCH3),1.04(s,9H,C(CH3)3),0.34(s,6H,2×CH3);13C NMR(75.5MHz,CDCl3)δ150.6,138.8,122.5,120.2,119.6,115.0,107.8,104.5,60.8,45.7,26.3,25.2,18.8,-3.6.
Example 39: n, N-dimethyl-2- (4- ((triisopropylsilyl) oxy) -1H-indol-3-yl) ethan-1-amine
A mixture of desphosphoric acid oudemansiella radiata (155 mg,0.76 mmol) in anhydrous DMF (3.5 mL) was treated with imidazole (103 mg,1.52 mmol) and TIPSCl (351 mg, 390. Mu.L, 1.82 mmol) under an atmosphere of N 2 followed by dropwise addition of N, N-diisopropylethylamine (235 mg, 317. Mu.L, 1.82 mmol). The mixture was stirred at room temperature for 24 hours, then the volatiles were removed under reduced pressure and EtOAc (50 mL) and saturated aqueous NaHCO 3 (20 mL) were added. The organic layer was separated, washed with H 2 O (20 mL), saturated brine (20 mL), dried (MgSO 4), filtered and the filtrate concentrated to give a solid, which was purified by column chromatography on silica gel, eluting with a gradient of MeOH in DCM to provide the product as a solid (255 mg, 92%). LC-MS (+ve mode ):m/z=361.25[M+H]+;1H NMR(300MHz,CDCl3)δ7.96(br.s,1H,NH),6.94(m,3H,3×ArH),6.46(dd,,J=7.2,1.3Hz,1H,ArH),3.19(m,2H,CH2),2.76(m,2H,CH2),2.35(s,6H,2×NCH3),1.41( seven peak) ,J=7.5Hz,3H,3×CH(CH3)2),1.04(d,J=7.5Hz,18H,3×CH(CH3)2);13C NMR(75.5MHz,CDCl3)δ151.0,138.8,122.6,120.2,119.7,114.7,107.5,104.4,60.5,45.5,24.9,18.3,13.7.
Example 40: n, N-dimethyl-2- (4- ((triethylsilyl) oxy) -1H-indol-3-yl) ethan-1-amine
Imidazole (127 mg,1.86 mmol) and TESCl (336 mg, 375. Mu.L, 2.23 mmol) were added to a mixture of dephosphorized nupharin (190 mg,0.93 mmol) in anhydrous DM F (4.2 mL) under an atmosphere of N 2, followed by dropwise addition of N, N-diisopropylethylamine (288 mg, 388. Mu.L, 2.23 mmol). The mixture was stirred at room temperature for 18 hours, then the volatiles were removed under reduced pressure and EtOAc (75 mL) and saturated aqueous NaHCO 3 (20 mL) were added. The organic layer was separated, washed with H 2 O (20 mL), saturated brine (20 mL), dried (MgSO 4), filtered and the filtrate concentrated to give crude oil (324 mg). This material was purified by column chromatography on silica gel eluting with a gradient of MeOH in DCM to provide the product as a semi-solid (236 mg, 80%). LC-MS (+ve mode) ):m/z=319.15[M+H]+;1H NMR(300MHz,CDCl3)δ8.00(br.s,1H,NH),6.93(m,3H,3×ArH),6.45(br.d,J=7.2Hz,1H,ArH),3.10(m,2H,CH2),2.68(m,2H,CH2),2.33(s,6H,2×NCH3),1.02(m,9H,3×CH2CH3),0.87(m,6H,3×CH2CH3);13C NMR(75.5MHz,CDCl3)δ150.5,138.8,122.6,120.4,119.5,115.0,107.2,104.6,61.2,45.7,25.2,6.9,5.4.
Example 41: (3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) methyl ethyl carbonate formate salt
Chloromethyl ethyl carbonate (234 mg,196 μl,1.69 mmol) was added to a suspension of nugesso de-phosphate (157 mg,0.77 mmol) and K 2CO3 (265 mg,1.92 mmol) in anhydrous DMF (6 mL) at room temperature under an atmosphere of N 2. The mixture was stirred at room temperature for 24 hours, the solids were removed by filtration through celite, and the filter cake was washed with MeC N. The combined filtrates were concentrated to give an oil (265 mg), which was dissolved in 5% aqueous formic acid and the resulting mixture was stirred at room temperature for 16 hours. The mixture was concentrated under reduced pressure and the residue was purified using reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.1% formic acid in H 2 O to give the product as a semi-solid (127 mg, 47%). LC-MS (+ve mode) ):m/z=307.10[M+H]+;1H NMR(300MHz,D2O)δ8.42(br.s,1H,HCO),7.53(d,J=8.3Hz,1H,ArH),7.34(m,2H,ArH),7.05(d,J=7.8Hz,1H,ArH),5.63(s,2H,OCH2O),4.40(q,J=7.1Hz,2H,CH2),3.44(m,2H,CH2),3.14(m,2H,CH2),2.92(s,6H,2×NCH3),1.38(t,J=7.1Hz,3H,CH3);13C NMR(75.5MHz,D2O)δ170.3,154.9,143.4,138.3,128.3,123.0,119.6,112.7,108.9,107.7,68.3,66.4,58.2,42.7,21.1,13.4.
Example 42: methyl pivalate ((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy)
Potassium carbonate (406 mg,2.94 mmol), potassium iodide (49 mg,0.29 mmol) and chloromethyl pivalate (443 mg, 424. Mu.L, 2.94 mmol) were added to a stirred mixture of nuphar rugoso-annulata dephosphorylation (0.60 g,2.94 mmol) in anhydrous DMF (15 mL) at room temperature under an atmosphere of N 2. The mixture was stirred at room temperature for 16 hours, then the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel eluting with a gradient of MeOH in EtOAc to provide 3- (2- (dimethylamino) ethyl) -1- ((pivaloyloxy) methyl) -1H-indol-4-yl pivalate C (192 mg, 16%), methyl (3- (2- (dimethylamino) ethyl) -4-hydroxy-1H-indol-1-yl) pivalate B (117 mg, 13%) as a solid (117 mg) and a fraction containing impure pivalic acid ((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) methyl ester a (170 mg) as an oil. The fraction containing compound a (170 mg) was purified by column chromatography on silica gel eluting with a gradient of MeOH in EtOAc to give a fraction containing compound a (82 mg) as an oil. This material (82 mg) was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in water to provide the title compound as a semi-solid (22 mg, 2%). LC-MS (+ve mode) ):m/z=319.15[M+H]+;1H NMR(300MHz,CDCl3)δ7.12(t,J=7.9Hz,1H,ArH),6.94(dd,J=8.2,0.8Hz,1H,ArH),6.89(s,1H,ArH),6.61(dd,J=7.7,0.9Hz,1H,ArH),5.96(s,2H,CH2),2.91(m,2H,CH2),2.70(m,2H,CH2),2.38(s,6H,2×NCH3),1.15(s,9H,3×Boc CH3).
Data for (3- (2- (dimethylamino) ethyl) -4-hydroxy-1H-indol-1-yl) methyl pivalate (B)
LC-MS (+ve mode) ):m/z=319.15[M+H]+;1H NMR(300MH z,CDCl3)δ7.37(dd,J=8.3,0.5Hz,1H,ArH),7.15(t,J=8.0Hz,1H,ArH),6.98(s,1H,ArH),6.68(dd,J=7.7,0.6Hz,1H,ArH),5.52(s,2H,CH2),2.86(t,J=7.3Hz,2H,CH2),2.63(t,J=7.3Hz,2H,CH2),2.25(s,6H,2×NCH3),1.41(s,9H,3×Boc CH3);13C NMR(75.5MHz,CDCl3)δ177.9,144.9,138.5,126.3,122.5,121.1,112.7,110.5,108.3,70.0,58.9,44.7,39.4,27.5,23.4.
Data for 3- (2- (dimethylamino) ethyl) -1- ((pivaloyloxy) methyl) -1H-indol-4-yl pivalate (C)
LC-MS (+ve mode) ):m/z=403.25[M+H]+;1H NMR(300MHz,CDCl3)δ7.30(dd,J=8.2,0.8Hz,1H,ArH),7.19(t,J=8.0Hz,1H,ArH),7.03(s,1H,ArH),6.75(dd,J=7.7,0.8Hz,1H,ArH),6.01(s,1H,CH2),2.92(m,2H,CH2),2.64(m,2H,CH2),2.30(s,6H,2×NCH3),1.43(s,9H,3×BocCH3),1.14(s,9H,3×Boc CH3);13C NMR(75.5MHz,CDCl3)δ178.4,177.7,145.1,139.0,126.15,122.9,121.5,114.2,113.3,107.4,68.9,59.9,45.7,39.4,39.1,27.5,27.1,24.7.
Example 43: di- (hydroxymethyl isopropyl) phosphate 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester
Cesium carbonate (88 mg,0.27 mmol) was added to a stirred suspension of oudemansiella radiata (70 mg,0.25 mmol) in DMF (3 mL) at room temperature under an atmosphere of N 2. After 15 minutes chloromethyl isopropyl carbonate (56 mg,49 μl,0.37 mmol) was added to the suspension and the mixture was stirred at room temperature for 16 hours. The solvent was removed under reduced pressure and the residual material was purified by reverse phase chromatography on C 18 silica eluting with a gradient of MeCN in 0.02% hydrochloric acid to provide the product as a semi-solid (17 mg). LC-MS (+ve mode): m/z=517.20 [ m+h ] +.
Example 44: bis (dimethyl pivalate) phosphate 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester
Bis (2, 2-dimethylpropionate) ((hydroxyphosphoryl) bis (oxy)) bis (methylene) (194 mg,0.60 mmol) was dissolved in anhydrous DCM (5 mL) containing DMF (5. Mu.L) at room temperature under an atmosphere of N 2 and a solution of (COCl) 2 (457 mg, 306. Mu.L, 3.57 mmol) in anhydrous DCM (5 mL) was added dropwise. The mixture was stirred at room temperature for 1 hour, then volatiles were removed under reduced pressure. The residue was dissolved in DCM (5 mL) and added to a mixture of nupharicin dephosphorylation (101 mg,496 μmol) in anhydrous pyridine at 0 ℃. The mixture was warmed to room temperature and stirred for 18 hours, then concentrated under reduced pressure to give an oil containing the product (359 mg). LC-MS (+ve mode): m/z=513.25 [ m+h ] +.
Alternative procedure:
cesium carbonate (161 mg,0.49 mmol) was added to a stirred suspension of oudemansiella radicata (70 mg,0.25 mmol) in anhydrous DMF (3 mL) under an atmosphere of N 2. After 15 minutes, chloromethyl pivalate (74 mg,71 μl,0.49 mmol) was added to the suspension and the mixture was heated to 50 ℃ and stirred for 16 hours. The solvent was removed under reduced pressure to provide a semi-solid containing the cultural compound. LC-MS (+ve mode): m/z= 513.25 (a), 399.15 (B), 597.30 (C), 483.20 (D), and 389.30 (E) [ m+h ] +.
Example 45:3- ((((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) sulfonyl) oxy) -2, 2-dimethylpropionic acid ethyl ester
Ethyl 3-hydroxy-2, 2-dimethylpropionate (351 mg,2.39 mmol) and pyridine (115 mg, 118. Mu.L, 1.46 mmol) were dissolved in anhydrous Et 2 O (3 mL) under an atmosphere of N 2 and the mixture was cooled to-78 ℃. A solution of SO 2Cl2 (200 mg, 118. Mu.L, 1.46 mmol) in anhydrous Et 2 O (10 mL) was added dropwise and the mixture stirred at-78℃for 30 min. The prepared suspension containing chlorosulfonyloxy intermediate was added dropwise to a solution of desphosphoric acid galectin (136 mg,0.664 mmol) in anhydrous pyridine (10 mL) at 0 ℃ under N 2 atmosphere, and the mixture was warmed to room temperature and stirred for 16 hours. The precipitate was removed by filtration, the filter cake was washed with DCM, and the filtrate was concentrated to give a semi-solid. LC-MS (+ve mode): m/z=413.15 [ m+h ] +.
Example 46: pharmacokinetics of the nupharicin-dephosphorylated prodrug was selected in rats after a single intravenous or oral administration.
Exemplary protocols used in PK studies are summarized in table 8 below.
Table 8. Summary of po or IV PK study protocol
/>
Analysis
Samples were sent via unique calibration lines and following acceptance QC for optimization and measurement of the method of both prodrug and parent compound (dephosphorylated galectin). Dose formulation concentrations were also measured and PK parameters (,Cmax(ng/mL)、Tmax(hr)、Cl(ml/min/kg)、Vdss(L/kg)、t1/2(hr)、AUC0-t(ng/mL*hr)、AUC0-inf(ng/mL*hr)、MRT(hr)、 bioavailability (% F) where necessary) were determined using WinNon Lin software. The data (including bioanalytical results and assay performance) are reported in tabular form.
Additional formulation details of PK study
Phosphoric acid. 85% phosphoric acid was diluted 8.5 times to yield a 10% solution.
Formulations for PO administration: for PO administration, the prodrug was formulated in 10% DMSO/40% PEG-400/water to a concentration of 2mg/mL dephosphorylated galectin. This provides a dose of 10mg/kg of dephosphorylated nupharicin when the prodrug is administered at 5mL/kg of dosing volume PO.
Formulations for IV administration: for IV administration, the prodrug was formulated in 10% DMSO/90% hydroxypropyl-beta-cyclodextrin (HPCD, 20% w/v in water) to a concentration of 0.5mg/mL dephosphorylated galectin. This provides a dose of 1mg/kg of dephosphorylated nupharicin when the prodrug is administered at a dosing volume IV of 2 mL/kg.
NB: the prodrug (without dephosphorylated galectin) was first dissolved in DMSO and then PEG was added, followed by water/0.5% methylcellulose, if necessary.
Measuring the concentration of the dephosphorylated ouabain after IV in vivo or oral administration of the dephosphorylated ouabain prodrug or derivative
The pharmacokinetic properties of IV or of the dephosphorylated galectin prodrug or derivative synthesized after oral administration in a rat model were evaluated. The concentration of dephosphorylated nupharicin in each rat is measured at a plurality of sampling time points after IV or oral administration of the synthetic dephosphorylated nupharicin prodrug or derivative to the rat.
Dosage formulations were prepared at equal concentrations of dephosphorylated galectin adjusted to the molecular weight of the compound tested. Nominal doses (1 mg/kg for IV and 2mg/kg for PO) were used in PK parameter determinations.
Example 2-1 dephosphorization of the parent Compound of nupharin (IV)
Chemical name: de-phosphate nupharicin
Structural category: parent body
Mechanism category: n/a-parent compounds
TABLE 2-1 dephosphorization of the parameters of the Phlomycete (IV) PK
FIG. 1 shows the average concentration-time profile of dephosphorylated ouabain after IV administration of dephosphorylated ouabain (1 mg/kg).
EXAMPLE 2-2 dephosphorization of the parent Compound of nupharin (PO)
Chemical name: de-phosphate nupharicin
Structural category: parent body
Mechanism category: n/a-parent compounds
TABLE 2 dephosphorization of the Phlomycete (PO) PK parameters
FIG. 2 shows the average concentration-time profile of dephosphorylated ouabain after oral administration of dephosphorylated ouabain (2 mg/kg).
EXAMPLES 2-3 Euonymus Alata Sieb
Chemical name: nuda cover mushroom extract
Structural category: phosphate prodrugs
Mechanism category: phosphatase enzyme
TABLE 2-3 De-phosphate nupharin PK parameters
FIG. 3 shows the average concentration-time profile of metabolite dephosphorylated ouabain after oral administration of ouabain (2 mg/kg).
Examples 2-4 dephosphorization of the Ussula Capsoides-O-TBDMS ether prodrugs
Chemical name: 2- (4- ((tert-butyldimethylsilyl) oxy) -1H-indol-3-yl) -N, N-dimethylethan-1-amine
Structural category: silyl ethers
Mechanism category: assuming non-enzymatic decomposition
TABLE 2-4 dephosphorization of the Phlomycete PK parameters
FIG. 4 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
EXAMPLES 2-5 dephosphorization of the Ulipstatin-O-TIPS Ether prodrugs
Chemical name: n, N-dimethyl-2- (4- ((triisopropylsilyl) oxy) -1H-indol-3-yl) ethan-1-amine
Structural category: silyl ethers
Mechanism category: assuming non-enzymatic decomposition
/>
TABLE 2-5 dephosphorization of the Phlomycete PK parameters
FIG. 5 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-6 dephosphorization of the Ussula Pubescentis extract O-adipate hydrochloride prodrug
Chemical name: 6- ((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) -6-oxohexanoic acid HCl salt
Structural category: half esters
Mechanism category: assuming esterase and/or assuming pH-dependent intramolecular cyclization
TABLE 2-6 dephosphorization of the Phlomycete PK parameters
FIG. 6 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
EXAMPLES 2-7 desphosphoric acid Eugenia-3-tetroxide hydrochloride prodrugs
Chemical name: tetrahydrofuran-3-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester HCl salt
Structural category: esters of
Mechanism category: assuming esterases
TABLE 2-7 De-phosphate nupharin PK parameters
FIG. 7 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-8 dephosphorization of the Uyghur extract trimethyl locked formate prodrug
Chemical name: 3- (2-Acetyloxy-4, 6-dimethylphenyl) -3-methylbutanoic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
Structural category: esters of
Mechanism category: assuming esterase+intramolecular cyclization
TABLE 2-8 dephosphorization of the Phlomycete PK parameters
FIG. 8 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-9 dephosphorization of the Heterol 2-oxa-6-azaspiro [3.3] heptanoate formate prodrugs
Chemical name: 2-oxa-6-azaspiro [3.3] heptane-6-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
Structural category: carbamates (Carbamates)
Mechanism category: assuming enzymatic hydrolysis
TABLE 2-9 dephosphorization of the Phlomycete PK parameters
/>
FIG. 9 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
EXAMPLES 2-10 dephosphorization of the Ussula Capsoides O-TES Ether prodrugs
Chemical name: n, N-dimethyl-2- (4- ((triethylsilyl) oxy) -1H-indol-3-yl) ethan-1-amine
Structural category: silyl ethers
Mechanism category: assuming non-enzymatic decomposition
TABLE 2-10 dephosphorization of the Phlomycete PK parameters
FIG. 10 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-11 dephosphorization of the Eugenia-D-lysine tri-hydrochloride prodrugs
Chemical name: l-lysine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester tri-hydrochloride
Structural category: esters of amino acids
Mechanism category: assuming esterases
TABLE 2-11 dephosphorization of the Phlomycete PK parameters
FIG. 11 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-12 dephosphorization of the Uyghur extract oxazolidine hydrochloride prodrugs
Chemical name: tetrahydro-2H-pyran-4-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester hydrochloride
Structural category: esters of
Mechanism category: assuming esterases
TABLE 2-12 dephosphorization of the Phlomycete PK parameters
FIG. 12 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-13 desphosphoric acid galectin morpholinocarbamate hydrochloride prodrugs
Chemical name: morpholine-4-carboxylic acid 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester HCl salt
Structural category: carbamates (Carbamates)
Mechanism category: assuming enzymatic hydrolysis
TABLE 2-13 De-phosphate nupharin PK parameters
FIG. 13 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-14 dephosphorization of the O-methylethyl formate prodrug of nupharin carbonate
Chemical name: (3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy) methyl ethyl carbonate formate salt
Structural category: methoxymethylene carbonate
Mechanism category: assuming esterase+chemical decomposition
TABLE 2-14 dephosphorization of the Phlomycetes Umbelliferae PK parameters
FIG. 14 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-15 dephosphorization of Di-tert-butyl Capsoxyphosphonate hydrochloride prodrugs
Chemical name: di-tert-butyl [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] phosphate HCl salt
Structural category: phosphonic acid esters
Mechanism category: assuming phosphatase
TABLE 2-15 dephosphorization of the Phlomycete PK parameters
FIG. 15 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg). * Plasma concentrations were below the quantitative limit (BLQ) at other time points.
Examples 2-16 dephosphorization of the Ussula galectin Boc-valine formate prodrugs
Chemical name: (tert-Butoxycarbonyl) -L-valine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
Structural category: protected amino acid ester prodrugs
Mechanism category: assuming esterases
TABLE 2-16 dephosphorization of the Phlomycete PK parameters
FIG. 16 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-17 dephosphorization of the Ussula galectin Boc-proline formate prodrugs
Chemical name: l-pyrrolidine-1, 2-dicarboxylic acid 1- (tert-butyl) 2- (3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) ester formate salt
Structural category: protected amino acid esters
Mechanism category: assuming esterases
TABLE 2-17 dephosphorization of the Phlomycete PK parameters
FIG. 17 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
EXAMPLES 2-18 desphosphoric acid Eugenia decursinol phenylalanine dihydrochloride prodrugs
Chemical name: l-phenylalanine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester 2HCl salt
Structural category: amino acid esters
Mechanism category: assuming esterases
TABLE 2-18 De-phosphate nupharin PK parameters
FIG. 18 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-19 dephosphorization of the Ussula Capsoides Boc-phenylalanine formate prodrugs
Chemical name: (tert-Butoxycarbonyl) -L-phenylalanine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
Structural category: protected amino acid esters
Mechanism category: assuming esterases
TABLE 2-19 dephosphorization of the Phlomycete PK parameters
FIG. 19 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-20 desphosphoric acid nupharin Pivaloyloxymethyl (POM) prodrugs
Chemical name: methyl pivalate ((3- (2- (dimethylamino) ethyl) -1H-indol-4-yl) oxy)
Structural category: pivaloyloxymethyl (POM) prodrugs
Mechanism category: assuming esterase+chemical decomposition
TABLE 2-20 De-phosphate nupharin PK parameters
FIG. 20 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-21 dephosphorization of the Ulmus-Tepsilosis O-proline ester dihydrochloride prodrugs
Chemical name: l-proline 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester 2HCl salt
Structural category: amino acid esters
Mechanism category: assuming esterases
TABLE 2-21 dephosphorization of the Phlomycete PK parameters
FIG. 21 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
EXAMPLES 2-22 dephosphorization of the Ussula galectin N-POM Ether prodrugs
Chemical name: novel methyl (3- (2- (dimethylamino) ethyl) -4-hydroxy-1H-indol-1-yl) pivalate
Structural category: N-Pivaloyloxymethyl (POM)
Mechanism category: assuming esterase+chemical decomposition
TABLE 2-22 dephosphorization of the Phlomycetes Umbelliferae PK parameters
FIG. 22 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-23 dephosphorization of the N-POM Ether O-pivaloyl prodrugs of nupharmic acid
Chemical name: 3- (2- (dimethylamino) ethyl) -1- ((pivaloyloxy) methyl) -1H-indol-4-yl pivalate
Structural category: N-Pivaloyloxymethyl (POM) and esters
Mechanism category: assuming esterase+chemical decomposition
TABLE 2-23 dephosphorization of the Phlomycete PK parameters
FIG. 23 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-24 dephosphorization of the Ulmus-Tenebrio-Volvin O-methyl glutarate ether tert-butyl ester prodrug
Chemical name: {3- [2- (dimethylamino) ethyl ] -4-indolyloxy } methylpentanedioic acid tert-butyl ester
Structural category: acyloxymethyl (AOM)
Mechanism category: assuming esterase and/or pH dependent intramolecular cyclization + chemical decomposition
TABLE 2-24 dephosphorization of the Phlomycete PK parameters
FIG. 24 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-25 dephosphorization of the Uyghur medicine O-methyl succinate ether tert-butyl ester prodrug
Chemical name: {3- [2- (dimethylamino) ethyl ] -4-indolyloxy } methyl succinic acid tert-butyl ester
Structural category: acyloxymethyl (AOM)
Mechanism category: assuming esterase and/or pH dependent intramolecular cyclization + chemical decomposition
TABLE 2-25 dephosphorization of the Phlomycete PK parameters
/>
FIG. 25 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-26 dephosphorization of the Ulmus-Tepsilosis O-methylpiperazine carbamate diformate prodrugs
Chemical name: 4-methylpiperazine-1-carboxylic acid [3- [2- (dimethylamino) ethyl ] -1H-indol-4-yl ] ester diformate
Structural category: carbamates (Carbamates)
Mechanism category: assuming enzymatic hydrolysis
TABLE 2-26 dephosphorization of the Phlomycete PK parameters
* Plasma concentration BLQ-below the limit of quantification
EXAMPLES 2-27 dephosphorization of the Ulmus-Tenebrio-calico-patent O-methyl adipate ether tert-butyl ester prodrug
Chemical name: {3- [2- (dimethylamino) ethyl ] -4-indolyloxy } methyl-hexanedioic acid tert-butyl ester
Structural category: acyloxymethyl (AOM)
Mechanism category: assuming esterase and/or pH dependent intramolecular cyclization + chemical decomposition
TABLE 2-27 dephosphorization of the Phlomycete PK parameters
FIG. 26 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
EXAMPLES 2-28 dephosphorization of the Eugenia-valine dihydrochloride prodrug
Chemical name: l-valine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester 2HCl
Structural category: amino acid esters
Mechanism category: assuming esterases
TABLE 2-28 dephosphorization of the Phlomycete PK parameters
FIG. 27 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-29 dephosphorization of the Ussula galectin N-Boc-L-phenylalanine-sarcosinate prodrugs
Chemical name: n- ((tert-Butoxycarbonyl) -L-phenylalanyl) -N-methylglycine 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl ester formate salt
Structural category: dipeptide
Mechanism category: assuming esterase and/or pH dependent intramolecular cyclization
TABLE 2-29 dephosphorization of the Phlomycete PK parameters
FIG. 28 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
Examples 2-30 dephosphorization of the Dimethylglycinate diformate prodrug of nupharin
Chemical name: 3- (2- (dimethylamino) ethyl) -1H-indol-4-yl dimethyl glycine ester diformate
Structural category: esters of
Mechanism category: assuming esterases
TABLE 2-30 dephosphorization of the Phlomycete PK parameters
/>
FIG. 29 shows the average concentration-time profile of metabolite dephosphorylated ouabain following oral administration of a dephosphorylated ouabain prodrug (2 mg/Kg).
While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Many modifications, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. The following claims are intended to define the scope of the invention and the methods and structures within the scope of these claims and their equivalents are covered thereby.
Claims (183)
1. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or isotopologue thereof:
Wherein:
R 1 is hydrogen, -OH, unsubstituted OR substituted alkyl, OR, OR C (O) OR; wherein R is unsubstituted alkyl;
R 2 is -C(O)R3、-C(O)OR3、-CH(R4)OC(O)R5、-CH(R4)OC(O)OR5、-C(O)NR6R7、-CH(R4)OC(O)NR6R7、-S(O)2NR6R7、-S(O)2OR5、-P(O)OR8(NR9R10)、-P(O)(OR11)(OR12)、-CH(R4)OP(O)(OR11)(OR12) or-Si (R 3)(R4)(R5);
Each of R 3、R4、R5 and R 8 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A;
Each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A; or R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A;
each of R 9 and R 10 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A, or R 9 and R 10 together with the atom to which they are attached form a heterocyclylalkyl ring or heteroaryl ring that is unsubstituted or substituted with one or more R A;
Each of R 11 and R 12 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A;
Each R A is independently alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl is unsubstituted OR substituted with one OR more alkyl, aryl, halogen 、-S-R13、-OR13、-NR(R18)R19、-C(O)R14、-OC(O)R15、-OC(O)OR16, OR-OC (O) N (R 18)R19;
Each of R 13、R14、R15、R16 or R 17 is independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or substituted with one or more R B;
Each of R 18 and R 19 is independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R B; or R 18 and R 19 together with the atoms to which they are attached form a heterocyclylalkyl ring or heteroaryl ring, each of which is unsubstituted or substituted with one or more R B;
Each R B is independently halogen, amino, cyano, hydroxy, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, -OC (O) R 18、-C(O)R18、-C(O)OR18、NHC(O)OR18, or heteroarylalkyl, wherein cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more halogen, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
2. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Ia):
3. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1 or claim 2, wherein R 3 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
4. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any of claims 1 to 3, wherein R 3 is unsubstituted or substituted alkyl.
5. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 4, wherein R 3 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
6. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 4 or claim 5, wherein R 3 is unsubstituted alkyl.
7. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 6, wherein R 3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
8. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 4 OR claim 5, wherein R 3 is alkyl substituted with-C (O) OR 13.
9. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 8, wherein R 13 is hydrogen or alkyl.
10. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 8, wherein R 13 is hydrogen, methyl, ethyl, or tert-butyl.
11. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 4 or claim 5, wherein R 3 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
12. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 4 or claim 5, wherein R 3 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
13. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 4 or claim 5, wherein R 3 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, benzoyl, phenyl, or NH-Boc.
14. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 4 or claim 5, wherein R 3 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
15. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 4 or claim 5, wherein R 3 is
16. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 4 or claim 5, wherein R 3 isWherein R C is the side chain of a natural amino acid and R' is hydrogen or-Boc.
17. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 16, wherein R 3 is
18. A compound or pharmaceutically acceptable salt, solvate or isotopologue as claimed in any one of claims 1 to 3 wherein R 3 is heterocyclylalkyl.
19. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 18, wherein R 3 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
20. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 4 or claim 5, wherein R 3 is
21. The compound of claim 4 or claim 5, or a pharmaceutically acceptable salt, solvate, or isotopologue thereof, wherein R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
22. A compound or pharmaceutically acceptable salt, solvate or isotopologue as claimed in any one of claims 1 to 3 wherein R 3 is heteroalkyl.
23. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any of claims 1 to 3, wherein R 3 is unsubstituted or substituted aryl (e.g., phenyl).
24. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 23, wherein R 3 is substituted phenyl.
25. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 24, wherein R 3 is phenyl substituted with-OC (O) R 18, wherein R 18 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl.
26. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Ib):
27. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 26, wherein R 3 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
28. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 26 or claim 20, wherein R 3 is unsubstituted or substituted alkyl.
29. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of any one of claims 19 to 21, wherein R 3 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)O R16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-O P (O) OR 20(OR21.
30. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 29, wherein R 3 is alkyl substituted with heterocyclylalkyl.
31. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 30, wherein R 3 is aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Substituted alkyl, wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
32. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 26 to 28, wherein R 3 is alkyl substituted with one or more-OC (O) R 15.
33. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 26 to 28, wherein R 3 is isopropyl substituted with two-OC (O) R 15, wherein each R 15 is alkyl.
34. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 26 to 28, wherein R 3 is unsubstituted alkyl.
35. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 34, wherein R 3 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
36. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 26 or 27, wherein R 3 is heteroalkyl.
37. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 26 or 27, wherein R 3 is heterocyclylalkyl.
38. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 37, wherein R 3 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
39. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 37, wherein R 3 is oxetanyl.
40. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 26 or 27, wherein R 3 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
41. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 26 or 27, wherein R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
42. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Ic):
43. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 42, wherein each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl are unsubstituted or substituted with one or more R A.
44. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 42, wherein R 6 and R 7, together with the atoms to which they are attached, form a heterocyclylalkyl or heteroaryl ring that is unsubstituted or substituted with one or more R A.
45. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 44, wherein R 6 and R 7, together with the atoms to which they are attached, form aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
46. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 45, wherein R 6 and R 7, together with the atoms to which they are attached, form
47. The compound, or pharmaceutically acceptable salt, solvate, or isotopologue of claim 42 or 43, wherein R 6 is methyl.
48. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 47, wherein R 7 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen OR alkyl.
49. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 47, wherein R 7 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen, methyl, ethyl, OR tert-butyl.
50. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Id):
51. The compound, or pharmaceutically acceptable salt, solvate, or isotopologue of claim 50, wherein R 4 is hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
52. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 50 or claim 51, wherein R 4 is hydrogen or unsubstituted or substituted alkyl.
53. The compound, or pharmaceutically acceptable salt, solvate, or isotopologue of claim 52, wherein R 4 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
54. The compound, or pharmaceutically acceptable salt, solvate, or isotopologue of claim 52, wherein R 4 is hydrogen.
55. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 54, wherein R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
56. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 55, wherein R 5 is unsubstituted or substituted alkyl.
57. The compound, OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 56, wherein R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(O R21).
58. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 56, wherein R 5 is unsubstituted alkyl.
59. The compound, or pharmaceutically acceptable salt, solvate, or isotopologue of claim 58, wherein R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
60. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of any one of claims 50 to 55, wherein R 5 is alkyl substituted with C (O) OR 13.
61. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 60, wherein R 13 is hydrogen or alkyl.
62. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 60, wherein R 13 is hydrogen, methyl, ethyl, or tert-butyl.
63. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 55, wherein R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
64. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 55, wherein R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
65. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 55, wherein R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
66. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 55, wherein R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
67. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 55, wherein R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
68. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 54, wherein R 5 is heterocyclylalkyl.
69. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 68, wherein R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
70. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 68, wherein R 5 is optionally substituted piperidinyl.
71. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 68, wherein R 5 is
72. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 55, wherein R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
73. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 54, wherein R 5 is heteroalkyl.
74. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 54, wherein R 5 is unsubstituted or substituted aryl (e.g., phenyl).
75. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 50 to 54, wherein R 5 is tert-butyl 、-CH(NH2)CH(CH3)2、-CH2N(CH3)2、-CH2CH2OCH3、-CH2CH2NH(CH3)2、-CH2CH2C(CH3)2OC(O)CH3、-CH2CH2C(CH3)2NHC(O)CH3 or-CH 2CH2C(CH3)2NHC(O)OCH2CH3.
76. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Ie):
77. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 76, wherein R 4 is hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
78. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 76 or claim 77, wherein R 4 is unsubstituted or substituted alkyl.
79. The compound, or pharmaceutically acceptable salt, solvate, or isotopologue of claim 78, wherein R 4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
80. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 76 or claim 77, wherein R 4 is hydrogen.
81. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 79, wherein R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
82. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 81, wherein R 5 is unsubstituted or substituted alkyl.
83. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 82, wherein R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(O R21.
84. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 82, wherein R 5 is unsubstituted alkyl.
85. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 84, wherein R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
86. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 83, wherein R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
87. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 83, wherein R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
88. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 83, wherein R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
89. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 83, wherein R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
90. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 79, wherein R 5 is heterocyclylalkyl.
91. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 90, wherein R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
92. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claims 76 to 83, wherein R 3 is alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
93. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 79, wherein R 5 is heteroalkyl.
94. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 79, wherein R 5 is unsubstituted or substituted aryl (e.g., phenyl).
95. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 76 to 79, wherein R 5 is morpholinyl, isopropyl, or ethyl.
96. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (If):
97. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 96, wherein R 4 is hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
98. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 96 or claim 97, wherein R 4 is unsubstituted or substituted alkyl.
99. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 98, wherein R 4 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
100. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 96 or 97, wherein R 4 is hydrogen.
101. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 96 to 100, wherein each of R 6 and R 7 is independently alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more R A.
102. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 101, wherein R 6 is hydrogen or methyl, and R 7 is hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more R A.
103. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 96 to 100, wherein R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl ring or heteroaryl ring that is unsubstituted or substituted with one or more R A.
104. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 103, wherein R 6 and R 7, together with the atoms to which they are attached, form aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
105. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 103, wherein R 6 and R 7 together with the atoms to which they are attached form an optionally substituted piperidinyl.
106. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 103, wherein R 6 and R 7 together with the atoms to which they are attached form
107. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Ig):
108. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 107, wherein each of R 6 and R 7 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more R A.
109. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 107, wherein R 6 and R 7 are each independently hydrogen or alkyl.
110. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 107, wherein R 6 and R 7 are each independently hydrogen or methyl.
111. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 107, wherein R 6 and R 7 are each hydrogen.
112. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 107, wherein R 6 and R 7 together with the atoms to which they are attached form a heterocyclylalkyl ring or heteroaryl ring that is unsubstituted or substituted with one or more R A.
113. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 112, wherein R 6 and R 7, together with the atoms to which they are attached, form aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl,Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
114. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Ih):
115. the compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 114, wherein each of R 11 and R 12 is independently hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
116. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 114 or 115, wherein each of R 11 and R 12 is independently hydrogen or unsubstituted or substituted alkyl.
117. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 115, wherein each of R 11 and R 12 is independently alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
118. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 114 or 115, wherein each of R 11 and R 12 is independently unsubstituted alkyl.
119. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 93, wherein each of R 11 and R 12 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
120. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 114 or 115, wherein each of R 11 and R 12 is independently alkyl substituted with-OC (O) R 15, wherein R 15 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
121. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 114 OR 115, wherein each of R 11 and R 12 is independently alkyl substituted with-OC (O) OR 16, wherein R 16 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, OR heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted OR further substituted with one OR more halo, amino, cyano, hydroxy, alkyl, acetyl, OR benzoyl.
122. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 121, wherein R 16 is hydrogen or alkyl.
123. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 121, wherein R 16 is hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
124. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 89 or claim 114, wherein each of R 11 and R 12 is independently heteroalkyl.
125. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 89 or claim 114, wherein each of R 11 and R 12 is independently unsubstituted or substituted aryl (e.g., phenyl).
126. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 114, wherein the compound has the structure of formula (Ih'):
Wherein R 4A and R 4A 'are each independently hydrogen or alkyl, and R 5A and R 5A' are each independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl groups.
127. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 126, wherein R 4A and R 4A' are each hydrogen.
128. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 126 or 127, wherein R 5A and R 5A' are each methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
129. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 126 or 127, wherein R 5A and R 5A' are each isopropyl or tert-butyl.
130. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 26, wherein the compound has the structure of formula (Ib'):
Wherein R 6A and R 6A' are each independently hydrogen or alkyl.
131. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 130, wherein R 6A and R 6A' are each independently -CH3、-C2H5、C3H7、C4H9、C5H11、C6H13、C7H15、C8H17、C9H19、C10H21、C11H23、C12H25、C13H27、C14H29、C15H31、C16H33 or C 17H35.
132. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 130 or 131, wherein R 6A and R 6A' are the same.
133. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 26, wherein the compound has the structure of formula (Ib'):
Wherein each of R 6A、R1B、R2B and R 3B is independently hydrogen or alkyl.
134. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 133, wherein R 6A is -CH3、-C2H5、C3H7、C4H9、C5H11、C6H13、C7H15、C8H17、C9H19、C10H21、C11H23、C12H25、C13H27、C14H29、C15H31、C16H33 or C 17H35.
135. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 133 or 134, wherein R 1B、R2B and R 3B are each independently alkyl.
136. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 135, wherein each of R 1B、R2B and R 3B is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
137. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 135, wherein R 1B、R2B and R 3B are each methyl.
138. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Ii):
139. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 138, wherein each of R 3、R4 and R 5 is independently hydrogen, unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
140. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 138 or 139, wherein each of R 3、R4 and R 5 is unsubstituted or substituted alkyl.
141. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of any one of claims 138 to 140, wherein each of R 3、R4 and R 5 is independently alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
142. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 138-140, wherein each of R 3、R4 and R 5 is independently unsubstituted alkyl.
143. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 142, wherein each of R 3、R4 and R 5 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H2 1.
144. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 142, wherein R 3、R4 and R 5 are the same unsubstituted alkyl.
145. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 142, wherein R 3 and R 4 are methyl, ethyl, or isopropyl.
146. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 145, wherein R 5 is ethyl, isopropyl, or tert-butyl.
147. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 142, wherein (i) R 3 and R 4 are methyl, R 5 is ethyl; (ii) R 3、R4 and R 5 are isopropyl; or (iii) R 3、R4 and R 5 are ethyl.
148. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 89 or claim 138, wherein each of R 3、R4 and R 5 is independently heteroalkyl.
149. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 89 or claim 138, wherein each of R 3、R4 and R 5 is independently unsubstituted or substituted aryl (e.g., phenyl).
150. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound has the structure of formula (Ij):
151. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 150, wherein R 5 is unsubstituted or substituted alkyl, heteroalkyl, cycloalkyl, or heterocyclylalkyl.
152. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 150 or 151, wherein R 5 is unsubstituted or substituted alkyl.
153. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of claim 150 OR 151, wherein R 5 is alkyl substituted with one OR more substituents R A, and wherein each R A is independently selected from alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, amino acid side chain 、-OR13、-N(R18)R19、-C(O)OR13、-N(R13)C(O)OR14、-N(R13)C(O)R14、-C(O)R14、-OC(O)R15、-OC(O)OR16、-OP(O)OR17[N(R18)R19]、-C(O)N(R18)R19、-OC(O)N(R18)R19, OR-OP (O) OR 20(OR21.
154. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 150 to 153, wherein R 5 is unsubstituted alkyl.
155. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 154, wherein R 5 is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, 3-methyl-1-butyl, or-C 10H21.
156. The compound OR pharmaceutically acceptable salt, solvate, OR isotopologue of any one of claims 150 to 153, wherein R 5 is alkyl substituted with-C (O) OR 13, wherein R 13 is hydrogen OR alkyl.
157. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 156, wherein R 5 is hydrogen, methyl, ethyl, isopropyl, or tert-butyl.
158. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 150 to 153, wherein R 5 is alkyl substituted with-N (R 18)R19, wherein each of R 18 and R 19 is independently hydrogen or methyl.
159. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 150 to 153, wherein R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 and R 14 is independently hydrogen or methyl.
160. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 150 to 153, wherein R 5 is alkyl substituted with-N (R 13)C(O)R14, wherein each of R 13 is hydrogen or methyl, and R 14 is hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl are unsubstituted or further substituted with one or more halo, amino, cyano, hydroxy, alkyl, acetyl, or benzoyl.
161. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 150 to 153, wherein R 5 is alkyl substituted with-N (R 13)C(O)OR14, wherein each of R 13 and R 14 is independently hydrogen, methyl, or ethyl.
162. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 150 or 151, wherein R 5 is heterocyclylalkyl.
163. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 162 wherein R 5 is selected from aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl dioxide, diazacyclohexanyl, Wherein X is-CH 2-、-O-、-S-、-SO2, -NH-or-NMe.
164. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 1 to 163, wherein R 1 is hydrogen.
165. A compound of formula (II), or a pharmaceutically acceptable salt, solvate or isotopologue thereof:
Wherein:
r 21 is CH 3、CH2D、CHD2 or CD 3;
Each of R 22 and R 23 is independently hydrogen or alkyl, wherein one or more hydrogens in the alkyl are optionally substituted with deuterium;
Each of Y 1、Y2、Y3、Y4、Y5、Y6、Y7、Y8 and Y 9 is independently hydrogen or deuterium; and
Wherein when R 21 is CH 3 and R 22 and R 23 do not include deuterium, then at least one of Y 1、Y2、Y3、Y4、Y5、Y6、Y7、Y8 and Y 9 is deuterium.
166. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 111, wherein R 21 is-CH 3.
167. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 111, wherein R 21 is-CD 3.
168. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 113, wherein R 22 and R 23 are each independently-CH 3、-CH2D、-CHD2 or-CD 3.
169. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 113, wherein at least one of R 22 and R 23 comprises deuterium.
170. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 113, wherein one of R 22 and R 23 is-CD 3.
171. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 113, wherein both R 22 and R 23 are-CD 3.
172. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 117, wherein Y 1 is D.
173. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 117, wherein Y 3 is D.
174. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 117, wherein Y 1 and Y 2 are each D.
175. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 117, wherein Y 3 and Y 4 are each D.
176. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 117, wherein Y 1、Y2、Y3 and Y 4 are each D.
177. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of any one of claims 111 to 117, wherein Y 6 is H.
178. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 111, wherein the compound is selected from the group consisting of:
/>
179. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound is a compound described in table 1.
180. The compound or pharmaceutically acceptable salt, solvate, or isotopologue of claim 1, wherein the compound is selected from the group consisting of:
/>
/>
181. a pharmaceutical composition comprising a compound according to any one of claims 1-180, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
182. A method of treating or preventing a disease, disorder, or condition in which increased levels of dephosphorylated nuphar mushroom are beneficial, the method comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt, solvate, or isotopologue of any of claims 1-180 or a pharmaceutical composition of claim 181.
183. The method of claim 182, wherein the disease, disorder, or condition is selected from post-traumatic stress disorder, major depressive disorder, schizophrenia, alzheimer's disease, frontotemporal dementia, parkinson's disease, parkinson's dementia, dementia with lewy bodies, multiple system atrophy, and abuse of drugs.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63/235,543 | 2021-08-20 | ||
US202163289025P | 2021-12-13 | 2021-12-13 | |
US63/289,025 | 2021-12-13 | ||
PCT/US2022/040922 WO2023023347A1 (en) | 2021-08-20 | 2022-08-19 | Prodrugs and derivatives of psilocin and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118119389A true CN118119389A (en) | 2024-05-31 |
Family
ID=91209028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280069600.6A Pending CN118119389A (en) | 2021-08-20 | 2022-08-19 | Prodrugs and derivatives of des-phosphate nupharicin and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118119389A (en) |
-
2022
- 2022-08-19 CN CN202280069600.6A patent/CN118119389A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW202315863A (en) | Prodrugs and derivatives of psilocin and uses thereof | |
KR101991327B1 (en) | Opioid Receptor Ligands and Methods of Using and Making Same | |
CN1315805C (en) | Compositions and methods of use thereof achiral analogues of CC-1065 and duocarmycins | |
US20240166610A1 (en) | Substituted pyridazine phenol derivatives | |
EP2565190B1 (en) | Tetrahydrobenzothiophene compound | |
CN112341457A (en) | KRAS mutein inhibitors | |
CN107001378A (en) | Pyrrolopyrimidine compounds | |
CN113631557B (en) | JAK kinase inhibitor, preparation method thereof and application thereof in medicine field | |
WO2011035540A1 (en) | 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors | |
US10501466B2 (en) | WDR5 inhibitors and modulators | |
US11866408B2 (en) | N,N-dimethyltryptamine and related psychedelics and uses thereof | |
CN112159401A (en) | Biased agonist and medical application thereof | |
CA3226724A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
JP2024517765A (en) | Expanded dosing regimens of integrin inhibitors | |
US10017507B2 (en) | Diaza-benzofluoranthrene compounds | |
WO2023115002A1 (en) | Analogs of 4-bromo-2,5-dimethoxyphenethylamine | |
TW202319043A (en) | 3,4-methylenedioxymethamphetamine and related psychedelics and uses thereof | |
CN118119389A (en) | Prodrugs and derivatives of des-phosphate nupharicin and uses thereof | |
US20230076435A1 (en) | Modifier of four-membered ring derivative, preparation method and application thereof | |
JP2022539197A (en) | Modulators of NMDA receptors | |
CN117956991A (en) | N, N-dimethyltryptamine and related hallucinogens and uses thereof | |
WO2023055731A1 (en) | Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof | |
CN117897149A (en) | 3, 4-methylenedioxymethamphetamine and related hallucinogens and uses thereof | |
US20220242849A1 (en) | Wdr5 inhibitors and modulators | |
JPH05306284A (en) | Indoloquinoline derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |